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Two major challenges in studying specific cell populations of embryos or 
adult organs are: a) getting the sample sufficiently pure for the cells of interest;   b) 
getting sufficient quantities of these cells. Current methods used for isolating specific 
cell populations from tissues are either too costly or technically challenging to obtain 
large quantities of samples, or do not yield sufficiently pure samples. We addressed 
these challenges by developing a  Magnetic Activated Cell Sorting(MACS)-based 
strategy to isolate rare cells of interest from complex animal tissue. 
 
We designed a two-component transgenic cell surface protein, BAP-Lngfr, so 
that two rounds of MACS can be performed --- the first round against the 
biotinylated BAP (Biotin Acceptor Peptide) component, and the second against the 
Lngfr component. Having a second round of sorting doubles the purity of the isolated 
cell sample, so that rare cell populations can be isolated to sufficient purity for 
sensitive downstream assays. We termed this strategy the „Two-step MACS‟, and 
showed that a rare population of cells (~1% of the 13.5 d.p.c mouse embryo) could 
be enriched to a sufficiently high purity (~85%) in this way. Sufficient quantities of 
cell sample can be achieved because the low cost, speed and technical ease of the 
Two-step MACS makes it scalable.  
 
A third challenge emerges when the cells of interest do not express a known 
cell surface marker. In these circumstances standard cell sorting approaches cannot 






defined by their expression of one or two specific genes of interest rather than known 
cell surface markers. We achieved this by ensuring the expression of BAP-Lngfr 
mirrored that of our gene of interest, Sox9. We placed the expression of BAP-Lngfr 
under the promoter control of Sox9 by gene targeting the Sox9 locus in ES cells, from 
which transgenic animal tissue can be derived. Sox9 was chosen as our model 
transcription factor of interest for its biological importance as the master regulator of 
chondrogenesis and for its known expression pattern. Our results demonstrate that 
even when only one-round of MACS was performed, the resulting enriched sample 
was sufficient for microarray transcription profiling to elucidate gene regulatory 
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Developing organisms are made up of many cell types, each differing from the next in 
function and gene expression. Each cell occupies its own specific spatio-temporal niche. Cell-
to-cell differentiation is directed by developmentally regulated transcription factors, which in 
turn regulate entire gene expression networks. The advent of many new profiling technologies 
over the last decade means that we can now study these gene regulatory networks in greater 
detail. These profiling technologies, like microarrays, tend to be highly sensitive. They 
therefore require samples that are highly pure, representative of the in vivo process studied, 
and of sufficient quantity and quality for an assay to be valid. However, current sample 
preparation methods used for isolating specific cell populations from tissue are either too 
costly or technically challenging to obtain in sufficiently large quantities, or do not yield 
sufficiently pure samples. 
In this thesis, I describe our development of a Magnetic Activated Cell Sorting 
(MACS)-based strategy to isolate rare cells of interest from complex animal tissue, where the 
cells of interest are defined by the expression of one or two specific genes of interest. This 
strategy required the design and transgenic expression of a two-component transgenic cell 
surface protein, BAP-Lngfr, for a Two-step MACS strategy. Here two rounds of MACS are 
performed, each against one of the protein‟s two components. The expression of BAP-Lngfr 
mirrors that of the gene of interest so that only cells expressing this gene will be isolated by 
the Two-step MACS. 
 Our method addresses the current dearth in cell isolation methods that can purify rare 
cells, expressing a specific gene of interest, from complex animal tissue in a way that is fast, 
affordable and can be scaled up to give sufficient sample quantities. Our aim is to develop 
such a cell isolation strategy that can be used for sensitive downstream assays, such as 





populations of cells within complex tissue can be studied.  
  Embryos and organs are made up of many interacting cell types. What goes on in cell 
cultures may be very different from what takes place within the complex microenvironments 
that exist only in tissues. Using samples that include different types of cells will not address 
the fine differences occurring within each type that are key to its function, differentiation and 
development. In the next chapter I review current methods of preparing samples to study 
specific cells of interest in tissues, arguing that the shortfalls of each method has resulted in 
inappropriate samples used for the questions they were intended to answer. I also argue that a 
MACS-based method would be the best one to base any new cell isolation strategies upon.  
The cell isolation strategy we developed defines the cells of interest by the specific 
expression of one or two genes of interest. Here, we define our cells of interest by the gene 
expression of the transcription factor Sox9. I review in the third section of the Background & 
Literature Review Chapter relevant information that is currently known about Sox9. In 
subsequent chapters, I also explain our choice of Sox9 for this project. Much of SOX9‟s 
functions and expression patterns have been studied. Gene regulatory networks both up- and 
down-stream of Sox9 have also been elucidated. This allows us to have good sets of positive 
controls to validate our cell isolation strategy. 
Over Chapters 4 to 7, I explain and describe how we developed and validated our cell 
isolation strategy. Through pilot studies with cell cultures, we ensured that MACS, by 
targeting cells expressing a transgenic cell surface Lngfr protein, was capable of isolating the 
desired cells to a satisfactory level of sample quantity, purity and recovery (Chapter 4). We 
then applied this strategy to animal tissues. Using transgenic teratomas derived from ES cell 
lines that have one Sox9 allele partially replaced with Lngfr, we dissociated the teratoma tissue 





insufficiently pure for sensitive downstream assays. A cell population of interest making up 
only 1% of the starting complex cell mixture could be enriched over 50-fold, but this meant 
that about half the sample would still consist of contaminating cells. Hence, we developed our 
strategy of using a two-component cell surface molecule for two consecutive rounds of 
MACS. The first component was the humanised-BirA-biotinylated Biotin Acceptor Peptide, 
and the other was Lngfr. We showed that the 1.1% rare cell population could be enriched to 
over 84.4% purity this way, which is then acceptable for sensitive downstream assays. We 
also showed that, despite the unsatisfactory cell enrichment using a single round of MACS, 
the transcriptome profile of our Sox9-expressing cell population of interest could still be 
elucidated using microarrays. Finally I conclude and explore subsequent work that can be 
undertaken following this study, and suggest studies for which our Two-step MACS cell 










Section 2.1 Current sample preparation methods are insufficiently 
representative of in vivo processes studied. 
The biological information that can be gleaned from any experiment depends very 
much on the sample used. The use of different sampling and subsequent RNA isolation 
methods tends to have greater impact on newer, more sensitive expression profiling platforms 
such as microarrays, as compared to older, less sensitive assays like Northern blots.How good 
a sample is depends on how representative it is for the biological process being studied, how 
easy it is to prepare, how pure they are, and whether sufficient amounts of sample can be 
obtained. In reality, most sampling methods have their pros and cons. Here, I describe and 
evaluate the common sampling methods used for studies into biological processes that are 
significantly affected by their highly complex microenvironment. In particular, I will be 
accessing how representative the resulting samples are of the biological process being 
investigated. Specific examples from my literature review will be used as evidence. The 
sampling methods and their resulting sample types evaluated here are: 1. Whole organs, 
tissues or biopsies 2. Microdissected tissue 3. Primary cell cultures  4. Established immortal 
cell lines   5. Fluorescence Activated Cell Sorted (FACS) cells  . Magnetic Activated Cell 
Sorting (MACS) is a commonly used method as well, but because our isolation strategy is 
based on MACS, I am devoting the entire next section to it, where I present a more detailed 
literature survey of studies utilizing MACS. In my evaluation of the sampling methods, I am 
taking into account the requirements of both human and animal studies and will make 
comparisons against MACS samples where appropriate. I will not be surveying plant or 
microbial studies.  
2.1.1 Whole organs, tissues or biopsies 
Animal tissue samples are sometimes used in place of, or to validate cell culture 





tissue may not necessarily be better representatives. Studies analyzing complex whole tissue, 
such as neural tissue, have shown that the composition of the tissue can affect the 
transcriptome profile significantly. Neuronal tissues have vastly distinct expression profiles 
and cannot be a good approximation of each other. A study suggested if whole pieces of brain 
tissue were used without isolating specific cell types, the difference in proportion of the 
different cell types between samples could artificially give different gene expression profiles. 
This can happen when gliomas and normal brain tissues are compared, or when infarcted and 
non-infarcted tissue are compared, as there would be an inherent bias between the test versus 
control samples in terms of the different proportion of neurons to glial cells in each (Wang, 
Wilfred et al. 2008). Still such comparisons between normal controls and diseased whole 
tissues are often made, for example, between fibroid and normal myometrium (Dimitrova, 
Richer et al. 2008), between pancreatic adenocarcinoma and normal pancreatic tissue (Lu, Hu 
et al. 2004), between cancerous and normal esophageal squamous cells (Ishibashi, Hanyu et al. 
2003),between benign and malignant prostate tumors (Kube, Savci-Heijink et al. 2007) and 
between recurring and no-reccuring prostate cancers (Nariculam, Freeman et al. 2009). 
Sugiyama et al. demonstrated through gene profiling that whole cancer tissue contains a 
significant proportion of normal cells that interfere with accurate profiling of cancer cells and 
that at least some form of isolation, like microdissection, is required (Sugiyama, Sugiyama et 
al. 2002).  
Expression profiles of whole tissue describe the average, not cell-type specific, profile. 
Using whole tissues, a particular gene expression profile cannot be assigned to any specific 
cell type. Often low or transiently expressed genes are masked by the presence of other 
irrelevant cell types (Steffensen, Neo et al. 2004; Capodieci, Donovan et al. 2005). A study by 





organs including liver, lung, brain and placenta in order to establish a database of tissue-
specific gene profiles in a normal healthy state, against which future studies could compare as 
a reference point (Wong, Hafeman et al. 2003) (Saito-Hisaminato, Katagiri et al. 2002). 
However, each of these tissue transcription profiles generated will be representation of a 
homogenous mix of cells, and will not represent any one particular cell type. Most disease 
states arise from the malfunctioning of only one or few cell types in a particular organ. Thus 
the study of diseases would be more effective if conducted at a cellular level, instead of a 
tissue level. The reference point would then be the transcription profile of that particular cell 
type in the normal state, rather than the profile of the entire organ. 
 Having samples consisting purely of cells of interest is especially relevant for 
developmentally regulated processes where each cell is spatio-temporally regulated by its 
microenvironment, and each cell has a specific fate which differs from other cells. Tissues are 
made up of closely knitted communities of different cell types which means that their gene 
expression profiles differ in very significant ways. Despite the heterogeneity of whole organs 
or tissues, their ease of preparation makes them a popular sampling method, even when they 
are not very representative of the biological process under investigation. For example, entire 
heads of 16.5 d.p.c. mouse embryos were used for RNA extraction to study the expression of 
genes involved in lens development (Kawauchi, Takahashi et al. 1999). Entire liver tissues at 
various developmental stages of the mouse were used to represent the transcriptome of 
hepatocytes (Yu, Zhang et al. 2001). RNA obtained from whole pancreas was used to identify 
genes important for the development of insulin-producing beta-islets (Wilding Crawford, 
Tweedie Ables et al. 2008). .While it could be argued that hepatocytes make up the majority 
of liver tissue and hence whole liver can be used as a good proxy, the same cannot be argued 






and pancreas, respectively. Gene expression profiles from the entire organ would be highly 
distorted.  
When specific biological processes or transcription regulatory activities are being 
studied at the molecular level, where they might differ between cell types, using whole tissue 
and organs disregards cell-to-cell differences within each organ. Yet we see multiple studies 
taking this approach. Emerging research implicating the cytochrome P450 superfamily in 
mammalian development led Choudhary et al. to embark on a study profiling the expression 
level of 40 members of the mouse cytochrome P450 at various developmental stages in the 
different organs. Here, they used RNA purified from whole organs, even though their aim was 
to determine the spatio-temporal expression patterns. That means that the unique expression 
profiles of the different cell types within each organ would be masked and the observed 
profiles merely represent an averaged pattern (Choudhary, Jansson et al. 2003). To give more 
examples, the extent of DNA methylation, an important feature of epigenic regulation, was 
compared between different organs. Entire organs – liver, spleen, kidney, cerebrum- were 
analyzed as a whole, homogenized tissue, and distinct differences in their hypomethylation 
and motifs were observed between the organs (Yagi, Hirabayashi et al. 2008). Epigenetic 
imprinting was studied using mice whole brains (Wang, Sun et al. 2008). To study the 
transcription factor Nr1, nuclear extracts of whole retina, liver and kidney were used. 
(Rehemtulla, Warwar et al. 1996). Entire embryonic orofacial tissue was used for transcription 
profiling to determine the genes that were developmentally regulated, in particular the 
TGFbeta-BMP families of genes (Mukhopadhyay, Greene et al. 2006). 
In some instances, using commercially prepared RNA from whole tissues saves the 
laboratory a lot of time. Commercial preparations are also used when animal facilities are 






need to gain the approval of ethics committees. However, they do have an impact on the 
experimental findings. ATP-binding cassette transporters serve a transport and regulator 
function and have been implicated in lipid disorders such as cardiovascular disease, because of 
their role in the transport of bile acid, phospholipid and sterol. To understand how these 
transporters are regulated the expression network of known regulatory members are examined 
in various human tissue known to express these proteins at a high level. However, 
commercially-obtained RNA from whole tissue, as well as immortalized cell lines was used 
(Langmann, Mauerer et al. 2003). In the former, the regulatory network profiles would not be 
representative of any particular cell type where these transporters play an important function 
because the level of each gene is an average of all the different cell types of each particular 
organ. In the latter, immortalized cell lines have been shown to differ significantly from their 
original in vivo state. 
 In all the studies reviewed here, information from whole tissue are taken to represent 
that of a small subset of cell types being studied. How valid it is to make these representations 
is questionable. This can be improved by using sampling methods that isolate only the specific 







To analyze samples at the single cell level, in situ hybridization, immunocytochemical 
or histochemical methods are often used. These are qualitative methods that do not provide 
quantitative information about gene or protein expression level changes. To obtain RNA for 
quantitative studies from the small subset of cells of interest, physical extraction methods such 
as microsurgery and microdissections are used, often after being identified by immunocyto- or 
immunohisto- chemical methods. Laser capture microdissection (LCM) has been used on a 
wide variety of tissues, including Langerhans cells (McClain, Cai et al. 2005), hepatocytes 
from liver (Marko-Varga, Berglund et al. 2003), hypothalamic neurons (Paulsen, Larsen et al. 
2009), intestinal epithelial cells (George, Wehkamp et al. 2008) and experimentally induced 
cerebral aneurysms in rat (Aoki, Kataoka et al. 2008). Trophoblasts were extracted from 
human placental tissue using LCM to determine the differences in the protein profile of 
normal and preeclampsia patients (Jin, Ma et al. 2008).  
LCM requires a high level of technical competency. The yield of RNA obtained tends 
to be very low, requiring RNA amplification, a step that can introduce bias. LCM also requires 
optimization of pre-microdissection tissue processing steps. Tissues have to be frozen and 
sectioned, fixed, and stained such that they can be recognized and excised. Tissues that are 
simply snap frozen without fixation presents problems with long term storage and preservation 
of histological detail (Perlmutter, Best et al. 2004). For complex tissue, like brain tissue, cell-
specific antibodies are required to identify cell types of interest, and precipitating fixatives are 
needed. If the markers are soluble proteins however, covalent-cross-linking fixatives are 
needed to prevent the markers from diffusing out of the tissue when stained. Choosing the 
appropriate fixative can be tricky. Formalin is often chosen as it penetrates and fixes tissues 






reverse transcribed. Ethanol, while not modifying RNA, often does not fix tissue well; RNA 
degradation occurs easily and tissues stain unevenly. DSP has been reported to be a better 
fixative, fixing the tissue efficiently, while still allowing good tissue staining, RNA 
preservation and allows RNA to be extracted and reverse transcribed readily (Xiang, Mezey et 
al. 2004).  
The time, labor and cost of LCM increases proportionately with increasing number of 
samples because each has to be done one at a time. Unlike MACS, it is not scalable (Croner, 
Guenther et al. 2004). Tangrea et al developed an automated system where 
immunohistochemical staining was recognized by the machine for laser capture, thus 
removing the operator bias and labor requirement (Tangrea, Chuaqui et al. 2004). Still, the 
method is inherently susceptible to contaminating cells which affects the transcription 
profiling and contributes to the variability between replicates when one tissue type is 
compared to another. Laser captured samples still contain the heterogeneity that whole tissue 
samples have, though to a lower level. Often the cell types to be studied, e.g. cancer cells, are 
surrounded by stromal, inflammatory and endothelial cells. These other cell types can 
confound the gene expression profile, and two sample types being compared can have its 
differences masked if they have sufficient percentages of similar irrelevant cell types 
(Sooriakumaran, Henderson et al. 2008). 
Apart from laser capture microscopy, Croner et al reported two other similar methods 
can be used to extract carcinoma cells from tissue. One is the „cryotomy after manual 
dissection‟ method, where tissue is snap frozen, cryosectioned at 7um intervals and 
histologically stained. When sections with 80% or more malignant tissue are identified, a 
series of 10 40um slices are made and collected in RNA isolation buffer. While this method is 






in the sample, so controls have to be done at regular section intervals. Another method is the 
„microscopically assisted manual dissection‟ method, where tissue is snap frozen and 
sectioned at 15um intervals, and put on slides. The slides are immediately fixed and 
dehydrated, and the malignant tissue excised under the microscope and incubated in RNA 
isolation buffer. This method is highly time- and labor-consuming, and requires skilled 
expertise. However, these methods have samples that can be kept and processed at a later time 
(Croner, Guenther et al. 2004). 
Another method used to isolate pure cell samples from complex brain tissue has been 
to enzymatically digest the tissue to single cells and then use a glass micropipette to collect 
cells of interest based on their morphology. This fine needle aspiration method is also used 
when an endogenous surface marker on a particular cell type of interest is expressed at a very 
low level, or has great similarities with surface proteins of other cell types, or is shared by 
other cells. In such cases, even FACS isolation may not produce cell samples of the required 
purity for gene expression analysis. To circumvent this problem, single cells have been picked 
out of primary cell cultures based on morphology, to give a yield of about 50pg of RNA from 
one to two cells (Jensen and Watt 2006), for single cell gene profiling. Single GFP-labelled 
GABAergic neural progenitor cells were also picked out of enzyme dissociated brain 
neocortex tissue for single cell gene profiling (Esumi, Wu et al. 2008). While this method 
gives clean samples, it is very labor intensive and time consuming. It is also very subjective 
and susceptible to operator bias and depends on personnel skilled in recognizing the cells of 
interest. Additionally, cells with similar morphology but very different transcriptomes cannot 
be distinguished (Xi, Kusano et al. 1999). Due to sheer human limitations, the number of cells 
picked out would be very limited. The small number of cells means that in vitro amplification 






al. 2006) (Davis, Eberwine et al. 2004). The above microdissection and fine needle aspirates 
are common methods used to physically isolate neoplastic cells from solid tumor tissue blocks 
or slides. However, these methods cannot be applied to malignancies where the neoplastic 
cells are dispersed amongst normal cells and do not grow in a compacted fashion. Examples of 
such malignancies are pancreatic carcinomas where the neoplastic cells make up widely 
separated malignant ducts amongst stromal cells, breast carcinomas with prominent 
lymphocytic responses, Brenner tumors of the ovary, lymphoepithelial gland carcinomas, 
thymomas etc. Because gene expression profiling is very sensitive to the contributions of both 
neoplastic and normal cells, it is important to get samples of pure populations of each to get 
meaningful results (Yaremko, Kelemen et al. 1996).  
In summary, although microdissected samples have less confounding irrelevant cells 
compared to whole tissue, they are laborious and technically challenging to prepare. This 
hinders large scale sample preparation. Without sufficient sample quantities, nucleic acid 
amplification is required, which can be a problematic source of bias. Because microdissection 
cannot totally eliminate irrelevant cell types surrounding the cells of interest, their 
confounding effects would be further amplified with the nucleic acid amplification, resulting 






2.1.3 Primary cell cultures 
Primary cell cultures are derived directly from animal tissue. Dissociated tissues are 
cultured in media, which promotes the growth of specific cell types of interest. Primary cell 
cultures serve two functions. Firstly, the media allows the growth of only specific cell types, 
thus enriching the final sample for the cells of interest. Secondly, cells from tissue are often 
limited in number. Expansion of the cells in culture increases the amount of sample obtainable 
from the same amount of animal tissue. Primary cultures have been made of both normal 
tissue, such as olfactory ensheathing glia and Schwann cells (Franssen, De Bree et al. 2008), 
as well as tumorous sources such as cultures from glioblastomas were compared with non-
neoplastic tissue in order to identify therapeutic targets (Scrideli, Carlotti et al. 2008). 
However, primary cultures are only a model and may not be sufficiently representative 
of cells in vivo. Cells in culture have often been described as a culture artifact that is never 
found in vivo. When cells are dissociated and cultured, their microenvironment is changed 
drastically and this has effects on gene expression. Also, the complexity of some organs 
means that the in vitro development of cells once they are in culture might be variable. 
Neurospheres are used as in vitro models for studying neurons, astrocytes and 
oligodendrocytes. Neurospheres form when brain tissue is dissociated and grown in culture. 
Each neural stem cell expands clonally to form neurospheres, but the differentiation program 
depends largely on the internal and external signals the neurosphere is exposed to. The brain, 
to begin with, is a highly complex organ and similar cells from slightly different regions can 
have different differentiation potentials. This results in widely varying potentials to 
differentiate towards the different lineages, giving rise to neurospheres that are complex 
structures with varying levels of heterogeneity. Furthermore, the variability increases with 






differentiation. As a model for studying neural differentiation, this variability produces 
problems, because gene expression profiles obtained show very high variability between 
different biological replicates, and it is difficult to ascertain which is most representative of in 
vivo gene expression profiles (Sievertzon, Wirta et al. 2005).  
Many studies have compared gene expression profiles from primary cell cultures, 
established immortal cell lines and tissues. To study hepatocytes, researchers have 
traditionally relied on primary hepatocyte cultures, which, depending on the culture conditions 
used, are representative of in vivo hepatocytes to varying degrees. Even with the best systems 
–the sandwich configuration where hepatocytes are isolated and cultured between two layers 
of collagen or Matrigel in a two-dimensional space- there is considerable variation in its gene 
expression and response to chemical challenges compared to freshly isolated cells. 
Immortalized cell lines such as the human hepatomas HepG2 and Huh7 were used as well. 
However, these cell lines did not express the basal level of genes involved in liver-specific 
functions and could not mount complex biological responses to chemical challenges, when 
compared against their primary hepatocyte culture counterpart. Microarrays  comparing whole 
liver samples and the primary hepatocytes gave correlation coefficients ranging from 0.68 to 
0.8; the acceptable correlation coefficient for biological replicates is 0.9 and above. Between 
the primary hepatocyte cultures of 10 donors, there was a correlation coefficient of 0.76, 
showing that there is great variability between independent primary culture preparations 
(Olsavsky, Page et al. 2007). In another study, a ChIP assay of HNF6 binding sites in human 
primary hepatocyte cultures and the HepG2 cell line show only 66% overlap (Odom, Dowell 






2.1.4 Established immortal cell lines 
Immortalised cell lines are highly popular because they are readily available, and can 
be used on-demand. For cell lines to be accepted as convenient representative models for in 
vivo processes, they must be fairly homogenous, well-characterized and easily manipulated. 
Conditionally immortalized cell lines are derived from known stages and locations during 
development, and can be conditionally differentiated in vitro under defined conditions. 
However it is widely accepted that these cells do not fully represent their in vivo counterparts 
as it is impossible to replicate all the signaling interactions and microenvironment in vivo cells 
experience, within a homogenous cell population.  
One reason why cell lines are often used is that they are easy and convenient to 
manipulate. However, reagents used to manipulate cells, e.g. Viruses, themselves can affect 
the genetic program of the cell lines. When cell lines are manipulated using siRNA or cationic 
liposomes, up to 10% of the gene expression changes can be due to the reagents alone. 
Significantly altered genes are involved in the cellular immune response, apoptosis, cell cycle, 
cell adhesion, metabolism, transcriptional regulation and signal transduction. Protein 
expression is also affected. These gene expression changes can trigger cell death (Tagami, 
Hirose et al. 2008). Including a „no nucleic acid‟ or „irrelevant nucleic acid‟ control is 
necessary and helpful; however, it cannot control for instances where the effects of the 
manipulations being tested are also affected by the transfection reagents themselves.  
Differentiating embryonic stem cell lines are often used as a representative sample for 
the mapping of transcription networks in specific embryonic processes. Despite claims that 
meaningful comparisons can be drawn between the differentiating embryonic stem cell lines 
and embryos, there has never been proof of equivalence. Also, not all cell types have known 






differentiation, embryonic carcinoma cells, embryonic stem cells, and neuronal stem cells 
were profiled. When two different embryonic carcinoma lines were directed to the neuronal 
lineage, there was significant differences between their gene expression patterns, even though 
they supposedly had a similar start and end point (Aiba, Sharov et al. 2006). The reason that 
cultured cells remain popular is that specific cell populations from the embryo are difficult to 
isolate and even when they are isolated, numbers are often insufficient. 
Established immortal cell lines often have been passaged many times by huge numbers 
of labs over the years. Such cell lines are very prone to genetic changes as there is no selective 
pressure on it to maintain a genotype required for anything more than growth and 
proliferation. Two laboratories supposedly using the same cell line might actually be dealing 
with very different samples. For example, between the hepatocellular carcinoma cell line 
HepG2, which is often used as a model for studying liver and hepatocyte functions and 
primary human liver, the genomic occupancy of the transcription factor HNF6 shared only 
66% in common. The HepG2 is severely aneuploid and has been propagated in culture over 
the last 20 years (Odom, Dowell et al. 2007).  
While tests may be done periodically to ensure that the cell lines used fulfil the criteria 
needed to be good models for in vivo cell types of interest, the parameters used to characterize 
and prove that the cells recapitulate in in vivo program are very limited, simply for 
practicality. Hence these cells usually share only a few defining characteristics with their in 
vivo counterparts, but may differ in a lot of other aspects there were not studied, which may 
have profound effects on studies (Holley, Kneebone et al. 2007). This is also true when newly 
derived and established cell lines are being evaluated for their use as representative models. 
Microfold cells exist within the lymphoid follicle –associated epithelia of the Peyer‟s patches 






barrier for immune system recognition, microfold cells are of particular interest, but are very 
difficult to isolate from tissue. Hence an in vitro model involving the co-culture of human 
colon carcinoma Caco-2 cells with murine Peyer‟s patch lymphocytes is often employed. 
However, transcriptome profiling shows that while the in vitro model recapitulates some of 
the in vivo microfold cell phenotypes, there are significant differences in the transcriptomes of 
the microfold cells and its in vitro representative (Lo, Tynan et al. 2004). 
Despite all these drawbacks, the ease of culture and scalability continues to make 
established cell lines a popular choice of sample. Cell line models are used to profile gene 
expression changes during angiogenesis (Kahn, Mehraban et al. 2000) and tumor progression 
(Shou, Soriano et al. 2002). To study transcription regulation in macrophages, the mouse 
macrophage cell line WR19M.1 and EOMA cell line are used. To study transcription 
regulation in endothelial cells, the human umbilical vein endothelial cell line is used 
(Huddleson, Ahmad et al. 2006). A conditionally immortal chochlea cell line was used to 
study gene expression changes during hair cell differentiation (Rivolta, Halsall et al. 2002). To 
study transcription factor regulation of insulin expression in Islet-beta-cells, pancreatic islet 
cell line beta-TC-3 were compared against the non-islet cell line HeLa (Matsuoka, Zhao et al. 
2003). Another study utilized the beta-cell line MIN-6 and alpha-cell line TC1.6 (Nishimura, 
Kondo et al. 2006).Neither primary nor established immortal cultures are accurate 
representations of in vivo biological processes, especially where developmental pathways and 
mechanisms are being studied. Many developmental processes are influenced by the 
heterogeneous cell types that surround it in vivo.  This microenvironment is lost in cell 
cultures. Cell cultures are also subject to environmental conditions which in turn impacts their 
gene expression. Still, they continue to be used for their convenience, ease of manipulation 






it would be best to study cells isolated from these tissues themselves, at specific 
spatiotemporal points. The longer cells are taken out of their in vivo microenvironment, the 
less of a reflection it is.  
2.1.5 FACS cells Fluorescence Activated Cell Sorting (FACS) 
FACS requires samples to be digested to single cell suspensions, which are then sorted 
with a fluorescence-based flow cytometer, based on their size, granularity, or fluorescence. 
The machine analyses the cells one at a time and sorts them out individually, hence FACS 
tends to give very pure sorting. However, FACS has to work at slow speeds for this single cell 
analysis – raising the rate of flow through the machine tends to decrease its purity, and fragile 
cells tend to die if the flow rate is too high. If large numbers of cells are being sorted, the time 
taken for sorting could result in decreased cell viability and gene expression changes. 
Traditional cell sorters handle about 1000 cells/second, whereas the most advanced high speed 
cell sorters can candle 100,000 cells a second. However, for accurate measurement that does 
minimal damage to the cells, even a high speed sorter typically takes about 1 hour to 
completely sort a 13. 5 d.p.c. mouse embryo. The startup cost of acquiring one of these 
machines is very high, often to the tune of the annual salaries of 10 postdocs. 
However, FACS is still often used because the pure samples they produce give more 
biologically representative and hence meaningful results. This is especially necessary for 
studying specific cell types from tissue. For example, to study astroglia, primary cultures are 
used. However, these cultures can only be prepared from neonatal rodent brain, and the 
cultures stem from only a small population of proliferating, immature, precursor cells. Even 
though the cultures express astrocyte markers, their origins are still ambiguous and have an 
unclear relationship with adult mature astrocytes. To obtain a more defined and representative 






EGFP under the promoter of a glial cell marker. Oligodendrocytes were first removed by 
immunopanning. Then FACS was used to purify the EGFP positive astrocytes to 99% purity. 
Gene expression profiling showed that the primary astroglia model differed significantly from 
FACS isolated astrocytes – 2103 culture-unique genes and 2819 FACS-unique genes were 
identified (Cahoy, Emery et al. 2008). 
There are several other similar examples of studies where specific cells of interest were 
made to express EGFP for sorting. GFP was expressed under the control of the Pax2 promoter 
to isolate Pax2 expressing cells by FACS from the mid-hindbrain of mice, so that the role of 
Pax2, known to be involved in mid-hindbrain boundary patterning, can be elucidated in detail 
(Bouchard, Grote et al. 2005). Co-expression of EGFP with markers of vascular, 
hematopoietic and pharyngeal arch cells of the zebrafish enabled the isolation of these cells by 
FACS. Gene expression profiling was then done on these cells (Covassin, Amigo et al. 
2006).GFP tagging also enabled the purification of neuronal cells in C. elegans (Von Stetina, 
Watson et al. 2007) and of side populations from bone marrow and muscle (Liadaki, Kho et al. 
2005). 
Cells can be fluorescently labelled with antibodies conjugated to fluorescent molecules 
such as Fluorescein isothiocyanate (FITC) or Phycoerythrin (PE). Kazutaka et al. used PE and 
FITC conjugated antibodies against microfold-cell-specific markers NKM 16-2-4 and UEA-1 
to isolate microfold cells from Peyers‟ Patch and small intestinal villous epithelia, using 
FACS, to a purity of 90 – 99% (Terahara, Yoshida et al. 2008). Hematopoietic stem cells of 
various types were isolated based on 5 different cell surface markers, using five-color FACS 
sorting (Zhong, Zhao et al. 2005).  
FACS can also separate cells purely based on non-fluorescent parameters. Dissociated 






obtain large and small retinal ganglion cells. The transcription profile for these two cell 
populations were compared as they have been known to be susceptible to different types of 
pathological symptoms (Ivanov, Dvoriantchikova et al. 2008).  
Due to the slow speeds of FACS, a pre-FACS round of cell enrichment for rare cells is 
sometimes done, so that the cells do not spend as long during the FACS process. 
Enterochromaffin cells, a neuroendocrine regulatory cell type of the small intestine, was 
isolated with a combination of Nycodenz gradient centrifugation followed by FACS from 
enzyme digested intestine. With Nycodenz gradient centrifugation alone, samples were not 
pure enough for precise analysis of enterochromaffin cells, but FACS brought the purity to 
greater than 99% (Kidd, Modlin et al. 2006). 
Other examples of FACS being used to separate tissue dissociated complex cell 
mixtures are: when neurons and astrocytes were isolated from adult mouse cortex (Lovatt, 
Sonnewald et al. 2007), when bronchioavleolar stem cells are FACS purified from mouse 
lungs for microRNA expression profiling (Qian, Ding et al. 2008) and when gonad cells were 
purified from dissociated Drosophila embryos (Shigenobu, Kitadate et al. 2006). In all these 
examples, FACS gives cell samples that are technically more convenient and cleaner, 
compared to microdissection or making primary tissue cultures, and is a lot more 
representative compared to established cell lines. However, the drawback of FACS is its high 
cost, relatively long sorting duration and the resulting difficulty in scaling up. What is required 






2.1.6 Survey of recent common sampling methods 
We conducted a literature search for experiments involving quantitative expression 
profiling of multicellular, complex eukaryotic organisms and processes, where pure specific 
cell populations isolated from animal tissue would have been the ideal representative sample. 
We excluded plant, pathogen, and single-cell organism studies. A random (first author names 
beginning with the letters R to Z) literature survey of 52 research articles published in 2008 
alone (Appendix 1), revealed in most cases, the samples studied are not sufficiently 
representative or sufficiently pure for the representative cells, for reasons discussed earlier 







Section 2.2 Magnetic Activated Cell Sorting is suited for low cost, rapid 
isolation of rare cells from tissue  
Magnetic Activated Cell Sorting (MACS), otherwise also known as immunomagnetic 
sorting, is a cell sorting technique where specific cells within a single-cell suspension are 
labelled with magnetic beads and separated from the unlabelled cells using a magnet. This 
labelling is achieved when magnetic bead-conjugated antibodies bind to their epitopes 
displayed on the extracellular cell surface of the targeted cells. Because of the simplicity of the 
MACS principle, it is a low cost procedure and highly scalable. Yet it had the potential to sort 
cells to the same purity as FACS because both operate on similar principles. FACS seperates 
cells based on fluorescent labels and MACS on magnetic labels. This, together with the 
diversity of antibodies available today, contributes to the extensive use of MACS in both the 






2.2.1 Clinical applications 
MACS has been used routinely and extensively in the clinical setting because of the 
large volumes of samples it can process at a time and because of its cost effectiveness. The 
ease and low cost of MACS makes it suitable for routine use in prenatal diagnosis 
(Pongsritasana, Wongratanacheewin et al. 2006). By first enriching for fetal cells using MACS 
against fetal specific antibodies (Zhao, Ozaki et al. 2002) (Ganshirt-Ahlert, Borjesson-Stoll et 
al. 1993), it becomes feasible to screen for aneuploid fetuses from maternal blood. Here, the 
antibodies used for MACS were the main determinant for the effectiveness of detection.  
MACS has been used for the selection of non-apoptotic spermatozoa for 
intracytoplasmic sperm injection as a form of fertility treatment. MACS selection yields a 
higher percentage of healthy sperm compared to traditional density gradient centrifugation, 
resulting in higher pregnancy and implantation rates. These sperm have higher motility and 
survive cryopreservation better (Said, Agarwal et al. 2006; Dirican, Ozgun et al. 2008; 
Makker, Agarwal et al. 2008) (Grunewald, Paasch et al. 2001; Said, Grunewald et al. 2005; 
Grunewald, Paasch et al. 2006). Conflicting observations have also been made. Chemotherapy 
and radiotherapy often affect mitotically active germinal tissue. For pre-pubescent males who 
do not have the option of cryopreserving spermatozoa, isolating stem cells from testicular 
tissue can be one way of preserving their fertility. In normal adult testicles, only two out of 
1000 germ cells is a progenitor, thus isolation methods are required. MACS has achieved 
progenitor samples of 25 – 55% purity, and density centrifugation with differential adhesion 
has achieved progenitor cell samples of 85% purity (reviewed in (Khaira, McLean et al. 2005). 
MACS is used to enrich for, and hence detect, tumour cells or pathogens in the clinical 
diagnosis of cancers or pathogenic infections. Sample types that MACS enrichment is applied 






2008) (Cools-Lartigue, McCauley et al. 2008) and bone marrow (Eide, Faye et al. 2008) 
(Wang, Li et al. 2008). MACS has been used to detect for pathogens from bronchoalveolar 
lavage fluid (Sethi, Gore et al. 2007), faeces (Robinson, Watkins et al. 2008), urine 
(Fernandes, Seixas et al. 2008), contaminated food (Irwin, Nguyen et al. 2008; Park, Cho et al. 
2008) (Hagren, von Lode et al. 2008) and water (Hibi, Ushio et al. 2008) and milk (Caroprese, 
Marzano et al. 2008).  
The high recovery of MACS when isolating specific cells from complex cell mixtures 
also means that it can deplete undesirable cells cleanly. This property of MACS has been 
harnessed for removal of malignant cells so that remaining non-malignant stem cells can be 
autologously transplanted to replace the lost tissue. When MACS was used to deplete 
malignant cells from hepatocytes for transplantation, sufficiently pure samples of hepatocytes 
could be obtained such that when transplanted to nude mice, no peritoneal tumours formed 
(Gunasegaram, Akhter et al. 2008). When MACS was used to deplete CD3 T-cells and B-cells 
from haploidentical peripheral blood progenitor cells or bone marrow for transplantation to 
prevent graft-versus-host disease, sufficient purity could be achieved in an efficient, rapid 
manner, for clinical use (Schumm, Handgretinger et al. 2006; Dykes, Toporski et al. 2007). 
(Tong, Xiong et al. 2007) (Kogler, Capdeville et al. 1990).  
 MACS is extensively used in the isolation of specific stem cell populations from 
blood or bone marrow (Zinno, Landi et al. 2008; Guenechea, Segovia et al. 2009) and cord 
blood (Kekarainen, Mannelin et al. 2006) for transplantation. To treat CD34-negative 
malignancies, CD34+ progenitors are purified by MACS to a purity of about 98.8% from 
peripheral blood and autologously transplanted back into patients after high-dose 
chemotherapy. This method can also be used to treat autoimmune diseases, for the autologous 






(Handgretinger, Lang et al. 1998). CD34+ transplantation is also used to treat pediatric 
patients with inherited metabolic storage diseases (Gaipa, Dassi et al. 2003) and aggressive B-
cell non-Hodgkin‟s lymphoma (De Rosa, Lalle et al. 2002). CD34+ cells isolated from bone 
marrow by MACS showed normal function when tested in vitro, even after cryopreservation 
and thawing (Martin-Henao, Ingles-Esteve et al. 1996; Zinno, Landi et al. 2008). . 
MACS also has been used for cell preparations for cell banks. Donor natural killer cell 
infusion can help to prevent or treat infections, graft failures and relapses associated with 
allogeneic bone marrow transplantation. Isolation of these CD56+ lymphocytes from 
peripheral mononuclear blood cells by MACS to 98% purity, with 57.2% recovery was 
achieved. The cells remain viable and functional, when tested for its natural killer activity and 
interleukin-2-induced proliferative response (Geiselhart, Neu et al. 1996). This method is 
rapid, cost-effective and efficient enough for large-scale automated purification of natural 
killer cells free of T and B cell contamination for clinical uses (Iyengar, Handgretinger et al. 
2003).  
However, there also have been reports that MACS does not purify cell preparations 
enough for transplantations. When MACS is used to deplete malignant cells from 
spermatogonial stem cells prior to autologous testicular stem cell transplantation, sufficient 
purity could not be achieved. One group reported that only 1 out of 11 purified samples were 
pure enough for transplantation (Geens, Van de Velde et al. 2007). Another group reported 
that in a rat model, only a third of contaminating leukaemic cells couple be removed from 
testicular cells and that all animals receiving the MACS purified autologous transplants died 
within two weeks. The failure to achieve sufficient purity was attributed to the variable cell 
sizes and surface antigen expression of the malignant cells (Hou, Andersson et al. 2007). In 






cells from testicular tissue for transplantation in human trials because even though the 
observed contamination level of 0.58% was considered good for MACS and FACS, it was 
sufficient for a relapse of the malignant tumour growth (Geens, Van de Velde et al. 2007),. 
Although MACS is not a perfect, problem-free technique, the long history and 
extensive utility of MACS in the clinical setting is a testament to its reliability and scalability 
in most instances. Observations from the clinical applications of MACS allow us to identify its 
potential and limitations, which allows us to refine MACS-based strategies further to suit 
research needs. This gives us confidence that MACS can be adapted and optimised for our 







2.2.2 Research applications  
In the research setting, MACS has been used quite often to isolate specific cell 
populations for study. In the large majority of these instances, cells are isolated from fluid 
tissue like blood, and antibodies against known cell surface markers are used for MACS. The 
extensive research data available for blood cells mean that many of the blood cell population 
subsets have been isolated by MACS. For example, MACS was used for the isolation of 
plasma cells, which are terminally differentiated B-lymphocytes from lamina propria. Plasma 
cells reside in the lamina propria in response to mucosal antigen stimulation. Lamina propria 
were collagenase-dissociated to single cells and plasma cells MACS purified using antibodies 
against CD54 (Medina, Segundo et al. 2004). In another example, mast cells were purified 
from highly heterogeneous rat bone marrow and peritoneal cell suspensions using MACS with 
a mast-cell specific monoclonal antibody (Jamur, Grodzki et al. 1997). Immunostaining was 
performed on the purified cells to study the stages of mast cell maturation, which traditionally 
has been difficult to observe due to the heterogeneity of the tissues that mast cells tend to be 
found in (Jamur, Grodzki et al. 1997). For research on human blood tissue cells, MACS is part 
of the procedure used for isolating CD4+ and CD8+ T-cells (Stanciu, Shute et al. 1996). 
Cocktails of monoclonal antibodies have been put together that enable highly efficient and 
specific MACS isolation of CD4 T-cells, achieving consistent recovery rates above 70% and 
purity of 93 – 99% (Kamala 2008).  
 MACS has not been used very extensively to isolate specific cell populations from 
animal tissue apart from those of the blood or immune system. Where they have been used for 
this purpose in other tissue, endogenous cell surface markers were targeted again, hence these 
cells were defined by their cell surface marker expression rather than by the expression of a 






desired cell population has to be available. To our knowledge, no study has utilised MACS to 
isolate cells defined by the expression of a specific gene that does not naturally code for a cell 
surface protein. Here, we have done an exhaustive search for studies where MACS is used for 
the purpose of isolating cells from tissue other than that of blood or the immune system. Listed 
below in descending chronological order are all the studies that have ever been done, to our 
knowledge, at the time of writing: 
 Astrocytes and microglia were MACS-isolated from mouse brain tissue. 
Oligodendrogial was first removed by antibody-mediated cytolysis, and 
microbeads targeting CD11b were used to positively select microglia. 
Astrocytes were negatively selected and collected in the unbound fraction 
(Makker, Agarwal et al. 2008).  
 Brain capillary endothelial cells were MACS isolated from rat brain tissue, 
using antibodies against PECAM-1. Compared to the traditional glass bead 
column method, there was significantly less neurons and astrocytes 
contaminating the sample; the sample was 85.9% pure based on PECAM-1 
expression (Ohtsuki, Yamaguchi et al. 2007).  
 MACS was used to isolate metastatic tumor cells from bone marrow in order to 
study their gene expression. Cells were also taken from the original metastace 
and their gene expression profiled. Genes involved in cell signaling, cell cycle 
regulation, angiogenesis were observed to be expressed. However, a high rate 
of false positives was noticed (Ree, Engebraaten et al. 2002).  
 To study the process of spermatogenesis, proliferating sperm precursors were 






CAM. These germ cells were co-cultured on Sertoli cell monolayers as long 
term primary cultures (van der Wee, Johnson et al. 2001). 
 Primodial germ cells isolated by MACS from 11.5day embryos allowed the 
establishment of germ cell lines (Durcova-Hills, Tokunaga et al. 1999).  
 To study neutrophil function, neutrophils were isolated from rat blood either by 
MACS or density gradient centrifugation. The yield and purity from MACS 
was higher, and the viability of both methods comparable (Jareo, Preheim et al. 
1997). 
 Rat islets were MACS purified from pancreas using anti-islet monoclonal 
antibodies. Up to 81% of islets were recovered, and they retained their insulin 
secretory response to glucose stimulation after purification (Nandigala, Chen et 
al. 1997). 
 Tubular epithelial cells were isolated from human renal tissue after collagenase 
digestion and Percoll density gradient centrifugation. However, to separate 
proximal tubular epithelial cells from distal cells, MACS was applied, where 
proximal cells were isolated using an antibody against aminopeptidase M, and 
distal cells using an antibody against Tamm-Horsfall glycoproteins. Both these 
cell surface proteins are specific to their respective cell types and purities of up 
to 98% were achieved, for establishment of primary cultures to be studied 
further (Baer, Nockher et al. 1997).  
 To obtain liver endothelial cells, Percoll gradient separation was first used to 






purify the cells by MACS, for studies of endothelial cells (Gomez, Hartzler et 
al. 1993).  
 
In my thesis, I describe how a MACS-based strategy is used to isolate Sox9-expressing 
cells from complex animal tissue. In embryos, cartilaginous and osteogenic progenitors form 
the majority of Sox9-expressing cells. Cartilaginous and osteogenic progenitors are among the 
cells that have previously been isolated by MACS as well. Precartilaginous stem cells were 
MACS purified from rat perichondrium using an antibody against FGFR3, to a purity of 93-
99%, of which about 80 – 85% were viable (Cheng, Chen et al. 2006). Osteoprogenitors were 
isolated from human bone marrow using an antibody against STRO-1, a stromal cell surface 
marker. The osteoprogenitors isolated differentiated down the osteoblastic lineage when 
cultured (Encina, Billotte et al. 1999). 
Apart from using MACS-isolated cells from tissue directly for downstream 
experiments, they can also be used as starting seed cells for primary cell cultures. MACS is 
ideal for this purpose as the quick, minimal and gentle manipulations ensure high cell 
viability. The enrichment of the cells of interest reduces the amount of undesired cells in 
culture than may overgrow rare cell populations. Often the isolated cells are not highly pure, 
but they provide sufficient enrichment for establishing the cell culture, where the media 
selectively promotes the growth of the cells of interest for further enrichment. Human 
myoblasts are isolated from human muscle for the study of muscular dystrophy. By 
introducing a MACS step positively selecting for myoblasts, in addition to the standard 
techniques of complement-mediated cytotoxicity and preplating, the purity of the myoblast 
culture was increased from the starting 30% to the final 92.8% (Park, Moon et al. 2006). 






MACS step to 85% purity for primary and secondary neurosphere culture (Yu, Zhang et al. 
2004). MACS can also be used after the primary cell culture is established, when the culture 
conditions do not sufficiently enrich for the cells of interest. Here, the primary culture serves 
as a step for increasing the amount of cell sample available. For example, MACS with 
antibodies against NCAM was used to isolate and compare NCAM positive cells from primary 
myogenic cultures from normal and dystrophic dogs (Prattis, Gebhart et al. 1993). 
One benefit of using cell culture systems is that they are easy to manipulate compared 
to animals. Genes can be overexpressed or knocked down by transfecting with the appropriate 
nucleic acids or by chemical treatment. When specific cell lines that have to be used for 
particular experiments have very low transfection efficiencies (e.g. 1 – 3%), and 
overexpression or transgenic expression is necessary, a method to enrich for transfected cells 
is necessary. Antibiotic selection is not always an option because certain cells have to be 
examined soon after transfection, and before the period of time necessary for selective 
antibiotics to kill the non-transfectants, or because the effects of the antibiotic exposure would 
confound observations. GFP selection requires a sufficiently high level of expression for 
FACS detection and hence it is difficult to work with cells that either express low GFP levels. 
Isolated samples would only contain the cells with high copy numbers of transfected genes, 
and cells with low copy numbers would escape the study. MACS can be used in such 
instances. Working with L929 cells, Greenfield Jr et al. transfected a vector that allows the 
expression of both the gene under study, as well as a hapten-specific, single-chain antibody 
fragment that is displayed on the cell surface. Using MACS to select for the cells after 48 – 72 
hours, he obtained cell samples that were 90 – 95% pure (Greenfield, Sun et al. 1997). L929 
fibroblast cell lines were used to express GABAA receptors for studying its pharmacological 






transfected cells, the cells were co-transfected to express a single-stranded cell surface 
antibody, sFv, which would be bound to magnetic beads coated with its antigen, phOx. 95% of 
these MACS purified cells were found to express GABAA receptors, which increased the ease 
and efficiency of downstream tests (Greenfield, Sun et al. 1997). HeLa and CV-1 cells were 
transfected with the TAC subunit of the human IL-2 receptor and MACS purified to more than 
90% purity (Padmanabhan, Corsico et al. 1988). Thus, MACS has been proven to substantially 
improve specificity and purity of isolated cell populations in multiple different models and 






2.2.3 Comparison of MACS with other methods 
In previous sections, I evaluated the strengths and weaknesses of the commonly used 
cell isolation methods. In this section, I review studies where MACS has been compared to 
other methods of cell isolation, and in so doing, argue that a MACS-based strategy would be 
most appropriate for the isolation of rare cells populations to sufficient purity and quantity. 
MACS has mainly been compared to FACS, because only these two sorting methods have the 
capability of sorting cells at the single cell level, directly from whole tissue. Here, these 
studies are reviewed and most find that the advantage of MACS lies in its speed, scalability 
and low cost, while FACS has the advantage of giving purer isolated cell fractions. This was 
especially so with very rare cell populations below 2% of the original starting heterogeneous 
input population. 
Ordog et al. attempted to use MACS to isolate Interstitial cells of Cajal, which are 
mesenchymal cells that are dispersed amongst the smooth muscle bundles of the 
gastrointestinal tract. This tissue was digested to single cell suspensions, but the scarcity of 
these cells made it difficult to obtain highly pure samples. Recovery in this experiment was 
46% and purity was 28%. Compared to MACS, FACS had lower recovery because MACS 
made use of both a primary antibody, and a bead-bound secondary antibody that amplified the 
detection capacity. The authors suggested using MACS as a pre-enrichment step to be 
followed by FACS for optimal purity and recovery (Ordog, Redelman et al. 2004).  
Megakaryocytes make up about 0.02 – 0.06% of nucleated cells found in the human 
bone marrow. They have traditionally been purified using bovine serum albumin or Percoll 
gradients, as well as centrifugation techniques like counterflow centrifugal elutriation, velocity 
and density centrifugation. These methods can isolate the cells to a purity of up to 94% when 






time-consuming. Radbruch et al. compared MACS against these traditional techniques, and 
found that MACS allows the isolation of megakaryocytes based on their marker expression, 
rather than on size. Isolation methods based on size tend to exclude subsets of 
megakaryocytes. MACS also allows direct FACS evaluation of the cells as well as 
downstream manipulations, without further processing of the isolated cells. They found that 
the magnetic particles are too small to affect the properties and behaviour of the cells, e.g. the 
forward and sideward FACS scatter, or the intercellular interactions. However, when MACS is 
used alone, starting from a 0.82% megakaryocyte cell suspension, the purity was low (47%) as 
was the recovery (37%). They hypothesized that the cell losses occurred during the labelling 
and washing process. The recovery of cells from the MACS column was about 85%. 
Combining Percoll density centrifugation increased both the purity (65%) and recovery (67%). 
They suggested that the pore size of the MACS column used can affect the morphology of the 
isolated cells because poor morphology was observed when the column pore size was that of 
the megakaryocytes – 30um (Schmitz, Radbruch et al. 1994).  
Embryonic stem cell cultures were transfected to express a modified human CD4 
molecule without the intracellular domain, under a phosphoglycerate kinase promoter. 
Transfection efficiency was between 0.6 – 16%. MACS for CD4 positive cells gave a purity of 
98.5%, independent of the ES cell differentiation state and independent of their starting 
proportion. When an EGFP protein was fused to the intracellular domain and FACS 
performed, the purity was 97%. However, with FACS, only 3000 cells per second could be 
sorted. For therapeutic applications, one of the main obstacles is the lack of methods available 
to purify only the specific differentiated cells from the undifferentiated embryonic stem cells. 
When cardiomyocytes differentiated from embryonic stem cells have to be purified for 






take more than 500 hours. High-speed FACS decreases the cell recovery and can damage 
fragile cells. FACS also affects the electrophysiological characteristics of these cells. 
Antibiotic selection takes several days to perform, and long term maintenance in antibiotic 
selection media has adverse effects on cells which may render them unsuitable for 
transplantation. MACS on the other hand, can sort up to 10^11 cells within an hour, to 
sufficiently high purities required for transplantation (David, Groebner et al. 2005). 
The enumeration of rare cells, e.g. circulating endothelial cells which exists at 0.01 - 
0.0001% of mononuclear cells, can be technically challenging because their numbers are 
below the background noise and false positive rates of most enumeration methods. 
Immunological methods of enumerations e.g. for FACS, often have to contend with non-
specific antibody binding to debris, dead cells, platelets etc. Certain cell types that exhibit a 
high level of autofluorescence are another confounding factor for FACS. Enumeration by 
FACS depends on the accuracy of pipetting cells and microbeads, and the flow rates and flow 
patterns through the cytometer. While MACS does not get rid of problems associated with 
non-specific antibody binding, it is unaffected by all the other factors. However, when Goon et 
al. compared both FACS and MACS, they found a high agreement between both 
methods(Goon, Boos et al. 2006).  
FACS and MACS were both evaluated as methods of isolating fetal cells from 
maternal blood. FACS was found to have a higher sorting yield and purity and higher 
fluorescence in situ hybridization (FISH) efficiency and more convenient microscopy, while 
MACS was found to stain fetal cells with greater specificity and lose less cells during FISH 
(Wang, Zhen et al. 2000).  
To isolate differentiated cells from stem cells for transplantation, MACS was 






phosphotransferase for lineage-specific selection of differentiated cells. While MACS was the 
cheapest alternative, the purity was insufficient (Heng and Cao 2005).  
Glial cells can be purified from enzymatically dissociated rat central nervous system 
by MACS with antibodies against A2B5 or RAN-2, found on glial cell surfaces. 99% purity 
was achieved in 2 hours, which makes this procedure much cheaper and faster than traditional 
methods of immunopanning or FACS, while achieving similar levels or purity and cell 
viability (Wright, Fitzgerald et al. 1997).  
MACS and FACS yielded similar results when CD8+ cells were sorted from bone 
marrow. The purity of cells isolated through both methods allows for transplantation (Sen-
Majumdar, Sheehan et al. 1998). 
MACS has also been compared to other methods of preparing samples that were 
reviewed in the previous section, as well as other isolation methods used in the research 
setting, including the ability of the cells to adhere, primary cultures and dissection methods. 
Traditionally, antibodies have been prohibitively expensive, and other methods of isolating 
cells from blood based on the physical properties of cells have been developed and have been 
used extensively in the clinical setting. With the increasing affordability of antibodies, many 
groups have found that replacing the older methods with, or including a step of, MACS 
improves the cell isolation process significantly. Compared to traditional methods of isolating 
brain capillary endothelial cells based on their ability to adhere to glass bead columns, there 
was 20-fold less contamination of cell samples by neurons after MACS based on PECAM-1 
cell surface expression (Ohtsuki, Yamaguchi et al. 2007). 
Monocyte-derived dendritic cells for immunotherapy must comply with standards of 






cells is by their adherence to plastic. However, MACS purification for CD14+ cells proved to 
be reproducibly of better yield and purity, of up to 97 – 99%, and maintains a purity of 91 – 
97% even after these MACS purified cells are cultured (Meyer-Wentrup and Burdach 2003). 
Cell function before and after selection and cryopreservation, as evaluated by marker 
expression and T cell stimulation was normal. Large-scale MACS was possible for clinical-
scale production of functional dendritic cells (Babatz, Rollig et al. 2003). 
Medina et al. isolated plasma cells from human colon lamina propia using MACS by 
selecting for CD54 positive cells which gives a plasma cell isolated population of 94% purity. 
The traditional method of isolation included dissections, enzymatic digestion and a lot of 
washes and the entire isolation procedure takes 15- 18 hours. The MACS protocol required 
only a 15 min collagenase digestion and the entire procedure took 1.5 hours. One drawback 
was that lamina propia cells tended to clump together and this was not solved by prior DNAse 
and mucolitic treatment, Ficoll centrifugation or nylon mesh filtration. Hence, columns with 
larger pores sizes had to be used to minimize column clogging, but this can also result in non-
specific cells being pulled along (Medina, Segundo et al. 2004). This issue of lowered purity 
due to clumping was also observed with the isolation of CD34+ cells (Martin-Henao, Picon et 
al. 2000). 
Isolating specific cell populations from embryos by methods such as microdissection 
can be very challenging because of their small size. MACS has proven to be a good alternative 
when physical isolation is difficult. The technical ease allows MACS to be scaled up for 
sufficient cell quantities to be isolated. Solid tissue are enzymatically digested to single cells, 
using enzymes like collagenase, pepsin and trypsin, at concentrations that do minimal damage 
to the cell surface markers that can be used for sorting (Yaremko, Kelemen et al. 1996). This 






cells retain their pluripotency. To create transgenic chicken, chicken blastodermal cells are 
stably modified and introduced back to recipient embryos to produce chimeric chickens. More 
chimeric chickens are obtained when higher ratios of modified to unmodified blastodermal 
cells are used. Hence, both the expression constructs for the transgene, and a transgenic cell 
surface marker – the mouse H-2Kk molecule, were coelectroporated into chicken blastodermal 
cells. MACS was performed to enrich for successfully transfected cells marked by the H-2Kk 
molecule and this enriched cell fraction was used to generate the chimeric chickens (Wei, 
Croy et al. 2001). The ability of cells to retain their pluripotency after MACS meant that stem 
cells can be purified from embryos for the derivation of stem cell lines. MACS with antibodies 
against SSEA-1 were used to isolate primodial germ cells from 8.5 – 11.5 d.p.c. mouse 
embryos to establish embryonic germ cell lines (Durcova-Hills, Tokunaga et al. 1999). MACS 
with antibodies against pluripotent stem cell marker SSEA-3 was used to derive embryonic 
carcinoma cell lines from germ cell tumors (Przyborski 2001). The retention of stem cell 
properties after the MACS process also provides assurance that any further studies done on 
these cells would be a good reflection of the cells in vivo. Besides stem cells, dendritic cells 
also remain fully functional and responsive after MACS (Boor, Ijzermans et al. 2005) 
Chondrogenic and osteogenic cells are of particular interest, because Sox9, our gene of 
interest, is involved in the differentiation towards this lineage. To study osteoprogenitors, 
primary cultures, osteoblast-derived cell lines from bone tumors and stromal cell lines from 
bone marrow have often been used. However, immortalizing cell lines, whether with or 
without transgenes, may cause cell property and gene expression changes. In order to study 
cells most representative of the in vivo situation, osteoprogenitors have been isolated from 
tissue for study directly. Osteoprogenitors comprise a small subset of mesenchymal stromal 






the bone marrow, there is 1 osteoprogenitor. To isolate osteoprogenitors from bone marrow 
for study, several techniques have been used. Collecting bone marrow stromal cells that 
adhere to plastic captures not only the osteoprogenitors but also other types of stromal cells. A 
density gradient step prior reduces the amounts of contaminating cells. MACS has been 
performed using the antibody against STRO-1. To test that the purity and properties of these 
cells, they were cultured for 21 days, after which 98% exhibited alkaline phosphatase activity 
and expressed osteoblastic gene markers (Encina, Billotte et al. 1999). 
In summary, MACS has been shown to be a cell enrichment technology that is cheap, 
rapid, technically easy and scalable, in comparison to other commonly used isolation methods 
like FACS and microdissections. While MACS is more costly if samples are few, the 
scalability and parallel processing power means that the time and financial costs does not 
increase linearly with increasing numbers of samples (Croner, Guenther et al. 2004). MACS is 
also more representative of in vivo cellular processes compared to primary and established, 
immortal cell cultures. It is gentle on the cells, thus post-sorting viability is high. However the 
degree of recovery and purity of the enriched or depleted fractions are highly variable. 
Another drawback is that most other methods have samples that can be kept and processed at a 
later time, while MACS samples have to be prepared fresh. Overall however, MACS seemed 
to have the greatest potential of all the sorting methods, to be developed for the isolation of 






Section 2.3 Sox9 is an ideal transcription factor for this study because of its 
biological importance and its  known expression patterns 
2.3.1 Sox9 as a master regulator of chondrogenesis 
The SOX9 transcription factor is part of the SRY-type high-mobility-group (HMG) 
box (SOX) family of more than 20 members. The SOX family is subdivided into 8 groups A- 
H, with two B subgroups, B1 and B2. SOX9 belongs to the SOX E group. They are so called 
because they have a HMG domain that is more than 60% similar to that of SRY, the sex-
determining gene on the Y chromosome (reviewed in Lefebvre V, Dumitriu B, 2007). The 
conserved motif RPMNAFMVW is present in their HMG domain. They bind to the DNA 
sequence (A/T)(A/T)CAA(A/T)G(Kiefer 2007) in the minor groove of DNA to bend it at an 
angle (ranging from 30˚ to 110˚), to assert transcriptionally activating or repressing effects 
(Lefebvre, Dumitriu et al. 2007).  
SOX9 is highly conserved throughout vertebrate evolution (Bagheri-Fam, Ferraz et al. 
2001). About 500 amino acids long, it has a serine-proline-glutamine rich C-terminal 
transactivation domain, a highly conserved proline-glutamine-alanine rich domain involved in 
male specific expression of Sox9 during gonad differentiation (Agrawal, Wessely et al. 2009). 
The HMG domain is about 100 amino acids from its N terminal. When SOX9 binds to the 
minor groove of DNA to induce DNA bending, it facilitates the interaction of proteins and 
DNA for the assembly of multiprotein-enhancer complexes necessary for transcriptional 
activity (reviewed in Lefebvre, Crombrugghe 1998).  
Sox9 is expressed in a wide variety of tissue types, even though chondrogenic tissues 
make up the biggest percentage. Its spatiotemporal expression pattern is controlled by 8 sets of 
highly conserved enhancers located up to 290kb 5‟upstream and 95kb 3‟ downstream of Sox9 
in mouse (Bagheri-Fam et al.) The BMP2-Noggin pathway, parathyroid hormone-related 






form part of the network regulating Sox9 expression and function (Yano, Kugimiya et al. 
2005) (Huang, Zhou et al. 2000; Huang, Chung et al. 2001; zur Nieden, Kempka et al. 2005; 
Mackie, Ahmed et al. 2008; Pan, Yu et al. 2008). Other factors essential for chondrogenesis 
include IGF-1, FGF-2, Ihh, TGF-beta and various Wnt proteins (Ikeda, Kamekura et al. 2004). 
 Sox9 expression begins at 8.5 d.p.c. mouse embryos. At this stage, it is expressed in 
the three major precartilaginous mesechymyl condensations, which eventually form the 
cartilaginous skeletal structure. The first condensation occurs in the first and second branchial 
arches that go on to form part of the craniofacial skeleton. The second condensation occurs in 
the sclerotomes where precursors for the axial skeleton reside. The third condensation occurs 
in the lateral plate mesoderm from which the appendicular skeleton arise. Sox9 expression 
peaks at 11.5 to 14.5 d.p.c. where it is expressed in cartilage tissue of the craniofacial region, 
the rips, vertebral column and limbs. It is also expressed in non-cartilaginous tissue such as the 
gonads, heart, notochord, neural tube, otic vesicle and certain areas of the brain (reviewed in 
Lefebvre, Crombrugghe 1998). Sox9 continues to be expressed in the brain and skin of 
neonates (Lefebvre, Huang 1997). 
Sox9 is necessary for cartilage formation, but a single copy is sufficient (Bi, 1999). 
Longitudinal growth occurs at the growth plates of endochondral bones, where chondrocytes 
flatten and proliferate unidirectionally. Chondrocytes secrete an extracellular matrix largely 
consisting of TypeII Collagen and the proteoglycan Aggrecan, thus enlarging the cartilage. 
When proliferation ceases, the cells become hypertropic and Sox9 expression is shut off. (Bi, 
Huang et al. 2001). Hormones like T4 are responsible for shutting down Sox9 expression and 
thus inducing hypertrophy (Okubo and Reddi 2003). SOX9 is degraded by the 26S 
proteosome after ubiquitination (Akiyama, Kamitani et al. 2005). Hypertrophic chondrocytes 






form a scaffold for invading osteoblasts. Hypertrophic chondrocytes then terminally 
differentiate by expressing bone-specific genes and then undergo apoptosis (Ikeda, Kawaguchi 
et al. 2005).  
The surrounding calcified cartilaginous matrix is then degraded and replaced by 
vasculature and bone (Eames, Sharpe et al. 2004). Osteoblasts are cells surrounding the 
hypertrophic chondrocytes. Together with the blood vessels and osteoclasts, they invade the 
mineralized cartilage and are responsible for depositing bone on the degraded matrix scaffold. 
Like chondrocytes, osteoblasts also come from Sox9-expressing mesenchymal precursors 
(Akiyama, Kim et al. 2005). From these common precursors, chondrocytes can form as SOX9 
inhibits osteogenesis to push cells down the chondrogenic lineage by exerting a dominant 
inhibitory effect over RUNX2, the master regulator of osteogenesis (Zhou, Zheng et al. 2006). 
Mineralization of matrix is dependent on alkaline phosphatase activity. Alkaline 
phosphatase is a membrane bound enzyme that hydrolyses organic phosphocompounds like 
extracellular pyrophosphate. Without alkaline phosphatase, chondrocytes are unable to 
undergo terminal hypotrophy (Encina, Billotte et al. 1999; Mackie, Ahmed et al. 2008). Both 
hypertrophic chondrocytes and secondary cartilage have alkaline phosphatase activity and 
Collagen Type 1 (Shibata, Suda et al. 2006). 
Secondary cartilage formation arises when bone precursor cells respond to mechanical 
stimuli at articular surfaces of bone. These cells express Sox9, Runx2, Col2, Col10 and Ihh and 
undergo hypertrophy as well. Here, Sox9 is responsible for responding to external stimuli such 
as mechanical stress and initiating the secondary cartilage formation (Eames, Sharpe et al. 
2004).  






(Uusitalo, Hiltunen et al. 2001).  The repair mechanism can be induced by conditions such as 
hypoxia (Lafont, Talma et al. 2008), hydrostatic pressure (Mio, Kirkham et al. 2007), 
increased loads (Papadopoulou, Papachristou et al. 2007) and compression (Takahashi, 
Nuckolls et al. 1998). Decreased Sox9 expression is correlated with cartilage degeneration in 
osteoarthiritis (Tew, Clegg et al. 2007). Sox9 gene therapy has been proposed for diseases with 
cartilage degeneration (Paul, Haydon et al. 2003) (Salminen, Vuorio et al. 2001).  
Sox9 is responsible for the proliferation and differentiation of chondrocytes during 
chondro-osteogenesis, but not patterning. Patterning involves transcription factors of the HOX 
and PAX families (Panda, Miao et al. 2001) although Hox genes have a regulatory effect on 






2.3.2 Sox9 targets, functions and expression patterns 
A number of downstream genes regulated by Sox9 have been identified, enabling us to 
use their expression profiles as positive controls to validate the transcription profiles of our 
isolated Sox9-expressing cell population. Many of these downstream genes identified are 
cartilage-related and are used as chondrogenic-exclusive markers. Most chondrogenic-
exclusive markers are secreted into the extracellular matrix, like the collagens e.g. Collagen 
Type II, and the proteoglycan e.g. Aggrecan(zur Nieden, Kempka et al. 2005). These proteins 
play both a structural role and a receptor-mediated cell-signaling role. Chrondrocyte survival 
is dependent on Collagen Type II generated signals (Mackie, Ahmed et al. 2008). 
Sox9 expression is well studied, providing a reference point from which to monitor the 
effect of the transgenic proteins and to monitor the effectiveness of the sorting method and its 
outcome on the gene expression profiling of Sox9 expressing cells. In addition to the 
chondrogenic cells, Sox9 is expressed in many other cell types and tissues, to regulate their 
development.  
The role of Sox9 in sex determination is well known. Absence of Sox9 function results 
in complete XY sex reversal. In humans, duplication of the Sox9 locus was found to produce 
complete female-to-male sex reversal, and in mice, aberrant overexpression of Sox9 can 
substitute for Sry as a testis-determining factor (Barrionuevo, Bagheri-Fam et al. 2006). Sox9 
alone is sufficient for testis development, as ectopic expression of Sox9 in XX gonads induce 
testis formation (Vidal, Chaboissier et al. 2001) (Wilhelm, Hiramatsu et al. 2007). 
Upregulated by Wt1, Sox9 acts downstream and is a direct target of Sry in mammalian sex 
determination (Sekido and Lovell-Badge 2008) (Kojima, Hayashi et al. 2008) (Qin and Bishop 
2005) (Chaboissier, Kobayashi et al. 2004) (Guo, Hammes et al. 2002; Gao, Maiti et al. 2006). 






the developing follicle in the ovary (Notarnicola, Malki et al. 2006) and in the human fetal 
prostate epithelium, where it is necessary for prostate development (Thomsen, Butler et al. 
2008; Thomsen, Francis et al. 2008; Wang, Leav et al. 2008).  
Sox9 is needed for heart valve and septum development, at both early and later stages. 
Sox9 is involved in the proliferation and differentiation of valve precursors and affects ECM 
organization and homeostasis as well. Sox9 expression is maintained through heart valve 
formation, from the precursor cells of the endothelial cushions until the mature valve leaflets 
are formed. Without Sox9, endocardial cushions fail to develop normally due to incomplete 
endothelial to mesenchymal cell transformation of the precursor cells, an important step 
needed for heart valve formation. Cartilage Link Protein is co-expressed with Sox9 during the 
early (13.5 d.p.c.) and late (18.5 d.p.c) stages of valve formation. When Sox9 is conditionally 
deleted only when Col2a1 is expressed, Col2 and Cartilage Link Protein is drastically 
reduced; the valves thicken and the organization of ECM is disrupted (Lincoln, Kist et al. 
2007) (Akiyama, Chaboissier et al. 2004) (Rahkonen, Savontaus et al. 2003) (Montero, Giron 
et al. 2002). 
In pancreatic development (Seymour, Freude et al. 2007) Sox9 is highly expressed in 
the early pancreatic epithelium. Sox9 is expressed when prepancreatic endodermal cells 
differentiate into the primary pancreatic progenitor. Markers of the primary pancreatic 
progenitor include Nkx2.2, Nkx6.1, Gata4, Gata6, Sox4, Hb9, Pdx1, Tcf2, Ptf1a, Foxa2, and 
Onecut1. These cells differentiate into either the primary endocrine cells or the secondary 
pancreatic progenitor, where Sox9 is still expressed, together with Gata6, Sox4, Tcf2, Foxa2 
and Onecut1. The expression of Sox9 is maintained by Foxa2 and, together with Tcf2 and 
Onecut1, they form part of the transcriptional network necessary for pancreatic organogenesis 






In intestinal crypt stem cells Sox9 expression is controlled by the action of insulin and 
is a direct target of Beta-catenin (Ramocki, Wilkins et al. 2008) (Mori-Akiyama, van den Born 
et al. 2007) (Bastide, Darido et al. 2007) (Blache, van de Wetering et al. 2004). 
Sox9 is extensively involved in nervous development. It is necessary for notochord 
maintenance (Barrionuevo, Taketo et al. 2006). Together with Sox10, Sox9 is necessary for 
myelin-forming oligodendrocyte specification in the central nervous system (Finzsch, Stolt et 
al. 2008) and acts together with Snail2 to promote neural crest development (Cheung and 
Briscoe 2003; Sakai, Suzuki et al. 2006). Sox9 is involved in glial cells differentiation in the 
brain (Pompolo and Harley 2001) and in the developing spinal cord by mediating the switch 
from neurogenesis to gliogenesis (Stolt, Lommes et al. 2003). 
Other areas where Sox9 plays a role in organ development include the lung (Perl, Kist 
et al. 2005), the inner ear (Barrionuevo, Naumann et al. 2008), the formation of teeth 
(Mitsiadis, Mucchielli et al. 1998) and in the skin, where Sox9 is needed (Garcia-Borron 2008) 






2.3.3 Sox9 mutant phenotypes 
Sox9 is necessary and sufficient for chondrogenesis (Hargus, Kist et al. 2008) (Kim, 
Do et al. 2005) and for the normal development of skeletal structures, such as the limbs 
(Akiyama, Stadler et al. 2007) and craniofacial regions (Nie 2006) (Bi, Huang et al. 2001). 
Knowing the phenotype of embryos or tissues with Sox9 insufficiency enables us to monitor 
any effects that targeting the Sox9 locus might have. 
Chimeras derived from both wildtype and Sox9-/- ES cells show that only wildtype 
cells contribute to the cartilaginous tissue. Teratomas derived Sox9-/- ES cells are unable to 
form cartilaginous tissue, while typeII collagen, Col9a2 and Agc expression was undetectable, 
unlike in teratomas derived from wildtype ES cells (Bi, Deng et al. 1999). Sox9-/- mice die at 
11.5 d.p.c., at the onset of testicular morphogenesis, of heart valve defects (Lincoln, Kist et al. 
2007).  
When a single Sox9 allele is knocked out, the heterozygotes die within 20 hours post-
partum, due to breathing difficulties. They have multiple deformities due to abnormal cartilage 
and skeletal development. They display hypoplasia of all bones that form through 
endochondral ossification of cartilage and these abnormalities begin to surface at 10.5 d.p.c. 
Many of the skeletal deformities observed in heterozygote mice are also observed in human 
Campomelic Dysplasia patients (Bi, Huang et al. 2001).Another paper reports that Sox9 
heterozygotes show early embryonic lethality with only an eighth of embryos progressing 
beyond 11.5 d.p.c. Death comes from a whole host of abnormalities including abnormal neural 
crest development, cardiac failure due to defective heart valve development and abnormal 
skeletal development (Barrionuevo, Bagheri-Fam et al. 2006). In order to generate Sox9 







2.3.4 Sox9 dysfunction in human disease conditions 
In addition to being a key player in mammalian development, Sox9 is also implicated 
in various medical conditions. The study of how Sox9 is regulated and how it regulates various 
biological processes would shed light on potential treatments.  
Campomelic Dysplasia (Fig. 2.3) is caused by mutations to Sox9 or the cis-regulatory 
elements of Sox9(Leipoldt, Erdel et al. 2007) (Velagaleti, Bien-Willner et al. 2005) (Pop, 
Zaragoza et al. 2005) (Olney, Kean et al. 1999) (McDowall, Argentaro et al. 1999) (Wunderle, 
Critcher et al. 1998). Most children with the disorder die within their first year; only about 5- 
10% of patients survive. Phenotypes of Campomelic Dysplasia includes autosomal sex 
reversal in three-quarters of males, (Hsiao, Tsai et al. 2006) skeletal structural abnormalities, 
upper respiratory problems, recurrent apnoea and learning difficulties (Mansour, Offiah et al. 
2002).  
Sox9 has also been implicated in various cancers, including intestinal cancers (Chang, Ueng et 
al. 2008), bladder cancers (Aleman, Adrien et al. 2008), prostate cancers (Wang, McKnight et 
al. 2007), ovarian cancers (Malki, Bibeau et al. 2007) and Sertoli cell tumors (Zhao, 
Bratthauer et al. 2007). RAR-agonists inhibit growth-factor stimulated proliferation of many 
































Section 3.1 Endpoint Polymerase Chain Reaction (PCR) 
For cloning work where point-mutation-free PCR products had to be generated, either 
the Roche High Fidelity Kit, Roche Long Template PCR kit or the Eppendorf TripleMaster 
(later bought over and marketed as Qiagen LongRange) PCR kits were used, according to the 
manufacturer‟s directions.  
For screening of bacteria colonies by PCR, the Qiagen Hotstar kit was used. For 
screening of ES cells by PCR where the amplicon length was longer than 1kb, either the 
Roche Long Template PCR kit or the Eppendorf TripleMaster (later bought over and marketed 






Section 3.2 Western Blotting 
3.2.1 Protein extraction 
Three main methods of protein extraction for Western blotting purposes were used. 
To obtain whole cell lysates, harvested cells were washed with PBS, homogenized in 2 
packed cell volumes of NP40 cell lysis buffer (150mM NaCl, 50mM TrisHCl pH 8, 1% NP40, 
1 mini EDTA-Free Protease Inhibitor Tablet (Roche) per 10ml buffer), subjected to 3 freeze-
thaw cycles and the unwanted debris pelleted down at 16,000g 10-20min, 4˚C. The 
supernatant was then boiled for 5 minutes with standard Laemli loading buffer. 
To obtain crude whole cell lysates quickly, harvested cells were homogenized in 2 
packed cell volumes of SDS cell lysis buffer ( 0.125M Tris-Cl pH6.8, 4% SDS, 2% Beta-
mercaptoethanol), subjected to 1 freeze-thaw-cycle, boiled for 10min and the unwanted debris 
pelleted down at 16,000g 10-20min, 4˚C. The supernatant was then boiled for 5 minutes with 
standard Laemli loading buffer.  
To obtain nuclear lysate, the Pierce NE-PER kit was used according to the 
manufacturer‟s instruction.  
3.2.2 Bradford Assay 
To measure the protein concentration, the Quick Start Bradford Protein Assay 






3.2.3  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated on a 1.5mm thick SDS-PAGE gel in 1x 1X Tris/Glycine/SDS 
Buffer (BioRad, USA) buffer, at 80 – 120V, using the BioRad Mini-Protean System until 
good resolution of protein ladders were obtained.  
3.2.4 Gel transfer 
Proteins were transferred onto nitrocellulose membranes in 20% methanol/80% 1x 
Tris/Glycine/SDS Buffer, at 160V for 0.5 to 3 hours, at 4˚C with ice-blocks being changed 
half-hourly, or 40V for 12 to 16 hours, at 4˚C. The Mini Trans-Blot Electrophoretic Transfer 
Cell (BioRad, USA) was used. 
3.2.5 Immunoblotting 
After the transfer, the nitrocellulose was stained with Ponceau (BioRad, USA), and 
then washed with TBST. Membranes were blocked for 1 hour at RT, incubated with the 
primary antibody for either 2 hours at RT or overnight at 4˚C and incubated with the 
secondary antibody for 1 hour at RT. Between each step, blots were washed 3 times over 15 
minutes in TBS (BioRad, USA) with 2% Tween (TBST). Blocking and antibody incubations 
were carried out in either 5% non-fat milk/TBST or 5% BSA/TBST if biotinylated proteins or 
antibodies were to be detected. SuperSignal West Pico Substrate ECL (Pierce, USA) was used 






Section 3.3 Southern Blotting 
For each sample, 10 – 20 ug of DNA was digested with 20 to 80 units of restriction 
enzymes (RE) at the RE‟s optimal working temperature for 6 to 16 hours, with spermidine 
added to increase the efficiency of RE digest. To digest BAC DNA, 5 to 100 ng of BAC DNA 
was digested with 20 to 80 units of restriction enzymes (RE) at the RE‟s optimal working 
temperature for 1 hour, with spermidine added as well. 
RE digested DNA was run on a 0.8% 1xTAE gel, at 20-30V over 12 – 48 hours, in the 
absence of ethidium bromide. Ethidium bromide visualisation was done after gel 
electrophoresis, followed by 2 half-hour incubations of the gel in 0.5M NaOH. Downward 
transfer onto nylon membranes was done over a 12 hour period or longer. The nylon 
membranes are then washed in 5x SSC for 0.5 hours, blocked with hybridization buffer (50% 
formamide, 0.9M NaCl, 50mM NaPhosphate pH 6.5, 2mM EDTA, 2x Denhart‟s, 1% SDS, 
0.5mg/ml freshly boiled Salmon Sperm DNA) for 1 hour at 42˚C and then hybridized with the 
probe overnight at 42˚C in rotating glass bottles.  
DIG-labelled probes were synthesized using the PCR DIG Probe Synthesis Kit 
(Roche). 200ng/ml of probe in the hybridisation buffer was used. Probe solutions were re-used 
until no longer working. 5% of fresh probe was added with each use. Washing of the blots 
after hybridisation and detection using the ready-to-use CSPD (Roche) was done according to 
the manufacturer‟s instructions. The temperature of the stringent wash is optimised 






Probes were designed to be between 0.5 to 1.5kb, in regions without significant 
repeats. Repeatmasker (www.repeatmasker.org) was used to identify such regions. External 
probes were designed to target sequences between the RE site used for the Southern Blot and 
the start or end of the closest construct targeting arm. Internal probes were designed along one 






Section 3.4 Cell Culture 
All cells were grown in a 37˚C humidified, 5% CO2  incubator. To freeze cells, cells 
were resuspended in 10%DMSO/culture media, allowed to cool slowly to -80˚C and then 
stored at -150˚C or liquid nitrogen for long term storage 
To passage cells, media was removed from adherent cell cultures and the cells were 
washed briefly with calcium- and magnesium-free Dulbecco‟s phosphate buffered saline (D-
PBS) at room temperature (RT). The cells were detached from culture plates by incubation 
with 0.05% Trypsin with EDTA 4Na (Gibco, USA) at 37˚C, for approximately 5 to 8 minutes, 
or until cells have detached. Cell culture media containing FBS was used to stop the trypsin. 
Cells were pelleted at 700g, resuspended in media and replated on fresh plates. 
3.4.1 ES Cells 
The V6.4 and R1 ES cell lines used were maintained on gelatine-coated plates, co-
cultured with mouse primary embryonic feeders that are either grown to replicative 
senescence or gamma-irradiated for 8 minutes in the blood irradiator at maximum power. 
Dulbecco's modified Eagle's medium (DMEM) 4500mg glucose/L with sodium bicarbonate, 
110mg/L sodium pyruvate and lacking L-glutamine (Biopolis BSF Media Preparation Facility, 
Singapore) is used as the base medium, supplemented with 15% ES-Qualified FCS (Gibco, 
USA), 0.1mM BME, 4mM L-glutamine, 40ug/ml gentamycin sulphate, 1000U/ml LIF, 1mM 






3.4.2 HEK293 cells, NIH3T3 cells 
The HEK293 cell line (ATCC CRL-1573)  and NIH3T3 (ATCC CRL-1658) cell line 
were kind gifts from Dr Lawrence Stanton and Dr Paul Robson‟s lab respectively.  
These were maintained in DMEM with high glucose (Biopolis BSF Media Preparation 
Facility, Singapore) supplemented with 10% standard FBS (Hyclone, USA), 40ug/ml 
gentamycin sulphate. Cells were maintained between 10% and 90% confluency and fed every 
2- 3 days.  
3.4.3 ATDC5 cells 
ATDC5 cells were obtained from Riken (Riken BioResource Center, No.RCB0565. 
Derived from teratocarcinoma AT805, mouse 129 background). They were maintained in 1:1 
DMEM / F12 media (Gibco, USA) supplemented with 5% standard FBS (Hyclone, USA), 
40ug/ml gentamycin sulphate. Cells were maintained between 10% and 90% confluency and 
media refreshed every 2- 3 days. 
3.4.4 FACS Fluorescence Activated Cell Sorting (FACS) 
BD LSR II three-laser at the Biopolis Shared Facility, Singapore, was used for all the 
Fluorescence Activated Cell Sorting (FACS) analysis, using the service provided by the in-
house technical support staff. Essentially, the analysis was done using PBE(D-
PBS/0.5%BSA/5mM EDTA pH 8.0)  as a carrier medium, with each sample containing 
between 10^5 and 10^8 of single cells resuspended in 1ml of PBE. Wildtype, pretransfected 






100,000 cells were analysed to obtain statistically significant readings.  
To stain dead cells with Propidium Iodide (PI) (Invitrogen, USA), 2ul of PI was added 
to 1ml of cell suspension in PBE and incubated for at least 15 min, but not more than 1 hour, 
in the dark at room temperature, before FACS analysis.  
The voltage settings for the following parameters were kept constant. For experiments 
using embryo-dissociated cells: FSC: 340, SSC: 280, GFP: 400. For experiments using 
teratoma-dissociated cells: FSC: 510, SSC: 310, FITC: 500. For cell cultures: GFP: 350. The 






Section 3.5 DNA Manipulation 
3.5.1 DNA extraction and purification 
Genomic DNA (gDNA) was prepared by first digesting the cells or tissue in 
approximately 5ml/g of Proteinase K digestion buffer (20mg/ml Proteinase K stocks) at 37˚C 
overnight, with Proteinase K added to a final concentration of 0.1 mg/ml (for cells) or 56˚C 
overnight with Proteinase K added to a final concentration of 1mg/ml (for tissue). Next, an 
equal volume of Phenol:Chloroform:IAA, 25:24:1, pH 7.9 (Ambion, USA) was added, 
homogenized and separated. gDNA was precipitated from the aqueous phase with absolute 
ethanol, washed with 70% ethanol and resuspended in water.  
To extract gDNA for high throughput PCR screening, the ZR-96 Genomic DNA-
Tissue MiniPrep kit (Zymo Research, USA) was used, according to the manufacturer‟s 
instructions. 
Plasmid DNA was extracted using the Qiaprep Spin miniprep kit, or HiSpeed Plasmid 
Maxi kit (Qiagen, USA) according to the manufacturer‟s instructions. 
Bacterial Artificial Chromosome (BAC) DNA was extracted by resuspending the 
E.coli pellet in P1, followed by P2 and P3 solutions of the Qiagen HiSpeed Plasmid Maxi kit. 
The precipitate was pelleted, the DNA in the supernatant precipitated with 0.7 volumes of 
isopropanol and washed with 70% ethanol. The BAC DNA pellet was resuspended in TE, an 
equal volume of Phenol:Chloroform:IAA, 25:24:1, pH 7.9 (Ambion, USA) was added, 






absolute ethanol, washed with 70% ethanol and resuspended in water. 
Gel purification was carried out using either the Zymoclean Gel DNA Recovery Kit 
(Zymo Research, USA) or QIAquick Gel Extraction Kit (Qiagen, USA). Enzymatic reaction 
clean up of DNA was performed using DNA Clean-up & Concentrator 5 (Zymo Research, 
USA) or QIAquick PCR Purification Kit (Qiagen, USA). The maufacturers‟ instructions were 
followed.  
DNA was quantified using the Nanodrop1000.  
3.5.2 Restriction Enzyme digestion  
Restriction enzymes were purchased from New England Biolabs (New England 
Biolabs, USA). Between 5 and 20 unit-hours of enzyme per ug DNA, at the optimal digestion 
temperature, in the optimal buffer supplied, was used.  
3.5.3 DNA ligation 
1ul of T4 DNA Ligase at, 2,000,000 cohesive end units/ml (New England Biolabs, 
USA) was used to ligate a total of about 50 - 200ng of 1: 3 - 10 vectors: insert DNA, in a 10ul 
reaction volume, for 15 – 60 min, at room temperature.  
3.5.4 DNA cloning and amplification in E. coli 
50ul of chemically competent E.coli was transformed with either 1ng of purified 
plasmid DNA, or 5 to 20ng of ligation reaction, by heat shock for 30 – 45 seconds at 42˚C. 






a XL1 Blue E.coli (Strategene, USA) or TOP10 E.coli (Invitrogen, USA) was used. When 
working with plasmids above 10kb, Stbl-2 E.coli (Invitrogen, USA) was used.  
BACs transformed into DH10B E.coli were purchased from CHORI, USA. All further 






Chapter 4. Pilot studies of MACS using Lngfr:  






Section 4.1 Introduction 
4.1.1 The aims and experimental set up Aims and experimental set up of pilot study 
Our ultimate aim was to generate transgenic mouse lines that express a transgenic cell 
surface marker under the control of the chosen gene of interest, which in our case was Sox9. 
This way, by digesting the mice tissues to single cell suspensions and applying MACS, we 
would isolate all the cells expressing the gene of interest because the cell surface marker was 
co-expressed. This called for the targeted modification of the endogenous Sox9 locus by 
homologous recombination, a process requiring much time, effort and financial input. Hence 
before we begun, we wanted to ensure that MACS did indeed live up to its name. Although 
many groups have reported that MACS is a quick method for isolating specific cell 
populations from a heterogeneous mix to a high degree of purity, we wanted to confirm if this 
was indeed so in our hands. To do this with minimum time, effort and financial investment, 
we used a cell culture model to determine the purity and recovery of MACS in our hands. 
For convenience, we decided to use a commercially available MACS system and we 
had to select the most suitable one for our eventual purpose of isolating specific cell 






4.1.2 Reasons for choice of Miltenyi’s MACS system 
To do the MACS, we wanted to make use of a convenient, commercially available 
system, one where antibody-beads and magnetic columns were optimised for cell sorting. Our 
literature survey revealed that almost all the published MACS research made use of either one 
of two commercial MACS systems: Miltenyi‟s MACS system, or Invitrogen‟s Dynal beads 
system (Fig. 4.1). 
Historically speaking, the magnetic separation of cells was initially carried out by 
labelling cells with large (diameter > 0.5um) magnetic beads and separating the labelled cells 
with a strong magnet placed against the external wall of the tube. The unlabelled fraction 
would then be removed by decanting or aspirating. This method of magnetic separation 
depleted unwanted cells efficiently, but positive selection of desired cells could not yield 
samples of high purity. When magnetized, the large beads also tended to aggregate and 
trapped cells non-specifically as a result. Optical properties of the labelled cells were altered 
and this complicated subsequent downstream FACS analysis. Eukaryotic cells are typically 
about 10um in diameter. The large beads interfered with cell viability and were difficult to 
detach from the cells.  
By decreasing the magnetic bead diameter to below 0.5um, the beads no longer 
aggregated even when in a magnetic field because of their small magnetic moment. They no 
longer affected the optical properties and viability of the cells and hence eliminated the need 
for removal. The drawback was that although they labelled the cells much faster, they also 






times took significantly longer as well.  
To decrease the time taken for cell separation by small beads, Molday and Molday 
(Molday and Molday 1984) developed the use of small superparamagnetic beads within a high 
gradient magnetic field. In 1984, Owen and Sykes described a method of labelling single cell 
suspensions with a magnetite-antibody conjugate and sorting the cells with high gradient 
magnetic separation as a rapid and efficient method to separate 100 million cells within 5 
minutes (Owen and Sykes 1984).  
 Superparamagnetic beads have a stronger magnetization capacity than paramagnetic 
beads and are made of magnetite crystals. Superparamagnetism is achieved when 
ferromagnetic particles, which are normally permanently magnetized, are reduced to diameter 
size below the critical value of 0.5um. Stefan Miltenyi et al. refined this system further to 
develop Miltenyi‟s Magnetic Cell Separation system (MACS), where 50nm biodegradable 
superparamagnetic beads are used to label cells and separated using the high gradient 
magnetic separation (HGMS) principle. These are ferrit-dextran beads, where sodium 
hydroxide was used to precipitate the ferrit out of a solution of Fe (II) and Fe (III) ions.  
HGMS has previously been used in mining and china clay industries. It has also been 
used to separate red blood cells which can be made paramagnetic due to its high iron content 
(Fig. 4.1 Bottom). These erythrocytes were treated with isotonic sodium dithionite to reduce 
the Fe(III) in haemoglobin to Fe(II), which is paramagnetic.  






wires, are placed in a magnetic field of about 4 Tesla, they disturb the field to produce high 
magnetic gradients and generate very strong magnetic forces in their immediate neighborhood. 
The magnetic strength of these forces goes up to 10^4 Tesla/m compared to the 10 Tesla/m 
generated by the external magnets used to separate cells labelled with large beads. As the 
50nm-bead-labelled cells pass through the column of steelwool wires, the cells only have to 
move over a distance of 0.1-0.2 mm to attach to the wire, as compared to moving through mm 
distances in a fluid medium to attach to an external magnet. The large surface area to volume 
ratio creates a gradient-intensifying effect and allows the cells to be retained over a larger 
surface. The small size also allows a large number of bead-conjugated antibodies to bind to 
the cell surface and cells can be labelled quantitatively. Together, these factors allow the 
labelled cells to be separated rapidly. Unlabelled cells flow through the matrix easily. When 
taken out of the magnetic field, the small steelwool structures and 50nm superparamagnetic 
beads rapidly demagnetize, allowing the elution of labelled cells. The speed and scalability 
that HGMS enabled, meant that separation could now be achieved on a high-throughput, large 
scale. To protect the cells from being damaged by the steelwool wires, and to protect the 
steelwool wires from corrosion, Miltenyi later added a polymer coating to these wires (Owen 
1978; Owen and Lindsay 1983; Owen and Sykes 1984; Miltenyi, Muller et al. 1990; Thomas, 
Abraham et al. 1992) (1996 United States Patent No. 5543289). 
Invitrogen‟s Dynal bead system (Fig. 4.1 Top right) makes use of the earlier non-
HGMS technology. Cells are incubated with magnetic bead-conjugated antibodies in generic 
1.5ml, 15-ml or 50ml tubes and then a strong external magnet is placed against wall of the 
tube, enabling the retention of labelled cells when the labelling and washing solutions are 
removed. Dynal beads come in three sizes: 1 µm, 2.8 µm and 4.5 µm, and are available with 






and ionic exchangers. Due to large sizes, Dynal beads must then be removed from the labelled 
cells (http://www.invitrogen.com/site/us/en/home/brands/Dynal.html). 
Miltenyi‟s MACS (Fig. 4.1 top left) on the other hand, utilizes HGMS technology. 
50nm biodegradable ferrit-dextran superparamagnetic microbeads are used to label cells. The 
starting labeled cell population to be put through the column is termed the „Input‟ fraction. 
They are separated on single-use HGMS columns of different volume and cell-binding 
capacities. These columns are placed within a strong magnetic field when labelled cells are to 
be retained on the columns. Unlabelled cells flow through. The column is washed with 4 
column volumes of cell suspension buffer to remove as much unlabelled cells as possible. The 
first flowthrough and the subsequent flowthroughs after the washes make up the „Unbound‟ 
fraction. The column is removed from the magnetic field when the labelled cells are to be 
eluted off. To elute the labelled cells, 2 column volumes of cell suspension buffer is applied to 
the column and a plunger is used to flush out all the labelled cells at high pressure, as gravity 
alone is insufficient to elute all the labelled cells. Due to their small size and ability to 
biodegrade, removal of the 50nm microbeads from labelled cells is 
unnecessary.(http://www.miltenyibiotec.com/en/NN_21_MACS_Cell_Separation.aspx). 
These eluted cells form the desired cell population that is termed the „Eluted‟ fraction.  
Oren et al. compared Dynal beads from Invitrogen against Miltenyi‟s microbeads, by 
isolating human natural killer cells from peripheral blood. The recovery of cells using Dynal 
beads was ~5.3% against Miltenyi‟s ~13%. The purity of the isolated cells using Dynal beads 
from processed peripheral blood lymphocytes was ~56% against Miltenyi‟s ~88.6% and the 






93.2% using Miltenyi‟s. Neither system affected cellular function as determined by IL-2 
stimulated response. The composition of the different subsets of natural killer cells in the 
isolated fraction did not differ much – T-cells made up ~34% and ~28% of the cells isolated 
using Dynal and Miltenyi‟s beads respectively. To determine if the isolation procedure 
activated the natural killer cells, the level of activation marker CD69 was compared. Dynal 
bead isolation showed three times the level of CD69 expression compared to Miltenyi‟s. 
Sorting with Dynal beads took about 1.5 hours, while sorting with Miltenyi‟s took 1 hour. Due 
to the significantly larger size of Dynal beads, bead removal was necessary, a procedure which 
takes an additional 16 hours. However, using Miltenyi‟s system costs 3–4 times more than 
Dynal beads (Oren, Husebo et al. 2005). 
Because Miltenyi‟s system seemed to have an advantage over Invitrogen‟s Dynal 
beads in every aspect tested, except for cost, we decided to make use of Miltenyi‟s system.  
Miltenyi offers 3 different MACSelect Systems ( 
http://www.miltenyibiotec.com/en/NN_166_MACSelect_Transfected_Cell_Selection_Kits.as
px ). Each MACSelect System utilizes a different extracellular marker – CD4, H-2Kk or 
LNGFR (low-affinity nerve growth factor receptor). Each of these extracellular markers is the 
truncated human versions of the protein, such that they are incapable of transducing further 
intracellular signals. The main advantage of using one of these markers is that expression 
plasmids coding for the extracellular marker, and its associated magnetic-bead conjugated 
antibody marker, are available from Miltenyi. Having this antibody eliminates the need for a 
secondary antibody. Furthermore, the parameters for antibody labelling and MACS had 






claimed was insensitive to trypsin exposure. For that reason, we chose to use the Lngfr as our 
extracellular surface marker.  
For the purpose of clarity and distinction, subsequent use of the term „Lngfr‟ refers to 
Miltenyi‟s truncated Lngfr extracellular surface markers and the endogenous full-length 
LNGFR will be referenced as such. 
The first reported instance of MACS being performed use antibodies against LNGFR 
was when Manent et al. targeted endogenous full-length LNGFR to purify mitotically active 
Schwann cell primary cultures from contaminating fibroblasts, after primary cultures of 
Scwhann cells were made from dissociated peripheral nerves of adult mice. MACS enriched 
the Schwann cell proportion from a starting 34 – 91% to a final proportion of 99%. This same 
method was also applied for the isolation of tumoral Schwann cells from mouse schwannomas 
(Manent, Oguievetskaia et al. 2003) 
Endogenously-occurring LNGFR (also called p75NTR) is the p75 neurotrophin 
receptor that is part of the Tumor Necrosis Factor receptors family. Together with TrkA, it is 
one of the two receptors of the nerve growth factor. It is expressed in the cells of the neural 
system, especially during development, where it is involved in many biological processes such 
as axon elongation, apoptosis, cell cycle control, cell stress modulation, cell growth and 
differentiation. It also has a role in Alzheimer‟s Disease (reviewed by (Dobrowsky and Carter 
2000; Lopez-Sanchez and Frade 2002; Schor 2005; Yamashita, Fujitani et al. 2005; 











4.1.3 Reasons for in vitro optimisation 
To evaluate the usefulness of MACS for achieving our purpose of sorting out gene-
expression-defined specific cell populations, we carried out preliminary tests and optimisation 
procedures on homogenous cell cultures. Homogenous cultures are a good starting point to 
establish the basic techniques and protocols for MACS, prior to modifying them to sort cells 
from more complex starting materials, for several reasons. Homogenous cell cultures are 
likely to sort well with little background, hence antibodies can be tested for their sensitivity 
and specificity and their working concentrations can be titrated, without much interference 
from a wide range of different background sources found in complex samples.  Cell cultures 
are easily scalable and so, compared to obtaining animal tissue, they are cheaper, more 
predictable and present less ethical issues. Cell cultures are also easily manipulated, allowing 
us to use different strategies to evaluate different aspects of the sorting process. 
The extracellular marker to be recognised by the magnetic bead-conjugated antibody is 
expressed in cells by transfecting the cells with its encoding plasmid DNA by lipofection. 
Sorting transfected from non-transfected cells has been reported widely to work, largely due to 
the high level of surface protein expression from multiple copies of the gene being expressed 
in the cell simultaneously. This makes MACS of transfected cells from untransfected cells a 
good positive control for MACS; if the MACS protocol evaluated could not give satisfactory 
results here, it would be unlikely to give satisfactory results with more complex samples and 
hence we would not invest any effort to test it in vivo. Thus, using homogenous cell cultures as 
our first-pass evaluation of different MACS protocols is a fast and simple strategy to 






For in vitro testing, we used two cell lines available in our laboratory that are 
commonly used for transient transfections: the NIH3T3 and HEK293 cell lines. These cell 
lines are transfected with great ease and efficiency using commercially available lipid-based 
transfection reagents 
1
,  express transgenes at high levels and are very easy to culture. The 
HEK293 (ATCC CRL-1573) cell line is a human adherent established immortalised epithelial 
cell line derived from embryonic kidney. The NIH/3T3 (ATCC CRL-1658) cell line is a 
mouse adherent established immortalised fibroblast cell line derived from the embryo of 
NIH/Swiss mouse strain. 
We used a mixture of Enhanced Green Fluorescent Protein (EGFP) expressing 
(EGFP+) cells and non-GFP expression (EGFP-) for MACS, so that FACS analysis could be 
used to monitor the proportion of each cell type in each fraction. By co-expressing EGFP 
either together with or without the extracellular surface molecule, we can expect the EGFP+ 
fraction to make up the Eluted fraction or the Unbound fraction respectively, and hence 
determine the purity and recovery of MACS. 
                                                          
1
  
Fugene HD (Roche)  
http://www.roche-applied-science.com/sis/transfection/index.jsp 
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Section 4.2 Methods 
 
4.2.1 Expression vector construction 
 
 pBAP-EGFP 
To express EGFP with the BAP epitope on its N-terminus, the pEGFP-N1 (Clontech, 
USA) base vector was used and the BAP epitope inserted into its MCS site upstream of and in 
frame with EGFP (Appendix 2.1a).  
The BAP sequence MA G GLNDIFE AQK* IEWHE was used, where K* refers to the 
biotinylated lysine. The oligos 5‟ 
TCGAGATGGCTGGCGGCCTGAACGACATCTTCGAAGCCCAGAAAATCGAATGGCA
CGAAGATACG 3‟ and 5‟ 
GATCCGTATCTTCGTGCCATTCGATTTTCTGGGCTTCGAAGATGTCGTTCAGGCCG
CCAGCCA TC 3‟, when annealed together has an XhoI and BamHI overhang on the 5‟ and 3‟ 
end respectively, enabling its insertion between the XhoI and BamHI sites in the MCS of 
pEGFP-N1. To keep the BAP epitope in frame with EGFP, „GATAC‟ is added before the 
BamHI site. This gives an extra DT to the tag, which is often used at the end of the BAP tag 
too. Linking the BAP tag to the EGFP protein is the a.a. DPPVAT, encoded by the pEGFP-









To express BAP-EGFP and Lngfr together under the control of the same promoter, 
IRES-Lngfr was cloned into pBAP-EGFP after the EGFP coding region (Appendix 2.1b).  
NotI-flanked-IRES-Lngfr was PCR generated with the primers 5‟ 
TCTCCCTCCCCCCCCCCTAAAG 3‟and 5‟ TCACCTCTTGAAGGCTATGT 3‟, using 
pMACS Lngfr-IRES (Miltenyi Biotech, Germany) as a template, and inserted into the NotI 




pMACS Lngfr Neo 
To express Lngfr, the plasmid pMACS Lngfr-IRES (Miltenyi Biotech, Germany) was 
used, with PGK-Neo cloned into its MCS upstream of the IRES-Lngfr, to allow for selection 
by G418 if desired. Hence, there are two promoters, the CMV promoter on the plasmid, 
followed by the PGK promoter, driving both neo and Lngfr. There is only one poly A site, 
after the Lngfr sequence (Appendix 2.1c).  
The PGK-Neo fragment was excised from an existing plasmid with EcoRI and BamHI 
and cloned between the EcoRI and BamHI sites in the pMACS Lngfr-IRES MCS. This 






4.2.2 Transient expression in cells 
Either HEK293 or NIH3T3 cells were used for transient protein expression. To 
overexpress proteins transiently in cultured cells, the cells were passaged 24 hours prior to the 
transfection, such that the cells would be approximately 80% confluent, by plate area 
coverage. For the transfection, either Fugene6 or Fugene HD (both from Roche, USA) was 
used. Fugene6 was used in all cell transfections prior to the release of the newer FugeneHD 
product at the end of 2006. The switch to FugeneHD was made due to its increased 
transfection efficiency and lower cell toxicity.  
When Fugene6 was used, 2.5ug of circular plasmid DNA and 2.5ug of PLUS reagent 
(Invitrogen, USA) was resuspended in 250ul of Optimem(Invitrogen, USA) and incubated for 
at least 5min at room temperature. 6.5ul of Fugene6 was added to another 250ul of Optimem 
and incubated for exactly 5min at room temperature, before the DNA and Fugene6 mixes were 
combined and incubated for 20min. 500ul of the mix was then added dropwise, with gentle 
swirling, to the cells grown in 2ml of appropriate (Section 3.4) normal media on a 6-well-plate 
well. Cell culture media was replaced between 16 and 24 hours later. 
When Fugene HD was used, 2.5ug of circular plasmid DNA was added to 500ul of 
Optimem, followed by 6.5ul of FugeneHD, and incubated for 20min. 500ul of the mix was 
then added dropwise, with gentle swirling, to the cells grown in 2ml of appropriate normal 
media on a 6-well-plate well. Cell culture media was not replaced.  






protocols were scaled up accordingly.  
4.2.3 Magnetic Activated Cell Sorting (MACS) 
Cells were trypsin harvested (Section IV.3.4), washed and resuspended in sterile, 
degassed, calcium- and magnesium-free D-PBS/0.5%BSA/5mM EDTA pH 8.0 (PBE). 
Magnetic-bead-conjugated anti-Lngfr antibody (Miltenyi Biotech, Germany) was added 
according to the manufacturer‟s recommendation: 80ul of antibody was added per 10^7 total 
cells per 320ul of PBE. The cells were nutated for 20 min at room temperature. 1ml of cold 
PBE was then added, the cells pelleted at 200g at 4˚C and resuspended in 1ml of PBE. The 
cells were then put over a 40um single cell filter and through an MS column (Miltenyi 
Biotech, Germany) that was freshly equilibrated with 0.5ml of cold PBE. The column was 
then washed with a total of 2ml cold PBE. Cells were eluted with 1ml cold PBE using the 
plunger, into a second freshly equilibrated MS column. They were washed again and finally 
eluted into a 1.7ml tube with 1ml cold PBE and kept on ice. All subsequent analysis was done 
immediately.  
To remove antibodies from cells, while maintaining their viability, cells were 
resuspended in 3-4 cell pellet volumes of 0.5M NaCl/ 0.2M Acetic acid, incubated on ice for 4 






Section 4.3 Results 
4.3.1 Overview of experimental approach 
In order to evaluate the purity and recovery of the MACS fractions, we set up two 
experiments as follows. To evaluate the purity of the MACS fractions, we overexpressed 
Lngfr in one plate of cells and EGFP in another. We sorted cells expressing Lngfr (Lngfr+) 
from cells expressing EGFP (EGFP+) (Fig. 4.3.1b left) and used FACS analysis to determine 
the percentage of contaminating EGFP+ cells in the Eluted fraction. We hypothesised that if 
MACS was sufficient for our study then Lngfr and EGFP cells would be efficiently separated. 
Ideally, the Eluted fraction should consist of only Lngfr+ cells and no EGFP+  cells, while the 
Unbound fraction should consist of EGFP+ cells and no Lngfr+ cells (Fig. 4.3.1a). The 
Unbound fraction is made up of both the unbound cells flowing through the column while the 
magnetic field is applied, as well as the cells that flow through with the three washes, before 
the bound cells are eluted. On the other hand, to evaluate the recovery of the Lngfr+ cells in 
the Eluted fraction (Fig. 4.3.1b right), we put EGFP under the control of the same promoter 
driving Lngfr expression, by means of an IRES sequence inserted between the Lngfr and 
EGFP sequences. In this way, only the Eluted fraction should consist of Lngfr+ and EGFP+ 
cells. Using FACS analysis, we determined the number of Lngfr+ and EGFP+ cells lost to the 
Unbound fraction, and so determined the recovery of positive cells in the Eluted fraction.  
To express EGFP, cells were transfected with the plasmid construct pEGFP-N1. To 
express Lngfr and EGFP simultaneously, cells were transfected with the plasmid construct 
pBAP-EGFP-Lngfr (EGFP was previously tagged with the small epitope tag BAP for 
convenient protein detection if need be. BAP will be further elaborated on in Chapter 6). To 






cm culture dishes, to achieve sufficient cell numbers so that a minimum of 10^5 cells would 
be present in each fraction for statistically reliable FACS analysis. 10^4 cells are the minimum 
number recommended for statistically significant FACS analysis. The cells were used for 
MACS sorting between 24 and 48 hours after transfection. MACS was done in two different 













4.3.2 MACS with HEK293 cells 
To test the purity and recovery of MACS in HEK293 cells, untransfected HEK293 
cells were used to set the baseline for fluorescence for FACS analysis. 46% of pEGFP-N1 and 
37.5% of pBAP-EGFP-Lngfr transfected HEK293 cells fell above this baseline, giving an 
indication of the transfection efficiency.  
In the first experiment (Fig. 4.3.2a right), pMACS-Lngfr-Neo cells were mixed with 
pEGFP-N1 transfected cells, inclusive of both the fluorescent and non-fluorescent cells, in a 
1:9 ratio. Because the transfection efficiency was not 100%, this cell mixture consisted not 
only of pMACS-Lngfr-Neo and pEGFP-N1 transfected cells, but also consisted of 
untransfected wild-type cells. This mixture had 41.7% fluorescent cells. After MACS, there 
were 49.7% fluorescing cells in the Unbound fraction and 34.5% in the Eluted fraction.  
Because we could not distinguish pMACS-Lngfr-Neo expressing cells from the 
untranfected ones, we assumed that for every fluorescent cell there was in a particular fraction, 
there were 1.2 untransfected cells. Our assumption was based on the fact that the extracellular 
membrane composition of EGFP+ cells were no different from that of untransfected cells, 
because EGFP was an intracellular protein, hence untransfected cells and EGFP+ cells would 
be expected to contribute equally to each fraction. Since the pEGFP-N1 transfected cells 
consists of only 46% fluorescent cells, we assumed that in any given fraction, the ratio of 
EGFP+ to untransfected cells would be 1: 54/46 = 1: ~1.2. This ratio would not take into 






of MACS in this experiment was estimated to be 24.1% and the recovery almost 100%.   
In the second experiment (Fig. 4.3.2.a left), pBAP-EGFP-Lngfr transfected cells, 
inclusive of both the 37.5% fluorescing and 62.5% non-fluorescing cells, were mixed with 
wild-type cells in a 1: 9 ratio. pBAP-EGFP-Lngfr transfected cells express both Lngfr and an 
EGFP with a BAP-epitope tag. The cell mixture had 2.1% fluorescing cells and was used as 
the Input fraction for MACS. After MACS, the Unbound fraction had 0.5% fluorescing cells, 
while the Eluted fraction had 36.9% fluorescing cells. There were 2.25x10^7 cells in the 
Unbound fraction and 1.24x10^6 cells in the Eluted fraction. Based on the percentage of 
fluorescing cells in these fractions, we calculated there were 1.125x10^5 BAP-EGFP-Lngfr 
expressing cells in the Unbound fraction and 4.576x10^5 in the Eluted fraction. 80.27% of 
BAP-EGFP-Lngfr expressing cells were found in the Eluted fraction and 19.73% in the 
Unbound fraction. Calculations based on the percentage of fluorescent cells in each fraction 
showed that the recovery rate was 77.2%
2
. Thus, MACS has a recovery rate of about 80% in 
this experiment, and a purity of about 37%.   
Cells from the different fractions assayed by Western Blotting using antibodies against 
EGFP (Clontech Cat no. 632375) reflected the results of the FACS analysis (Fig. 4.3.2b ) 
Recovery was good :when non-fluorescent cells were spiked with cells expressing both Lngfr 
and EGFP, EGFP could be detected only in the Eluted fraction and not in the Input or 
                                                          
2
 Given that the percentage of wild-type cells and EGFP-Lngfr-expressing cells is 97.9% and 2.1% 
respectively in the Input fraction, 99.5% and 0.5% respectively in the Unbound fraction, and 63.1% and 
36.9% respectively in the Eluted fraction, based on EGFP fluorescence, we calculated the % Recovery 




where the %Recovery =( 36.9x/ 2.1)100% 
 







Unbound fraction. Purity of MACS was poor; when fluorescent cells are spiked with non-












4.3.3 MACS with NIH3T3 cells 
To test the purity and recovery of MACS in NIH3T3 cells, untransfected NIH3T3 cells 
were used to set the baseline for fluorescence for FACS analysis. 36.1% of pEGFP-N1 and 
21.2% of pBAP-EGFP-Lngfr transfected NIH3T3 cells fell above this baseline, giving an 
indication of the transfection efficiency.  
In the first experiment (Fig. 4.3.3.1a), pMACS-Lngfr-Neo cells were mixed with 
pEGFP-N1 transfected cells, inclusive of both the fluorescent and non-fluorescent cells, in a 
1:9 ratio. Again, the transfection efficiency was not 100%, so this cell mixture consisted not 
only of pMACS-Lngfr-Neo and pEGFP-N1 transfected cells, but also consisted of 
untransfected wild-type cells. This mixture had 33.2% fluorescent cells. After MACS, there 
were 33.1% fluorescing cells in the Unbound fraction and 0.2% in the Eluted fraction. Using 
the same assumptions for our calculations as we used for the HEK293 experiment, the purity 
of MACS in this experiment was estimated to be 99. 4%.   
In the second experiment (Fig. 4.3.3.1b), pBAP-EGFP-Lngfr transfected cells, 
inclusive of both the fluorescing and non-fluorescing cells, were mixed with wild-type cells, in 
a 1: 9 ratio. This cell mixture had 2.6% fluorescing cells and was used as the Input fraction for 






fraction had 98.6% fluorescing cells. Calculating from the percentage of fluorescing cells 
within each fraction, we deduced that the % recovery was 28%
3
.  
There were 1.1x10^7 cells in the Unbound fraction and 1.8x10^5 cells in the Eluted 
fraction. Based on the percentage of fluorescing cells in these fractions, we calculated there 
were 2.09x10^5 BAP-EGFP-Lngfr expressing cells in the Unbound fraction and 1.77x10^5 in 
the Eluted fraction. This meant that 45.8% of BAP-EGFP-Lngfr expressing cells were found 
in the Eluted fraction and 54.2% in the Unbound fraction, giving MACS a recovery rate of 
about 45.8% in this experiment. The difference between the recovery rate of MACS when 
calculating based on percentage of fluorescing cells within each fraction (– 28%), compared to 
calculating based on the number of cells counted (– 45.8%,) was probably due to the 
variations in cell numbers in the different samples of the fractions. The purity of MACS in this 
experiment is very high, at 98.6%, as determined by FACS analysis (Fig. 4.3.3.2).   
The cell surface expression of the Lngfr protein depends on the efficiency of the cell‟s 
Lngfr protein synthesis and translocation. To assess the proportion of cells actually expressing 
the Lngfr molecule on the extracellular cell surface, we stained the pMACS-Lngfr-Neo 
transfected NIH3T3 cells with the same anti-Lngfr antibody, but conjugated with FITC instead 
of the magnetic bead. Only 4.1% of the cells were FITC positive. This may explain the low 
recovery rate of MACS with NIH3T3 cells. Assuming that the transfection efficiency of 
                                                          
3
 Given that the percentage of wild-type cells and EGFP-Lngfr-expressing cells is 97.4% and 2.6% 
respectively in the Input fraction, 98.1% and 1.9% respectively in the Negative fraction, and 1.4% and 
98.6% respectively in the Eluted fraction, based on EGFP fluorescence, we calculated the % Recovery 




where the %Recovery =( 98.6x/ 2.6)100% 
 







pMACS-Lngfr-Neo and pBAP-EGFP-Lngfr are similar, both about 21.2%, it would mean 
only about 4.1% / 21.2% = ~ 1/5 of transfected, fluorescent cells actually have enough Lngfr 
on the extracellular cell surface to be detected by the antibody. Hence only about 20% of 
fluorescent cells would be expected to be eluted in the Eluted fraction, which is close to the 
recovery rate of 28% actually observed. This means that the recovery rate of MACS is 
actually satisfyingly high.  
To test this hypothesis, we took cells from the Eluted fraction after MACS of pBAP-
EGFP-Lngfr cells, stripped the antibodies away from the cells and used these “true positives” 
to spike into wild-type NIH3T3 cells. This cell mixture was then subjected to MACS. This 


















4.3.4 MACS antibody binding optimisation 
To see if the manufacturer‟s recommended protocol for anti-Lngfr antibody binding to 
cells could be further optimised to increase the recovery of positive cells, we varied the 
temperature, time and concentration parameters (Fig. 4.3.4) for the antibody-cell incubation.  
NIH3T3 cells were transfected with pMACS-Lngfr-Neo to express Lngfr on their cell 
surface without any EGFP expression. Single cell suspensions were incubated with the FITC 
conjugated anti-Lngfr antibody, washed and FACS analysed. The antibody used here is the 
same as the one used for MACS, but with FITC instead of a magnetic bead conjugated.  
The temperature at which MACS is performed can be crucial for certain applications. 
CD8+ T lymphocytes have been shown to phagocytose the magnetic beads that adhere to the 
cells when incubated together at room temperature and so a lower temperature of 4˚ C had to 
be used throughout (Burkhardt and Merker 2002).  
When cells were incubated at either 4˚C (recommended), 8˚C, room temperature 
(21˚C) or 37˚C for the recommended 20 minutes at an antibody: cell suspension concentration 
of 1:11 v/v, there was no significant difference in the percentage of cells labelled - ranging 
from 1% to 1.3% (Fig. 4.3.4 top left). An untransfected cell control incubated at 37˚C had 
0.3% of cells fluorescing.  






(recommended), 1:5, 1:2.5 or 1:1 v/v for 20 minutes at 4˚C, there was a slight increase in the 
percentage of fluorescent cells, from 1.2% to 1.7% (Fig. 4.3.4 bottom). However, the 
background also increased; the untransfected cell control incubated at a 1:1 v/v concentration 
had 0.4% of cells fluorescing.  
When the time of antibody incubation was increased from 20 minutes to 1 hour at 4˚C, 
at a 1:11 v/v concentration, there was no significant effect; the percentage of fluorescent cells 
was 1.2% after 15 minutes incubation and 1% after 1 hour incubation (Fig. 4.3.4 top right).  
We thus concluded that the manufacturer‟s recommendation was optimal and that there 
was not much variation in antibody binding with variation of the incubation parameters. For 
convenience, we used the manufacturer‟s recommended bead-conjugated antibody: cell 
suspension concentration of 80ul: 320ul per 10^7 cells, incubated for 20 minutes in sterile, 








4.3.5 Cell dissociation optimisation 
The extracellular domain of Lngfr contains 14 trypsin sites (predicted by ExPASy 
PeptideCutter; Appendix 3), such that if the site closest to the cell surface is cleaved, there will 
only be 46 amino acids left for the anti-Lngfr antibody to recognise and bind. As the anti-
Lngfr supplied by Miltenyi is a polyclonal antibody, this shortened fragment would 
theoretically be sufficient for the antibody to bind and retain the cell on the MACS column. 
We wondered, however, if the recovery of positive cells could actually be improved if we did 
not use trypsin in the harvesting of our cells. Eluted cells tend to be more highly fluorescent 
(Fig. 4.3.5.1) than non-eluted BAP-Lngfr-EGFP-expressing fluorescent cells, suggesting that 
the number of available epitopes does play a part, since fluorescence reflects the expression 
level of Lngfr as well.  
To test this hypothesis, we transfected NIH3T3 cells with pBAP-EGFP-Lngfr and 
harvested the cells either with 0.05% Trypsin with EDTA 4Na (Gibco, USA) at 37˚C, for 
approximately 5 minutes, or with 5mM EDTA, which was the concentration used in PBE. As 
a control, we harvested and treated wild-type untransfected cells the same way. As the 
transfection efficiency was about 20%, we did not mix transfected cells with wild-type cells. 
Instead, we performed MACS on the transfected cells directly after harvesting. From our 
previous experiments – where cells had always been trypsin harvested- we knew that only 
about 1/5 of the fluorescent cells, or about 4% of the total number of transfected cells, would 
have sufficient Lngfr on their cell surface to be retained on the column and eluted. Here, we 






the recovery of cells harvested by Trypsin was 3.7%, close to the expected 4% (Fig. 4.3.5.2). 
Given that the transfection efficiency was about 20%, 16.5% of cells recovered meant a 
recovery rate of 82.5% of positive, fluorescent cells, confirming our hypothesis. The recovery 
of cells when wild-type cells were subjected to MACS was 0.26% and 0.32% when trypsin 
and EDTA harvested respectively. 
There was a compromise in the purity of the Eluted fraction however. In this 
experiment, trypsin harvested cells gave a purity of 91.6% while EDTA harvested cells gave a 
purity of 69.7%. There was a huge drop in cell viability (Fig. 4.3.5.2) as well. The increase in 
dead cells being bound non-specifically by the antibody explains the drop in the purity of the 
Eluted fraction and also explains the increase in background observed with the MACS of 


















Section 4.4 Discussion 
Although our overall aim was to generate genetically modified mouse lines expressing 
the extracellular cell surface marker, Lngfr, under the promoter control of our gene of interest, 
Sox9, the extensive amount of effort and cost involved demanded that we do preliminary 
testing and optimisation in simple in vitro systems first. We tested MACS using both HEK293 
and NIH3T3, transfecting them to express either EGFP alone, Lngfr alone or both Lngfr and 
EGFP. The performance of MACS was assessed by mixing cells in fixed, known proportions, 
and doing FACS analysis on the resulting fractions to determine the sorting purity and 
recovery. 
Our experiments showed that high levels of purity and recovery could be obtained, 
even though HEK293 and NIH3T3 cells differed significantly from each other. With HEK293 
cells, the purity of the Eluted fraction was very poor (~24 – 37%), but the recovery was 
excellent (~80 – 100%). With NIH3T3, the opposite was true; the level of purity achieved was 
very high (~98 – 99%) while the recovery was very poor (~28 – 45%). These experiments 
were conducted using the manufacturer‟s recommendations. To determine if these 
recommendations were optimal for our purposes, we carried out our own optimisations by 
testing variations of antibody concentrations, antibody-labelling temperature and duration, as 
well as cell dissociation agents.  
One benefit of using a commercially developed system is that some of the major 
factors determining the success of MACS are already optimised. To isolate specific cell 






low-affinity nerve growth factor (Lngfr) as a unique extracellular cell surface marker. 
Magnetic beads conjugated with anti-Lngfr antibody bind to cells expressing the marker and 
can be separated from the unbound population by magnetism. This commercially developed 
human Lngfr has been truncated so that only its transmembrane and extracellular domains are 
left. The truncated Lngfr is no longer capable of cell signaling and is supposedly insensitive to 
trypsinization. Specific, high affinity antibodies against the human Lngfr are also 
commercially available. Labelled cells are separated from unlabelled ones on Miltenyi‟s 
MACS columns, which utilise the HGMS technology. 
 In their original paper, Miltenyi et al. reported that MACS was found to be affected by 
the extent to which each cell was labelled, the capacity and consistency of the ferromagnetic 
matrix, as well as the speed and volume of the washes. To ensure that unlabelled cells were 
removed thoroughly, high flow (several column volumes/ min) and wash rates were 
recommended, whereas to ensure that recovery of labelled cells were high, slow flow rates (1 
column volume/min) were necessary (Miltenyi, Muller et al. 1990). Later, Busch et al. also 
made similar observations. He found that depletion was most efficient at low flow rates of 
0.1ml/min, while enrichment rates were optimal at high flow rates of 0.35ml/min (Busch, 
Huber et al. 1994). These parameters are primarily dependant on the design of the column and 
the recommended protocol was already optimized to be in line with Miltenyi et al.‟s 
recommendations.,  
The fact that the two different cell lines yielded opposite results suggested that the cell 
type made a significant difference to the performance of MACS. When NIH3T3 cells were 






but only about 1/5 of the transfected cells were recovered in the Eluted fraction. However, 
when NIH3T3 cells that expressed only Lngfr were stained with fluorescent antibody, only 
~4% of the cells were stained. Taken together, they suggested that only 1/5 of successfully 
transfected NIH3T3 cells expressed sufficient Lngfr at the extracellular cell surface for 
MACS. Further evidence supporting this hypothesis was given by stripping the antibodies 
from the cell surface of eluted EGFP+/ Lngfr+ cells and mixing them with untransfected cells 
to be sorted again. This time almost all the cells were recovered in the Eluted fraction.  
Rubbi et al. made an observation which could be an alternative explanation for the low 
number of cells displaying sufficient Lngfr on the cell surface. The magnetic-bead conjugated 
antibody was observed to detach significant amounts of antigens from the cell surfaces, giving 
rise to viable cells with their antigens depleted (Rubbi, Patel et al. 1993) and these cells would 
not be retained on the column to be eluted in the Eluted fraction. In addition, cells like 
macrophages have been reportedly challenging to MACS, because they can internalize the 
primary antibody used to label the cells, preventing bead-bound secondary antibodies from 
binding (Ordog, Redelman et al. 2004). This phenomenon may also explain our results with 
NIH3T3‟s low recovery.  
The level of magnetic bead-conjugated antibody binding to cells correlates with the 
level of cell surface epitope expression (Swann, Dealtry et al. 1992). Another explanation for 
the low recovery with NIH3T3 cells is that there is insufficient bead-conjugated antibody 
bound to the surface of cells in 80% of successfully transfected cells. This is supported by the 
observation that the Eluted fraction contains very brightly fluorescent cells. Studying the 






there was still sufficient epitopes available after trypsin removal of much of its N-terminus 
portion for the polyclonal antibody to bind to. We experimented with harvesting cells using 
EDTA instead of trypsin and we found that by increasing the amount of antibody epitopes, 
and hence more cell-bound-beads, on the cell surface, the recovery improved to ~80%. The 
unrecovered 20% probably do not have sufficient epitopes for enough beads to be bound, even 
when Lngfr is not trypsin-cleaved. However, EDTA is toxic to the cells and the viability of 
EDTA harvested cells is lower than that of trypsin harvested cells. The increase in the number 
of dead cells resulted in a corresponding increase in non-specific antibody binding, which 
significantly lowered the purity of the Eluted fraction.  
In the case of the HEK293 cells, the low purity of the Eluted fraction suggests that 
untransfected HEK293 express either cell surface proteins that cross-react with the anti-Lngfr 
antibody or endogenous LNGFR. The high recovery rate also lends support to this explanation 
because endogenous cell surface proteins would increase the amount of epitopes available for 
the bead-conjugated antibody to bind. However, this protein does not seem to be expressed 
uniformly at sufficiently high levels because most of the untransfected cells still flow through 
in the Unbound fraction.  
Our efforts at varying the antibody concentration did not produce any substantial 
difference in the proportion of labelled cells. We did not think that the low recovery of MACS 
with NIH3T3 cells was substantially due to suboptimal antibody labelling conditions. Thomas 
et al.observed that lowering the antibody concentration did not decrease the level of 
contaminating non-specific cells, but resulted in a lower recovery of desired cells instead 






gave us further confidence that the manufacturer‟s recommendation was optimal for our 
purposes and that our problem of low purity with HEK293 cells could not be solved by 
altering the antibody labelling conditions. Our observations also showed that the 
manufacturer‟s recommendations of antibody labelling temperature and duration were optimal 
for our purposes.  
Because both the HEK293 and NIH3T3 cell lines were merely a system for us to test 
the MACS using the Lngfr cell surface marker, and also because the system was eventually to 
be used for different cell types from tissue, we invested no further effort in determining the 
exact causes of the issues we faced with the cell lines, given that the causes stemmed from the 
nature of the cells itself rather than with the MACS system. This included doing replicate 
experiments to establish the standard deviations for the sorting purity and recovery of each 
experiment, as we had already shown qualitatively that the MACS worked.  
We were confident of the MACS system itself, because it was capable of sorting cells 
to almost 100% purity and 100% recovery in our hands, depending on the cell types and 
dissociation methods used. We rationalised that if the cell types themselves were an important 
factor affecting MACS, then the only way we would know if they would work with tissues 






Chapter 5. Single step MACS of tissue-dissociated 
cells: Background levels of non-specifically 






Section 5.1 Introduction  
Having established the success of MACS based on the presence or absence of 
extracellular cell surface truncated Lngfr, to which magnetic bead-conjugated anti-Lngfr 
antibodies bind, we now wanted to move from developing the MACS method in a 
comparatively homogenous cell culture system to one that is a lot more complex – that of cells 
from animal tissue.  To this end, we aimed to generate transgenic mice from modified ES cells 
whose endogenous Sox9 coding region was modified to express the truncated Lngfr under 
endogenous Sox9 promoter control. In these Sox9
+/Lngfr 
ES cell lines and transgenic mice, one 
Sox9
 
allele would be modified only, so that the transgenic Lngfr was co-expressed in the same 
cells with Sox9. Due to the long duration required to generate transgenic mice, we pursued two 
other different strategies in parallel. The first parallel strategy was to perform MACS on 
teratoma samples generated from the Sox9
+/Lngfr
modified ES cell lines. The second parallel 
strategy was to perform MACS on wildtype mouse embryos to determine what the 
background level of non-specifically binding cells in the Eluted fraction was.  
5.1.1 Experimental aim and set up 
Our ultimate goal was to develop a method of sorting specific cell populations from 
complex tissues, where the cell populations were defined by their gene expression rather than 
cell surface marker expression. To achieve this, the desired cell population in the animal must 
co-express a unique cell surface marker together with the gene of interest. To prove our 
principle, we aimed to isolate cells from mice tissues that express Sox9 at the mRNA level.  






to keep the expression pattern of our transgenic Lngfr as close as possible to that of the gene 
of interest, Sox9. We wanted to express the transgenic Lngfr under the endogenous Sox9 
promoter‟s control, within the endogenous Sox9 coding region itself, using the Sox9 
translation start site (Fig. 5.1.2). By targeting the Sox9 locus itself, we ensured that the 
transgenic Lngfr was regulated by the same enhancers and suppressors, and was subject to the 
same locus effects as Sox9, so that its expression pattern will be as close to that of Sox9‟s 
itself. Since homologous recombination technology to target specific genes in embryonic stem 
cells was available for mice, and these modified embryonic cells could be used to generate 
whole animals with the modified genotypes, we decided to use the mouse as our model 
organism. Our goal was to obtain transgenic embryos at various developmental stages, from 
which Sox9-expressing cells could be sorted out, so that we could study how Sox9 controlled 
chondrogenic differentiation in vivo. The mouse is also one of the most well studied model 












5.1.2 Reasons for the choice of Sox9 
We chose to use Sox9 as our model transcription factor for the development of the 
MACS strategy for several reasons. Firstly, Sox9 is a very highly expressed gene and it is 
extensively expressed in the developing skeleton, which is a relatively large organ in the 
developing mouse embryo. This would mean that there would be a significant number of cells 
highly expressing the transgenic Lngfr on its surface. Since we did not know the level of Lngfr 
on the surface that is needed for a cell to be successfully retained on the column, we decided 
to start with the most highly expressed transcription factor our laboratory had worked with. 
The rationale was that if our protocol could not successfully sort cells based on one of the 
most highly expressed transcription factors, then it would likely fail with any transcription 
factor that was expressed at a lower level than Sox9. In this way, if the protocol we tested 
failed, we could rule out the possibility that there was insufficient Lngfr molecules on the cell 
surface due to it being controlled by a weak promoter and we could thus rule out the 
possibility of the protocol working on a more highly expressed transcription factor, since we 
were already testing our protocol on one of those most highly expressed. The second reason 
why Sox9 was chosen was that its expression pattern (reviewed above in Section 2.3.3) during 
development had already been studied and hence we would be able to correlate the 
transcriptome map at each stage with Sox9‟s function at each stage. A third reason for 
choosing Sox9 was that it plays a master regulatory role in chondrogenic development 
(Reviewed in Section 2.3.1). Thus the information gained from mapping out the changes in its 
transciptome will allow us to elucidate the molecular events in chondrogenic stem cell 
differentiation in vivo. Sox9 defects in humans can either be lethal or very debilitating, thus 






5.1.3 Homologous recombination in ES cells 
In 1985, Smithies (Smithies O 1985) pioneered the targeting of endogenous genes 
when he modified the beta-globin gene by homologous recombination in human cells. Later, 
the homologous recombination mechanism was harnessed for gene targeting in mouse ES 
cells, which could then be injected into blastocysts, forming germline transmitting chimeric 
mice, which could produce fully transgenic mice. In 1989, the first transgenic mice that had 
their HPRT locus modified were reported (Thompson, Clarke et al. 1989) . The homologous 
recombination mechanism requires a targeting vector to be introduced into the ES cells, 
mostly by electroporation. The targeting vector consists of the modified DNA sequences 
desired, flanked by arms homologous to the locus being targeted. The total length of these 
arms has to be at least 2kb, with the short arm being at least 0.5kb (Melton 2002) . Generally, 
a longer homology arm increases the frequency of successful homologous recombination 
events amongst cells that take up the targeting vector DNA, but reduces the frequency of cells 
taking up the targeting vector.  
In ES cells, the rate of successful homologous recombination events is typically 1 per 
100 to 1000 DNA integration events and typically between 1 per 10^4-5 ES cells 
electroporated with the targeting vector will take up and integrate the DNA. To select for cells 
that have taken up the targeting vector, the bacterial neomycin phosphotransferase (neo) gene, 
driven by the phosphoglycerate kinase-1 (PGK) promoter, is often used as a component on the 
targeting vector (Adra, Boer et al. 1987) . The addition of a bacterial promoter, such as gb2
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allows neo to be expressed in E. coli as well. neo confers mammalian cells resistance to the 
synthetic antibiotic G418 and bacterial cells resistance to kanamycin (Melton 2002) Insertion 
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of a reporter gene like lacZ (Singh and Knox 1984) or GFP (Prasher, Eckenrode et al. 1992) 
also aids in the identification of homologous recombination events.  
The Cre (Causes REcombination) recombinase (38kDa) recognizes and mediates 
recombination between two loxP (LOcus of crossover (x) in P1 bacteriophage) sequences 
(34bp). Originally derived from the P1 bacteriophage, it can be used effectively in mammalian 
cells because it does not require any other co-factors or accessory proteins, it works optimally 
at 37˚C and the loxP sequence, or any sequence similar enough to be recognised by Cre, is not 
found in mammalian genomes. The short loxP sequence also means that it has minimal effects 
on the locus or gene it has been inserted into. In the process of recombination between the 
loxP sites, the intervening DNA sequence is excised as a circular molecule. One loxP is left on 
the original strand, and another on the excised circular strand. Cre also catalyses the reversed 
reaction (Nagy 2000) (Kuhn 2002).  
In order to select for ES cells that have successfully, albeit randomly, integrated our 
targeting construct, we included the neo gene, driven by both the PGK and gb2 promoters, on 
our construct. This expression cassette was flanked by LoxP sites to enable the neo to be 
removed, in the event that its expression interfered with Lngfr expression. Because Sox9 is not 
expressed in ES cells, we could not select for successful homologous recombination events 
using lacZ or neo that would be driven by the endogenous promoter. Hence, after expanding 
the G418 resistant colonies, we had to screen for the cells where the construct had inserted to 
the Sox9 locus by homologous recombination, from the larger population of colonies where 






5.1.4 ES cell lines used: V6.4 and R1 
We used two different ES cell lines for gene targeting. The R1 line is derived from the 
129/Ola mouse substrain (Nagy, Rossant et al. 1993) . The other line we used was the V6.4 
line. Jaenisch's group has derived 6 F1 hybrid ES cell lines, including the V6.5 line that he 
showed could be successfully gene targeted.  The V6.4 ES cell line that we use was similarly 
derived and shares the same C57BL/6J x 129/Sv genetic background as the V6.5 line (Eggan, 
Akutsu et al. 2001). Inbred lines have the advantage of having well characterised phenotypes 
and tend to breed colonies with fairly uniform phenotypes. However, using inbred lines has 
been observed to result in transgenic mice with lower viability and greater abnormalities 
compared to using ES cells derived from F1 hybrid mice strains (You, Bersgtram et al. 1998) . 
Hybrid lines tend to benefit from hybrid vigour - they have higher viability and fewer 






5.1.5 MACS with teratomas 
The disadvantage of generating transgenic mice using gene-targeted homologous 
recombination technology is the long period of time taken from the construction of the DNA 
targeting constructs, to the generation of transgenic mice. Rather than waiting until we had 
transgenic embryos, we generated teratoma tissue from the modified ES cell lines, on which 
we performed MACS to determine the purity and efficiency of the sorting on tissue material.  
Teratomas are tumorous tissue derived wholly from ES cells. To form teratomas ES 
cells are subcutaneously injected into immunodeficient mice, where the ES cells 
spontaneously and randomly differentiate into all tissue types from all three germ layers. 
These tissue types include cartilage tissue, for whose differentiation Sox9 is essential. 
Teratomas would also contain Sox9 expressing cells of every spatiotemporal stage, unlike 
embryos where only a specific temporal stage would be represented. Thus, teratomas are 
highly complex tissues containing both Sox9- and non-Sox9- expressing cells, to be sorted by 
MACS. Unlike the generation of transgenic embryos, which can potentially take years to 
obtain because of the unpredictability of obtaining the necessary male chimeric mouse able to 
germline transmit at a high frequency, we can consistently get teratomas from injected 
immunodeficient mice, between 2 to 4 weeks after injection (Martin 1975; Martin 1980) . 
Teratomas are benign tumours that quickly grow into a lump of randomly distributed 
differentiated tissue. They are neither metastatic nor retransplantable (Aleckovic and Simon 
2008) which makes teratomas an ideal tissue for in vivo testing of MACS.  






capable of preventing the engraftment and growth of transplanted cells. The three most often 
used immunodeficient hosts are nude, Severe Combined Immunodeficient (SCID) and Rag1 
mice. SCID and Rag1 mice have a more severely compromised immune system than nude 
mice. Between SCID and Rag1 mice, Rag1 mice have no possibility of functional B and T 
cells while SCID mice have a very small percentage of such cells forming after 12 weeks of 
age. However, SCID mice are more easily available in our animal resource facility, cost less 
and can host ES cells derived teratomas satisfactorily for our experiments. Hence we chose to 
use SCID mice. 
SCID mice have defective DNA repair that results in defects in the late phases of 
variable, diversity and joining recombination, needed for antibody production. SCID mice 
have an intact innate immune system, but a crippled acquired immunity.  
Our SCID mice are bred on a C.B-17/IcrHanHsd-Prkdc
scid 
background and have a non-
functional prkdc (protein kinase, DNA activated, catalytic polypeptide) gene, resulting in a 






5.1.6 MACS with wild-type embryos 
To circumvent the long waiting time for the generation of transgenic mice, we also 
performed in vivo experiments in parallel with in vitro preliminary tests, rather than waiting 
for the completion of in vitro tests before proceeding to in vivo tests. Wild-type mouse 
embryos of 12.5 – 14.5 d.p.c. were dissociated to a suspension of single cells. Cultured cells 
(HEK293 or NIH3T3) were transiently made to express both the extracellular cell surface 
truncated Lngfr and EGFP. Cells expressing both Lngfr and EGFP were spiked into the cells 
derived from wild-type mouse embryos. The spiked wild-type mouse embryo cell suspension 
was then subjected to MACS. The EGFP in the Lngfr positive cells enabled each fraction of 
the MACS process to be analysed by fluorescence on a FACS analyser.  
This experimental strategy allowed us to optimise tissue dissociation and MACS 
protocols on wild-type embryos, which are relatively easy to obtain compared to transgenic 
embryos. By performing MACS on wild type embryos, we could also determine the 






Section 5.2 Methods 
 
5.2.1 MACS with other tags Screening of candidate tags for MACS 
MACS was performed as described in Section 4.2.3, except that a list of antibodies to 
different epitopes was used, instead of the magnetic-bead conjugated anti-Lngfr antibody. 
Magnetic-bead conjugated anti-mouse or anti-rabbit antibodies from Miltenyi Biotec 
were used as secondary antibodies, after the primary antibody incubation. These antibodies 
were used in a 1: 4 vol:vol antibody:cell suspension concentration.  
5.2.2 Dissociation and MACS of cells from tissues 
 Dissociation of tissue was carried out by a combination of enzymatic (mainly 
collagenase and dispase) and mechanical dissociation. Embryo or teratoma tissue was cut into 
small pieces of approximately 3mm x 3mm x 3mm. The pieces were immersed in 5 – 10x 
tissue volume of Liver Digest Media (Invitrogen, USA) at room temperature for enzymatic 
dissociation. Mechanical dissociation was employed by pipetting up and down with a wide-
bore 1ml pipette tip, followed by a narrow-bore 1ml pipette tip. Embryo tissue is usually 
completely dissociated to single cells by this step. 5 volumes of cold calcium-, magnesium- 
and phenol red- free Hanks Buffered Salt Solution (HBSS) (Gibco, USA) was added to dilute 
out the Liver Digest Media and reduce the enzymatic activity. Dissociated cells were collected 
by decanting the cell suspension into a fresh tube, leaving the larger pieces of undissociated 
teratoma tissue.  GentleMACS machine (Miltenyi Biotec, Germany) was used to dissociate the 
remaining tissue. The C-columns were used and the tissue pieces in Liver Digest Media were 






HBSS was added and the suspension of dissociated cells were collected at this stage. The 
remaining tissue was then dissociated in Liver Digest Media with pre-programmed protocols 
A and B. Cold HBSS was added again and the dissociated cells were collected . 
Dissociated cells were pelleted, resuspended in cold HBSS, and passed through a 40 
micron single cell filter and collected on ice. The entire process took approximately 1 hour.  
5.2.3 Dead Cell Removal  
The Dead Cell Removal Kit (Miltenyi Biotec, Germany) was used to remove dead 
cells from cell samples, following the manufacturer‟s instructions.  
5.2.4 Alcian Blue Staining 
Freshly harvested animal tissue were fixed in Bouin‟s Fixative (Sigma, USA) for 24 
(embryo) or 48 (teratoma) hours, rinsed in water, then bleached with at least 4 changes of 
1%NH3/ 70% ethanol of at least 1 hour each, until the yellow from the Bouin‟s Fixative  was 
completely removed.  
To perform whole mount Alcian Blue staining of cartilage tissue, the fixed tissue was 
then stained in 0.05%Alcian Blue (Sigma, USA)/ 5% acetic acid for 24 (embryos) or 48 
(teratoma) hours. The tissue sample was then washed in 5% acetic acid three times for 1-2 
hours each and then once overnight. Samples were dehydrated through graded ethanols, 
cleared and stored in 2:1 benzyl alcohol:benzyl benzoate (Sigma, USA).  






graded ethanols, embedded in paraffin wax and sectioned at 7um intervals. Sections on glass 
slides were dewaxed with Histo-clear (AGTC Bioproducts, UK), rehydrated through graded 
ethanols, stained in 1% Alcian Blue 8GX (Sigma, USA) in 3% glacial acetic acid for 30 min 
and washed under running water for 2 minutes. Slides were mounted and stored.  
5.2.5 Sox9 targeting construct for Lngfr knock-in 
A construct was made to knock the extracellular, transgenic truncated human Lngfr 
into the Sox9 locus, immediately after the ATG site of the first exon, and in that process, 
knock out Sox9 by deleting the first 138bp of the first exon (Fig. 5.1.2b). LoxP-flanked Neo, 
driven by both the eukaryotic PGK promoter and E.coli gb2 promoter, was added behind the 
Lngfr sequence. Because Lngfr expression is controlled by the Sox9 promoter, it follows the 
gene expression pattern of Sox9. 
PGK-gb2-Neo was first excised from a pre-existing sequenced plasmid using NotI and 
cloned into the NotI site of pBluescript II SK(+)(pBS), GenBank/EMBL accession number 
X52328 (Fermentas, USA). A SalI and SpeI flanked Lngfr coding region was PCR generated 
from the pMACS Lngfr IRES (Miltenyi Biotech, Germany) vector using the primers 5‟ 
TCTGTCGACATGGGGGCAGGTGCCACCGG 3‟ and 5‟ 
AGAACTAGTATAATCAGCCATACCACATT 3‟, and cloned between the XhoI and XbaI 
site, thereby destroying the XhoI, XbaI, SalI and SpeI sites. This construct, termed pBS Lngfr-
neo (Appendix 2.2a), was then used as a template to PCR generate the Lngfr-LoxP-PGK-gb2-
Neo-LoxP - fragment for RED/ET mediated BAC homologous recombination (Gene Bridges, 







GCAGGTGCCACCGG 3‟ and 5‟ 
CGGGTGTTCTCCGTGTCCGAGCCGGAGCCCGAGGGACAGGGCGAACCAGCATAA
CTTCGTATAATGTATG 3‟. This knocked out 138bp of the first Sox9 exon after the ATG 
site. The modified RP24-248D4 BAC, which contains the Sox9 locus, was digested with 
HindIII and shotgun cloned into the HindIII site of a pBS vector. Kanamycin-Ampicillin dual 
selection was used to select for only those vectors which took up the PGK-gb2-Neo containing 
region. This vector was pSox9 Lngfr Neo (Appendix 2.2b). It was linearized at the unique 
XhoI site and electroporated into both R1 and V6.4 ES cells.  
To screen for modified ES cells, PCR was carried out using the primers 5' CAA ATG 
CCC ACT TCG GAA GA 3' with 5' AGG GCT CAC ACA CGG TCT GGT 3' which gives an 
amplicon size of 2153bp. PCR conditions used were: 1x [94 C 2‟] 10x [94 C 10”, 65  C 30”, 
68 C 2‟] 35x [94 C 15”, 64  C 30”, 68  C 2‟+5”/cycle] 1x [68 C 10‟] 
Confirmation was done by Southern Blot, the gDNA was digested with EcoRI and 
probed with 2 probes, Soxprobe 2 (471bp) and Soxprobe 7 (492bp), external to the 5‟ short 
left homology arm. These were PCR generated with the primer pairs 5‟ 
AACACAGTGGTATCGGCACAG 3' with 5' TTCTGGCACAAAGGCAACGAA 3', and 5' 
GCCTTTGTGCCAGAATACGTG 3' with 5' AATCGGCCTGTATCATATCAA 3', 
respectively. Wildtype Sox9 locus gives a band size of 7kb and the modified one 5.2kb. When 
neo is removed after transiently transfecting mutant with Cre-expressing plasmid, the 
modified Sox9 locus gives a band size of 8.1kb.  






with the primer sets 5' GGCAGACCAGTACCCGCATCT 3' with 5' 
CTCCGCCTCCTCCACGAAG 3', and 5' AAAGTTGATCTGAAGCGAGAG 3‟ with 5' 
GCTGCGTGACTGTAGTAGG 3' respectively. Cells without any constructs integrated give a 
wildtype band size of 7kb and those with the construct integrated in the genome had a 4.5kb 
band.  
The Southern Blot probes PCR used the RP24-248D4 BAC template. PCR conditions 
used were: 1x [95 C 5‟] 7x [95 C 45”, 60  C -1 C/cycle 45”, 72  C 90”] 35x [95 C 30”, 54  C 
30”, 72 C 90”] 1x [72 C 10‟]. These probes were used at a concentration of 200ng/ml. Stringent 
0.5xSSC washes were made at 43˚C.  
5.2.6 Establishing modified ES cell lines 
Plasmid constructs for gene targeting were linearized and sterilized, before being 
introduced into cells by electroporation. R1 and V6.4 ES cells were passaged within 24 hours 
of electroporation and seeded such that the density at electroporation would be 50 – 80% by 
plate area coverage. To electroporate cells, they were harvested, washed and 10^7 cells 
resuspended in 400ul of ES cell media. 10ug of linearized DNA was mixed well into the cell 
suspension, which was then transferred into a sterile 4mm electroporation cuvette (Biorad, 
USA). Cells were then electroporated at 125uFarads, 0.4kVolts, which usually resulted in a 
time constant of about 3milliseconds. The cells were allowed to stand for about 5 – 10min, 
then resuspended in 1ml of media and split equally over 6 gelatin-coated 10-cm plates. A 
control electroporation was done in parallel with water, instead of DNA, added.    






media with G418 added. A range of different G418 concentrations were used for each the 6 
plates – 150, 200, 250, 300, 350, 400 ug/ml. The negative control set was treated the same 
way. When the negative control cells had completely died out, typically after 12 to 15 days, 
colonies were picked from the DNA-transfected plates into 96-well plates. Typically 48 
colonies from each G418 selection concentration were picked.  
Picked colonies were trypsinized the next day and passaged until a 24-well-plate well 
was confluent. Cells were then frozen or harvested and screened for successful gene targeting 
by Southern Blot analysis.  Successfully gene targeted clones were stored as frozen stocks or 
maintained in culture.  
To express Cre transiently in ES cells to remove DNA sequences between 2 loxP sites, 
the same protocol as above was employed, except that only an 80% confluent 24-well-plate of 
cells were used and the Cre expression plasmid was not linearized. Two rounds of G418 
(200ug/ml) sensitivity tests were done to screen for successful neo removal and these were 
confirmed using Southern Blot analysis.  
5.2.7 Generation of transgenic embryos 
ES cells were passaged within 24 hours prior to microinjection into blastocysts, such 
that they were 50% to 80% confluent by plate area coverage. Cells were harvested, washed 
and resuspended in M2 media (Specialty Media, USA). The cells were then sent to an in-
house microinjection service (Genome Inst. Of Singapore Gene Alteration Platform) for 
microinjections in 8-cell stage morulas or blastocysts and reimplantated into surrogate mothers 






Committee ( IACUC )). The C57BL/6J strain of mice was used. C57BL/6J mice are known to 
have good reproductive performance; females have longer and more regular oestrus cycles and 
have large litter sizes (mean litter size of 6.2) compared to other common inbred strains 
(http://www.informatics.jax.org/external/festing/mouse/docs/C57BL.shtml). Chimeric mice 
were identified by agouti patches on their black fur coat and male chimeric mice were mated 
with wild-type C57BL/6 mice. As the Sox9+/- genotype results in embryonic lethality, 
embryos were removed from the mother between embryonic days 10.5 to 13.5 and screened 
for a transgenic genotype by Southern Blotting as described above.  
5.2.8 Generation of transgenic teratomas 
SCID mice on a C.B-17/IcrHanHsd-Prkdc
scid 
background were used as hosts for 
teratomas. ES cells were passaged such that they were 50% to 80% confluent by plate area 
coverage 24 hours later. Cells were harvested, washed and resuspended in saline to a 
concentration of 10^6 cells / 0.1 ml. Between 50 – 100ul of cell suspension was 
subcutaneously injected with a 23-gauge needle into the left and right flank each of an 
Avertin-anesthetized (240 mg/kg) SCID mouse. Both male and female mice were used and 
were aged between 8 and 10 weeks at the time of injection. Mice were sacrificed by carbon 
dioxide asphyxiation and teratomas harvested when at approximately 1 to 1.5cm in diameter, 
typically after 3 to 4 weeks.  
The protocol is approved under Institutional Use and Care of Animals Committee 






5.2.9 MACS isolation of teratoma-dissociated cell samples 
2 male and 2 female SCID mice were injected on their left and right flanks for each 
cell line, so as to obtain sufficient material. Very briefly, the teratoma harvested immediately 
after sacrificing the animals and placed in ice-cold PBS to be rinsed. The teratoma were 
digested to single cells and subjected to the MACS-based dead cell removal protocol 
described above. The live single cells were then labelled with the bead-conjugated antibodies 
against the cell surface molecule, followed by the cell separation on the MACS column. The 
Eluted fraction was homogenised in Trizol and stored at -80˚C until used. At each stage, cells 






Section 5.3 Results  
5.3.1 Generation of Sox9
+/Lngfr
 ES cell lines 
In order to test and develop our strategy of isolating Sox9-expressing cells from 
complex tissue through MACS, we modified ES cells to co-express Lngfr with Sox9. These 
modified cell lines were used to generate mouse teratoma tissue, from which our desired cells 
were isolated by MACS using magnetic bead-conjugated antibodies against the cell surface 
Lngfr.  
To modify the ES cells by gene targeting, we made a plasmid Sox9-targeting construct 
(Appendix 2.2b) where Sox9‟s first exon is disrupted by the insertion of the Lngfr coding 
sequence, followed by loxP-flanked neomycin resistance gene (Fig. 5.2.1c). The Lngfr 
depends on the endogenous Sox9 promoter and translation start site so that it will only be 
expressed when Sox9 is, but the neomycin resistance gene depends on the PGK promoter for 
G418 selection after ES cell transfection (Fig. 5.2.1b). The gene cassettes are flanked by arms 
homologous to the Sox9 gene for homologous recombination into R1 and V6.4 ESCs. The left 
5‟ arm is 1.8 kb and the right 3‟ arm is 9.8kb long. Following ES cell transfection and 
selection, 47 and 306 G418-resistant colonies were picked from R1 and V6.4 ES background 
respectively. Southern Blot revealed that about 70-80% of these integrated the construct into 
their genome. 9 putative colonies were identified by PCR screening and Southern-blot analysis 
confirmed 5 successful homologous recombination events (Fig. 5.3.1.1). 1 was of the R1 line 
and 4 of the V6.4 line. All of these were selected with G418 concentrations of 250ug/ml and 
below. After identifying ES cell clones with the desired modifications, we expressed Cre 
transiently in these modified lines to establish lines that are Sox9
+/Lngfr 
, but do not have 






G418 resistance. The Cre-mediated recombination efficiency was between 18% in R1 and 56 
– 74% in V6.4. We picked 3 G418-sensitive clones for Southern Blot confirmation and 



















5.3.2 Generation of Sox9
+/Lngfr
 mouse tissue 
Sox9
+/Lngfr 
ES cells were microinjected into 8-cell stage morulas or blastocysts and 
reimplanted into surrogate mothers. The C57BL/6 strain of mice was used. 11 chimeras of 2-
65% chimerism (by coat color) were generated (Fig. 5.3.2.1). The male chimeras were crossed 
to wild type C57BL/6J mice to obtain fully transgenic embryos. Obtaining transgenic embryos 
by mating fully transgenic parent is possible only if mice of the heterozygous genotype are 
viable. In our study, Lngfr replaces one Sox9 allele. Sox9+/- mice are known to have a high 
rate of embryonic lethality (Bi, Huang et al. 2001) ; (Barrionuevo, Bagheri-Fam et al. 2006), 
so generating transgenic adult mice from the chimeras for breeding more heterozygote or 
homozygote transgenic mice was not a feasible option. 
This embryonic lethality also meant that we had to sacrifice the mothers between 10 to 
13 days of pregnancy to genotype the embryos by Southern Blotting. Because MACS has to 
be carried out on fresh embryos so that the subsequent RNA isolation can be performed on 
live cells, we could not wait for the genotyping results before performing MACS on the 
transgenic animals. The strategy we decided on instead was to identify male chimeras that 
germline transmitted to produce fully Sox9
+/Lngfr
 transgenic offspring at a high frequency. This 
way, it would be feasible for all the embryos from that particular male chimera could be 
subjected to MACS and a portion of the Unbound fraction cells could be taken for genotyping, 
while the Eluted fraction could be kept in Trizol. Only samples that were subsequently tested 
to be transgenic would then be used for transcriptome profiling. Unfortunately we have yet to 
obtain such a high-frequency germline transmitting chimera. Thus far 321 embryos have been 






We rationalised that it may be a long time before we could obtain Sox9
+/Lngfr 
embryos. 
In order to circumvent a likely long wait and to reliably obtain Sox9
+/Lngfr
mouse tissue in a 
shorter time, we decided to make teratoma tissue from the same Sox9
+/Lngfr 
ES cells.Teratomas 
arise when ES cells injected into immunodeficient mice differentiate spontaneously into a 
random, complex assortment of cells within a solid tumour. Such teratomas consist of Sox9-
expressing cells from the complete range of spatiotemporal stage. They could therefore be 
used in an experimental proof of principle that Sox9-expressing cells can be MACS-isolated 
by engineering these cells to express cell surface Lngfr under the endogenous Sox9 promoter.   
The teratoma tissue generated were stained with Alcian Blue and for Alkaline 
Phosphatase (Fig. 5.3.2.2). Both of these stains are positive for cartilage tissue. Both whole 
mount and sections were stained and compared with wildtype embryonic tissue, as well as 
teratoma tissue generated from Sox9-null ES cells. The Alcian Blue-stained and Alkaline 
Phosphatase positive structures in both our teratomas and wildtype embryo were very similar. 
Such structures were absent from all sections and whole mount samples from Sox9-null 
teratomas. This showed that our Sox9
+/Lngfr
teratomas were indeed capable of forming cartilage 
tissue, demonstrating that they were capable of forming Sox9-expressing cells.  
To determine the proportion of cells with the Lngfr transgene expression, we generated 






. Each of 
these were digested to single cells and subjected to FACS (Fig. 5.3.2.3). In 
Sox9
+/Lngfr
teratomas, 3.6 % of cells stained with FITC-conjugated anti-Lngfr antibody 
fluoresced above the unstained background. These 3.6% of cells were made up of Sox9-






length cell surface Lngfr, as well as background non-specific cells and dead cells. These cells 
were subjected to MACS, in parallel with dissociated wildtype 12.5 d.p.c embryos spiked with 
Lngfr+ cells as a positive control. Each fraction was labelled with FITC-conjugated anti-Lngfr 
for FACS analysis. As expected with single-round MACS of complex cell populations, the 
Eluted fraction was only about 53.2% pure. Sox9
+/EGFP
gave a better idea of the proportion of 
cells that express both Sox9 and the transgene. These cells are almost identical to the 
Sox9
+/Lngfr
cells, except they express EGFP in place of Lngfr under the Sox9 promoter control 
on one allele. Thus they fluoresce only when the Sox9 promoter is activated. Of course, EGFP 
has to be expressed above the baseline level of wildtype cells for the fluorescence to be 
detected. Here 2-5.5% of the teratoma cells were fluorescent (Fig. 5.3.2.3a). Sox9
EGFP/EGFP
has 
both copies of Sox9 replaced with EGFP. Some of these cell types may not survive in the 
absence of Sox9 or may differentiate into other non-Sox9-expressing cell lineages, while 
others survive with the Sox9 promoter still active even though no Sox9 is actually produced. 
The last group of cells would show up as fluorescent cells. Fluorescent cells would also 
consist of cells in the early stages of Sox9 expression when the promoter is just activated but 
before the cells respond to the lack of the Sox9 transcript or protein. Indeed FACS showed that 
1.2-2.4% of the Sox9
EGFP/EGFP
teratoma did fluoresce (Fig. 5.3.2.3a). The percentages of 
fluorescent cells between each teratoma cannot be compared meaningfully, however, as the 
differentiation of cells within a teratoma is random and every teratoma would have a different 
composition of the different cell types. This is the inherent limitation of teratomas. This again 
reinforces the need for developing sorting strategies rather than using whole tissue for 
studying biological processes unique to each cell type. With MACS, samples consisting 
largely of the cell type of interest can be obtained from different teratoma tissue, making 
























5.3.3 MACS with teratoma tissue 
Having established that teratoma tissue would be a meaningful sample to develop and 
evaluate the MACS isolation of specific cell populations expressing a gene of interest, we 
made teratoma tissue of each Sox9
+/Lngfr
cell line (Fig. 5.3.3.2b). Both R1 and V6.4 cell lines 
were used, both cells with and without neo were used, while both wildtype and Sox9-null 
teratomas served as controls. Teratoma MACS samples from different modified lines served 
as biological replicates that were later used for microarray anlaysis (Fig. 5.3.3.1 ). 
To determine the percentage of Lngfr+ cells that made up each fraction, we stained 
each fraction with FITC-conjugated anti-Lngfr and performed FACS analysis on them. The 
results are summarised in Fig 5.3.3.2a.(In Fig. 5.3.3.2a, Lngfr+ tissue refers to those generated 
from Sox9
+/Lngfr
cell lines and Lngfr- tissue refers to the wildtype and Sox9-null tissue). Despite 
a common protocol being applied across the board, there were variations as expected, 
reflecting the differences in cell composition of these teratomas. However, on the whole, the 
Input fraction of Sox9
+/Lngfr
dissociated cells had more fluorescent cells than the Input fraction 
of the wildtype and Sox9-null (Sox9
EGFP/EGFP
) cells: 12.15% vs 2.46% fluorescent cells on 
average. In theory, wildtype and Sox9-null teratomas do not have Sox9
+/Lngfr
cells, so the 
proportion of fluorescent cells they contain can be taken to represent the background levels of 
antibody binding. While the Eluted fraction of the wildtype and Sox9-null cells had nearly the 
same percentages (mean 21.55%, range 7.2-42.9%) of fluorescent cells as the inputs, the 
Eluted fraction of Sox9
+/Lngfr
cells had significantly higher percentages of fluorescent cells, 
ranging from about 31.2 % to 84.7% (mean 57.56%). This showed that MACS could enrich 
for cells of interest from a complex cell mixture derived from animal tissue. This was also an 






include those non-Sox9 expressing cells that bound non-specifically to the antibodies. By cell 
count, about 10-22% of the number input cells was consistently recovered in the Eluted 
fraction of Sox9
+/Lngfr+
 cells, while about 0.275-1.1% of the number of input cells was 
consistently recovered from the Eluted fraction of the wildtype and Sox9-null cells. This 
indicates that the background level of non-specific cells bound and eluted by anti-Lngfr is 
between 0.275-1.1%. This also implies that the purity of the eluted cells may be much higher 


















5.3.4 MACS background in embryo tissue 
The purity of MACS depends very much on the proportion of background cells 
compared with the proportion of the cells of interest in the entire input cell population When 
we spiked the wildtype single cell suspension from dissociated 13.5 d.p.c. mouse embryos 
with Lngfr+ cells at an ultra low level of less than 0.1%, the purity of the Eluted fraction was 
very low. Using the bead conjugated anti-Lngfr, a purity of only 5.8% was obtained. Using the 
biotin-conjugated anti-Lngfr, followed by a secondary bead conjugated anti-biotin, a purity of 
6% was obtained. This was in contrast to the NIH3T3 positive control where the Eluted 
fraction had a purity of 98.6% starting with an input cell population of 21.2% (Fig. 5.3.4.1). 
Cell counts revealed that the background level of cells was 0.75 %, using the bead-conjugated 
anti-Lngfr, consistent with what we got from the teratomas. Using a primary and secondary 
antibody gave a background of 2.26% by cell count. However, the recovery was fairly high, 
by cell count. Using a single antibody, the recovery was 58.5%, and using a primary and 
secondary antibody, the recovery was 100%. Despite the high recovery, the purity of MACS-
isolated rare cells was unacceptably low.  
As MACS depends on the antibody specificity, using different antibodies against the 
same or different epitopes would be expected to have a different level of background cells. 













5.3.5 Screening of candidate tags for MACS 
In order to find out if any other proteins could serve as better extracellular molecules 
for magnetic-bead antibodies to bind and capture, we decided to determine the background 
level of reputable antibodies against common epitope tags when used with live tissue-derived 
single cell suspensions. We tested antibodies against the HIS, Flag, Myc, V5, S-tag, CBP, HA, 
and biotin tags. Because most of these tags did not have antibodies against them that were 
conjugated to magnetic beads, we had to use magnetic-bead conjugated secondary antibodies, 
available from Miltenyi, against these primary antibodies. To determine how much 
background was contributed by the primary antibodies, we also tested the background of the 
secondary antibodies alone.  
Briefly, we made single cell suspensions of 14.5 d.p.c.CD1 mice embryos and 
removed the dead cells from the cell suspension to reduce the background caused by dead 
cells. We then labelled the cells with the magnetic-bead bound secondary antibodies and 
performed MACS. This served two purposes: firstly, to determine the background level of the 
secondary antibodies: secondly, to remove all the cells that contribute to the background due 
to the secondary antibodies. Cells from the Unbound fraction were then labelled with the 
primary antibodies against the tags, washed and then labelled with the secondary antibodies 
against the primary antibodies and then subjected to MACS again. The Eluted fraction here 
gives the background level of the tags. All the antibodies were used at concentrations 
recommended by their manufacturers for immunocytochemical staining for FACS.   






tissue-derived single cell suspensions. The anti-rabbit antibody gave the lowest background 
level of 0.1% (Fig. 5.3.5.2) and the anti-biotin antibody gave the highest background level of 
3.13%. Amongst the antibodies against the epitope tags, anti-HA gave the lowest background 
level of 0.36%. Lngfr has a background level of 0.76% and most other antibodies have a 
background level of 0.46-0.92%. Determining the background level of these epitope-tag 
antibodies has given us an idea of which tags that would be best to use as cell surface 
transgenic proteins for MACS. It also has provided us a benchmark to assess how suitable 


















Section 5.4 Discussion 
 
In order to isolate cells expressing a specific gene of interest from animal tissue, these 
cells must co-express a cell surface marker whose expression mirrors that of the gene of 
interest. To this end, we created ES cell lines whose Sox9 locus has been targeted, such that 
one Sox9 allele has been partially replaced by the transgenic Lngfr sequence. We made 
teratomas out of these modified cell lines, and showed that these teratomas contained 
chondrogenic tissue. This showed that the teratoma contained Sox9-expressing cells as the 
transcription factor SOX9 is the master regulator of chondrogenesis. These Sox9-expressing 
cells would express the Lngfr cell surface protein as Lngfr expression is controlled by the 
endogenous Sox9 promoter. We performed a single round of MACS against cells dissociated 
from these teratomas, targeting the Sox9
+/Lngfr
 cells using magnetic bead-conjugated 
antibodies. We also performed controls in parallel using teratomas derived from wildtype and 
Sox9-null ES cells. About 10 to 20 fold more cells were consistently recovered from 
Sox9
+/Lngfr
 teratoma compared to the negative controls. The average purity of the positive 
eluted cells was about 60%. Even though the purity of the Eluted fraction was less than ideal, 
these sorted cell fractions were of sufficient quality and quantity for Sox9-related gene 
pathways to be elucidated by microarray assays that I will describe in Chapter 7.  
To test the purity and efficiency of MACS performed on animal tissue, we generated 
teratomas from Sox9
+/Lngfr 
ES cells. Using teratoma rather than embryonic tissue was 
advantageous in two main ways. Firstly, teratomas were easy and reliable to generate. Due to 
the embryonic lethality of the Sox9+/- phenotype, transgenic embryo material could not be 
obtained reliably through mating of Sox9+/- parents. Instead, we had to depend on the 






unpredictable. This was also very inconvenient as MACS had to be performed on fresh tissue, 
to ensure the greatest amounts of live cells. Teratoma tissue consistently form within 2 to 4 
weeks after injecting ES cells into the flanks of SCID mice, providing a predictable and 
reliable supply of tissue material needed for MACS. The second advantage of using teratomas 
is that Sox9-expressing cells isolated from each teratoma will consist of cells of all tissue types 
expressing Sox9 at all developmental stages. This allows the discovery of a wider range of 
Sox9 associated genes and proteins from a single sample. This very same characteristic of 
teratomas is also its biggest limitation. Because the formation of tissue is random, every 
teratoma will have a different composition of Sox9-expressing cell types, each with a different 
transcriptome profile. Hence the variation of the transcriptome profiles for teratomas will be 
greater than that of embryos at a particular developmental stage. The transcriptome profile 
from teratomas might also be less biologically meaningful for embryonic developmental study 
because they do not represent any particular spatiotemporal developmental stage. However, 
the MACS protocol established with teratomas can be directly applied to embryonic material, 
so that developmental stage specific transcriptomes can be mapped out and validated.  
We showed that the Sox9
+/Lngfr
 teratoma was capable of generating Sox9-expressing 
cells that express the transgenic Lngfr in three ways. Firstly, chondrogenic tissue structures 
similar to those found in wildtype embryos were found in the Sox9
+/Lngfr
 and wildtype 
teratoma but not the Sox9-null teratoma. These structures were positively stained with Alcian 
Blue and for Alkaline Phosphatase, as expected. Secondly, we used an EGFP reporter to show 
that the Sox9 promoter was active in teratoma derived from modified ES cells. In previous 
work done in our lab (manuscript under preparation), two modified ES cell lines were created. 
In the first line, a single Sox9 allele was replaced by EGFP, the same way that it was replaced 






way. Because EGFP is easy to visualize, we used these cell lines to confirm that ES cells were 
capable of differentiating into Sox9-expressing cells during teratoma formation. Teratoma 
tissue was generated and digested to single cells. FACS analysis was performed to determine 
that fluorescent Sox9-expressing cells were present, at a proportion of about 2-5.5% of the 
teratoma cells.The advantage of EGFP reporter visualization is that it is unaffected by non-
specific antibody-binding background. However, the fluorescence of these Sox9-expressing 
cells have to be above the background level of all the cell types found in the teratoma, in order 
to be detected. Hence the proportion of the Sox9-expressing cells within the embryo that can 
be visualized by EGFP fluorescence is likely to be an underestimate. Thirdly, the quantity and 
purity of the positive eluted MACS fraction from Sox9
+/Lngfr
 dissociated teratoma was 
significantly higher compared to the wildtype and Sox9-null negative controls represent. 
Sox9
+/Lngfr
 teratoma consistently yielded about 10 to 20 times more cells in the Eluted fraction 
compared to the negative controls, with an average purity of 57.56% compared to 21.55% for 
the negative controls. The seemingly high composition of cells in the wildtype and Sox9-null 
negative control teratomas can be explained by the non-specific antibody binding, resulting in 




 In addition to the desired population of cells expressing the truncated Lngfr on its 
extracellular cell surface, there will be other cells that bind to the magnetic-bead conjugated 
antibodies and get retained on the column, to be eluted into the Eluted fraction with the 
desired cells of interest. We have termed these cells as the background. Three main sources 
contribute to the background of MACS: cells that express endogenous LNGFR, dead cells, 
and cells expressing proteins on their extracellular surface that bind non-specifically to the 






against human LNGFR, and although the truncated Lngfr used as the cell surface marker was 
of the human form, the mouse and human LNGFR share sufficient amino acid similarity to 
make cross-reactivity of the antibody a possibility (Fig. 5.4.1). These cells expressing 
endogenous mouse LNGFR would be bound to the magnetic bead-conjugated anti-Lngfr 
antibody, and would be eluted together with the desired cells of interest.  
Embryos and animal tissues start to die the moment they are removed from the mother 
or animal respectively. During the tissue dissociation process required to obtain single cell 
suspensions, the mechanical force and enzymes will further kill a proportion of the cells. Dead 
cells tend to bind antibodies non-specifically and form the second major source of background 
cells. They tend to be sticky as well and will form clumps with each other, which might in turn 
trap live cells. These clumps tend to be retained on the column and get eluted out with the 
desired cells of interest in the Eluted fraction.We addressed the issue of dead cells in two 
ways. Firstly, we minimized cell death as much as possible by minimizing the time spent from 
the sacrifice of the host animal, until the cells are completely sorted and dissolved in Trizol for 
RNA extraction. Cells were kept on ice wherever possible. Secondly, we introduced a dead 
cell removal step using Miltenyi‟s Dead Cell Removal Kit between the cell dissociation steps 
and the MACS procedure. Here, magnetic-bead conjugated antibodies against various 
apoptotic and necrotic cell surface markers bind to dead or dying cells, which themselves tend 
to bind easily and non-specifically to antibodies anyway. When the cell suspension is put 
through the magnetised column, the dead and dying cells are retained, allowing only live cells 
to pass through.  






surface that bind non-specifically to the anti-Lngfr antibody. Comparing cells from cultures 
that are homogenous or of low-complexity with complex cell samples from tissue, there will 
be two different outcomes: Either there will be a significantly higher proportion of background 
cells if the particular cell line being cultured expresses cell surface proteins that bind to anti-
Lngfr antibody non-specifically, as the homogeneity means that all or a large proportion of the 
culture cells express the same protein; or, there will be a significantly lower proportion of 
background cells if the culture cells do not express such a protein.  When dealing with 
complex tissues from entire embryos, teratomas or other animal tissue, there would be a good 
chance of such cell types present, and often, there will be a significant level of background 
cells resulting from non-specific binding.  
The background level in the starting cell sample is determined by the cumulative 
proportion of these three cell types. However, the proportion of these background cells in the 
Eluted fraction is not just determined by the background level in the starting cell sample; the 
percentage of desired cells of interest within the starting cell sample is a major determinant 
too. For example, if the background cells make up 1% of the starting cell sample and the 
desired cell population also makes up 1% of the starting cell sample, then the Eluted fraction 
will consist of 50% background cells and 50% desired cells. The effects of the background 
level become very pronounced when the proportion of the cells of interest approximates or 
drops below the level of the background. This makes it important to establish both these levels 
to evaluate the suitability of MACS for the desired isolation. In our case, experiments with the 
teratoma, spike-in experiments, and experiments to determine the background level of the 
anti-Lngfr- antibodies in wildtype embryos agreed that the background level was 






decreasing proportion of positive cells in the Input fraction.  
We decided to explore whether we could use a cell surface marker with a lower 
background level instead of Lngfr. Empirical determination of each antibody available in our 
laboratory against each candidate tag revealed that the Lngfr we used was very similar to most 
of the others. We tested antibodies against the HIS, Flag, Myc, V5, S-tag, CBP, HA, and 
biotin tags. HA and anti-rabbit were the cleanest antibodies to use, while anti-biotin gave the 
highest background. These tags are very commonly attached to proteins and used for protein 
purification with their specific antibodies.  
To address the challenge of achieving highly pure Eluted fractions from MACS even 
when the desired cell population was present at levels similar to the background in these 
complex cell mixures, we realised we needed a radical change in cell sorting strategy. In the 
next chapter, we describe the novel Two-step MACS strategy we designed to tackle this 
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Chapter 6. Two-step MACS of cells from tissue: 







Section 6.1 Introduction  
 
In the last chapter single-step MACS was found to be insufficient for our needs. Most 
of the commonly used epitope tags yielded ~1% background rate of non-specifically binding 
cells when a single round of MACS was performed. When the proportion of the cells of 
interest within a complex mixture of cells approaches this background level, the resultant 
MACS Eluted fraction would have a purity of about 50% only. In this chapter I describe how 
we developed and optimized a Two-step MACS to address this issue. We enriched cells of 
interest from a 1% proportion to ~85% purtity. This is a large improvement upon the single-
step MACS and sufficient for our needs.  
6.1.1 Rationale behind the Two-step MACS 
The difficulty of achieving high purities using MACS when desired cells were 1% or 
less of the starting population was acknowledged by Miltenyi et al (Miltenyi, Muller et al. 
1990).  
Several groups have also made the observation that the final purity of cell samples 
depends on its proportion within the starting input cell population (Martin-Henao, Picon et al. 
2000). When the proportion of cells to be isolated are very rare, they become very susceptible 
to the effects arising from non-specific staining, debris, particles in the sheath fluid, dead cells, 
measurement and even statistical evaluation (Busch, Huber et al. 1994). The enumeration of 
rare cells, e.g. circulating endothelial cells which exists at 0.01 - 0.0001% of mononuclear 






and false positive rates of most enumeration methods. (Goon, Boos et al. 2006).  
However, by doing two rounds of cell isolation, where both rounds are based on 
different sorting parameters, the purity of the final sample can be increased significantly. In 
the second round of sorting, the starting sample would have a much higher percentage of 
desired cells already, which would be much higher than the background noise and false 
positives. Several groups have utilized more than one round of cell sorting to obtain samples 
of sufficient purity. Combining the MACS procedure with Percoll density centrifugation 
increased both the purity (65%) and recovery (67%) of work with human bone marrow cells 
(Schmitz, Radbruch et al. 1994). Megakaryocytes make up about 0.02 – 0.06% of nucleated 
cells found in the human bone marrow. When MACS was used alone, starting from a 0.82% 
megakaryocyte cell suspension, the purity was low (47%) as was the recovery (37%). The 
authors correctly hypothesized that the cell losses came during the labelling and washing 
process. The recovery of cells from the MACS column was about 85%.  
Interstitial cells of Cajal are mesenchymal cells that are dispersed amongst the smooth 
muscle bundles of the gastrointestinal tract. Because of their scarcity and limited accessibility 
in intact tissue, and because they have to be transformed from single cells to large-scale 
networks for them to function in culture, obtaining pure samples of interstitial cells of Cajal 
for study has been difficult. Ordog et al. attempted to use MACS to isolate these cells from 
tissue digested to single cell suspensions, but found that the scarcity of these cells made it 
difficult to obtain highly pure samples. Non-specific binding of 1.8% of input cells was 
calculated to produce an isolated cell population that is only ~28% pure, which was what the 






enrichment step to be followed by FACS for optimal purity and recovery (Ordog, Redelman et 
al. 2004).  
In a clinical setting, MACS has been evaluated for enriching fetal cells from maternal 
blood. Fetal cells are exceedingly rare in maternal blood, but they are a less invasive and risky 
source of obtaining fetal cells for analysis, compared to amniocentesis where the risk of 
miscarriage is significantly higher. Several groups have independently found that having two 
rounds or more of isolation is necessary. When the addition of a MACS enrichment step with 
use of a single or double Percoll density gradient to enrich for fetal cells from maternal blood 
was evaluated, the purity of the fetal erythroblasts increased 200-fold (Smits, Holzgreve et al. 
2000). 
By including MACS positive selection of CD45 and CD71 positive cells as part of a 
multi-step method together with triple density gradient, cytospin centrifugation to enrich for 
fetal nucleated red blood cells, the group managed to get an average of 13.7 fetal cells from 
20ml of maternal blood. With these multistep sorting, sex determination showed above 90% 
sensitivity and specificity, confirmed by cells from amniocentesis or chorionic villus sampling 
(Yang, Jee et al. 2000) ; (Mavrou, Colialexi et al. 1998) ; (Zheng, Craigo et al. 1995). 
Busch et al. also reported a double MACS protocol. Here, CD45+ leukocytes were first 
labelled and depleted from peripheral blood. The depleted fraction was then incubated with 
magnetic bead conjugated anti-CD71 and this time the CD71+ cells were positively selected 
for, to a final purity of 62-87%. The first round of MACS depletion enriched for CD71+ by 






rates for the positive selection ranged from 38 – 55%.(Busch, Huber et al. 1994) 
In another example, a dual step MACS procedure was used to isolate fetal cells from 
peripheral maternal blood for paternity testing. CD45+ and CD14+ cells were depleted by 
780-fold from peripheral blood mononuclear cells. From this fraction, CD71 cells were 
enriched by 500-fold to 80% purity by MACS, with a recovery of 40 – 55 %. PCR detected 
paternal DNA sequences from the purified fetal cell fraction, but not from the unsorted 
maternal blood (Zheng, Carter et al. 1993).  
The above cases of multiple rounds of cell isolation were possible because several 
methods of sorting were already available for each cell type. For example, a lot of cell types 
from blood either have multiple cell surface markers identified, or they have unique cell sizes 
and densities that separate them from other cell types.  
In our case, we are developing a generic method to isolate cells, defined by their 
expression of a particular gene of interest, from complex tissues, some of which are solid 
tissues. Without prior further knowledge of these cells, or prior purification to define their 
properties, it is difficult to purify the cells by density, or to know what kinds of cell surface 
markers are unique to those cells. This was why we had to express a transgenic cell surface 
marker under the same promoter control of our gene of interest, so that we would have a cell 
surface marker to sort the cells by. In order to be able to have two rounds of sorting, we would 
need two markers for sorting.There are a few ways to achieve this. 






interest, each with a different marker. However, this would require two rounds of gene 
targeting, or the generation of two separate lines of mice for cross-mating. Both of these are 
time consuming. The more rounds of gene targeting a cell line goes through, the more likely it 
is to accumulate random genetic mutations. Generating two lines of mice for cross-mating 
would work only if the mice remain viable or fertile after the gene modifications. This is not 
always possible. In this pilot study, we were replacing one Sox9 allele with Lngfr. Most Sox9 
heterozygotes die in utero around 13.5 d.p.c.  
The second way is to have two separate cell surface markers one after the other, linked 
by an Internal-Ribosomal Entry Site (IRES) or F2A (Foot and mouth virus 2A peptide) 
(Chinnasamy, Milsom et al. 2006) sequence, so that both will be co-expressed under the same 
promoter. Using the IRES, the expression level of both markers will be reduced, due to 
competition for ribosomes, resulting in less epitopes on the cell surface for antibody binding. 
Using the F2A sequence where both markers will be expressed at an equally high level as if 
there were only one marker, would double the number of transgenic molecules on the cell 
surface, increasing the potential of having an altered cell phenotype. F2A is a viral peptide that 
has self-processing activity; cleavage occurs between the glycine and proline.  
The third way would be to express both markers fused together as a single protein. 
This way, there would be minimal rounds of gene targeting, the level of both markers would 
remain equally high, but the total number of transgenic molecules on the cell surface remains 
the same as if there were only a single marker. The second component can be a small epitope 
tag whose size would theoretically have less adverse effects on the cells. Additionally, there 






Peptide (BAP) epitope as the second component for sorting. These were the reasons for us 






6.1.2 Biotin Acceptor Peptide 
Biotin protein ligases catalyze the attachment of biotin to the biotin carboxylases and 
decarboxylases. These are key enzymes in glucogenesis, lipogenesis, amino acid degradation 
and energy transduction; they use the biotin cofactor as a mobile carboxyl carrier. The biotin 
ligation is ATP dependent and results in an amide linkage between the biotin carboxyl group 
and the amino group of a specific lysine residue on the carboxylase protein. Biotin protein 
ligases are found in a wide range of organisms, including prokaryotes, plants, fungi, and 
mammals. The ligases and substrate peptide sequences are conserved to the extent that 
biotinylation can occur between ligase and substrate from two different species as divergent as 
bacteria and human (reviewed by (Chapman-Smith and Cronan 1999; Chapman-Smith and 
Cronan 1999; Chapman-Smith and Cronan 1999). BirA, of size 35.5 kD, is the E.coli biotin 
protein ligase that has been most studied and used in biotechnology (Barker and Campbell 
1981). 
In E.coli, BirA has only a single substrate, the biotin carboyxl carrier protein subunit of 
acetyl-CoA. Therefore, many early studies made use of the minimal 75 amino acid sequence 
from the biotinylated site of the biotin carboxyl carrier protein to attach to their protein of 
interest. The use of this very large tag was later replaced by a 13 amino acid sequence 
identified by Schatz (Schatz 1993; Beckett, Kovaleva et al. 1999) through library screens. This 
sequence has little resemblance to the original 75 amino acid sequence apart from the lysine to 
be biotinylated, but it increases the efficiency of biotinylation on the tagged protein (Beckett, 






Biotinylated proteins are affinity purified using Avidin (Lesley and Groskreutz 1997). 
Strepavidin is a 60kD tetramer derived from the actinobacterium Straptomyces avidinii. It 
binds to four molecules of biotin in a non-covalent fashion, with an affinity of Kd = 10
-15
M 
that is the strongest protein-ligand interaction known and several (10
3
 – 106) orders of 
magnitude greater than most antibody-antigen bindings (Diamandis and Christopoulos 1991; 
Scott, Martin et al. 2000; Parrott and Barry 2001). Either Strepavidin or anti-biotin can be 
used for MACS. 
In vivo biotinylation has been used for purification of recombinant proteins from 
mammalian cells and mice (Scott, Martin et al. 2000; Parrott and Barry 2001), labelling Ig Fab 
fragments (Saviranta, Haavisto et al. 1998; Sibler, Kempf et al. 1999), labelling secreted and 
cell surface proteins, labelling surface proteins with probes and labelling proteins for 
chromatin immunoprecipitation. Despite the existence of a native biotin protein ligase in 
mammalian cells, studies have shown that the biotinylation of BAP-tagged proteins are only 
enabled by the BirA (de Boer, Rodriguez et al. 2003; Driegen, Ferreira et al. 2005). 
 In order to biotin-tag transcription factors in vivo, transcription factors must carry the 
BAP at either the C or N terminus (Chapman-Smith and Cronan 1999) and the BirA biotin 
ligase must be expressed in the same cell to catalyze the addition of the biotin moiety to the 
BAP. Because BirA is not present in mammals, transgenic mice expressing both BirA and the 






Because using the BAP as one of the components would require this expression of 
BirA in trans, this allows an added layer of control and specification. Taking Sox9 as an 
example, in order to isolate all the Sox9-expressing cells in the embryo, BirA can be 
expressed in a ubiquitous fashion by targeting the ROSA26 locus. To isolate only the 
Sox9 cells of the chondrogenic lineage, BirA can be targeted to, and expressed under the 
promoter control of, Bapx1, another early marker of the chondrogenic lineage (Provot, 
Kempf et al. 2006) (Lengner, Hassan et al. 2005). In this way, only cells expressing both 
Bapx1 and Sox9 will be isolated, as the expression of both genes is needed for the protein 
expression of the biotinylated-BAP. If the Sox9 cells involved in sex determination are to 
be isolated, then BirA can be put under the promoter control of Sry, and only cells 
expressing both Sry and Sox9 will be isolated. Thus by including the BAP as one of the 
components for our 2-component cell surface marker, we can isolate specific subsets of 
cells expressing our gene of interest.  
Another alternative means of expressing BirA in trans is to have the BirA under 
the control of the promoter of the gene of interest together with the cell surface molecule, 
using IRES or F2A. This would potentially reduce the effort of creating additional cell 
lines and transgenic mice to express BirA separately. The drawback of this strategy is that 
with IRES, the expression level of both the cell surface molecule and hBirA would be 
reduced and this may affect the sorting efficiency. With both the IRES and F2A, 
including the BirA may mean that other proteins e.g. EGFP for tracking, may not be 
expressed. Also, the BirA would have to be knocked-in with the cell surface molecule 






6.1.3 Our Strategy Two-step MACS experimental strategy 
Our approach to isolating rare cells from a complex mix of cell types to a 
sufficient purity was to express a two-component cell surface marker under the promoter 
control of the gene of interest for two sequential rounds of MACS. One of the 
components is the BAP tag, for the first round MACS. We decided to express the biotin 
ligase, BirA, using two different approaches. With the first, the biotin ligase was knocked 
in to another gene locus to provide further specification of the cell type to be isolated. We 
chose to use the ubiquitous ROSA26 locus. With the second approach, we expressed the 
biotin ligase under the same promoter control as the cell surface marker, using the IRES. 
As with the single-step MACS experiments earlier, we replaced part of the Sox9 first 
exon with our transgenes. We continued to use Lngfr as the other component of the cell 
surface marker. 
The BirA sequence we used is a humanized one, meaning that while the amino 
acid sequence encoded for is exactly the same as the E. coli endogenous BirA, the codons 
used to encode each amino acid have been changed to the most frequently occurring one 
in humans (Sharp, Cowe et al. 1988) by Ogryzkos‟s group (Mechold, Gilbert et al. 2005) 
(Appendix 6). Due to the species-specific pattern of codon usage, we rationalized that the 
humanized BirA (hBirA) would be more optimal for expression in mice, especially at the 
protein level.  
We decided to put the BAP on the N terminus of the cell surface marker, such that 






tags in succession, rather than a single one, to increase the number of epitopes and thus 
improve retention on the column. Apart from conjugating antibodies to the beads, lectins 
like concanavalinA (Porter, Robinson et al. 1998) and Streptavidin have also been 
conjugated to magnetic beads, to bind to cells. The Strepavidin-biotin binding is one of 
the strongest non-covalent bonds known between biomolecules and can be used in the 
first round of MACS to target the 3xBAPs. Since both rounds of sorting depended on 
MACS, there was a need to remove the magnetic bead-conjugated antibodies from the 
first round of sorting.  
Lngfr has 14 trypsin sites. Miltenyi‟s claim that MACS using Lngfr is trypsin-
insensitive does hold in a way, because even after trypsin cleavage, there is still a 
sufficient length of the polypeptide (46 amino acids) exposed on the cell surface to 
provide the epitopes for the polyclonal anti-Lngfr antibody to bind. With the 2-
component marker, the N-terminal 3xBAP would be lost if the Lngfr was cleaved with 
trypsin. Hence, trypsin cannot be used as one of the enzymes for tissue dissociation to 
single cell suspensions. However, by treating the cells briefly with trypsin between the 
first and second rounds, the 3xBAPs and the bead-conjugated antibodies recognising 
biotin, would be lost. Magnetic bead-conjugated anti-Lngfr antibody can then be used for 
the second round of sorting.  
Theoretically, if the cell population expressing the gene of interest makes up 1% 
of the complex cell mixture and the background, non-specifically bound cells make up 
1% of the complex mixture too, then the Eluted fraction following the first round of 






that the second round of MACS also non-specifically picks up 1% of a given complex 
cell mixture, then the purity of the final purified sample would be about 98% (50% 
specific cell population + 1% background).  
In order to rapidly ascertain the effectiveness of our rare cell isolation strategy, 
termed „Two-Step MACS‟,before investing time, effort and cost into making transgenic 
mice with this two-component cell surface protein, we tested the strategy in vitro. We 
made transient-expression constructs, expressed these markers in NIH3T3 or HEK293 
cells, spiked the transfected cells into a suspension of cells from dissociated wildtype 
embryos, and performed MACS to recover the transfected cells. The expression 
constructs also encoded EGFP so that the various fractions of the MACS could be 
analysed by FACS. We successfully developed and optimised the Two-step MACS 
strategy and enriched the spiked-in cells of interest from ~1% purity to ~85% purity. 
Because we eventually want to test the Two-step MACS in vivo, we also made targeting 






Section 6.2 Methods 
6.2.1 Construction of pDisplay  targeting vectors 
The constructs for transient transfection and expression in cell cultures were based 
on the pDisplay (Invitrogen, USA) vector. 3 consecutive BAP epitopes were cloned after 
and in frame with the HA tags on the vector. The base vector was modified such that 4 
versions were made: One with IRES-hBirA-IRES-EGFP (Appendix 2.3a), one with an 
IRES-hBirA (Appendix 2.3b), one with EGFP in frame (Appendix 2.3a), and hence fused 
to the transmembrane region on the intracellular side and another one without anything 
but the BAP epitopes. The IRES-hBirA, or IRES-hBirA-IRES-EGFP was cloned in after 
the STOP codon of the transmembrane protein, but before the BghPolyA tail. 6 different 
candidates for the second component of the sorting molecule were also tested. The first 4 
were permutations of the Miltenyi Lngfr truncated protein. The coding region used began 




 codon after the translational start codon, to remove the Leader 
Sequence. The coding region ended either one codon before the transmembrane region or 
one codon before the stop codon of the truncated transmembrane region. The rabbit 
heavy-chain constant region and EGFP were the two remaining candidates tested (Fig. 
6.2).  
To obtain the IRES-hBirA-IRES-EGFP fragment, an XhoI-NotI-AfeI-XhoI 
polylinker was inserted into the SalI site of the pGAG-ihBirA-iEGFP-SV40neo (App 2.7) 
vector, thereby destroying the SalI and XhoI sites. The plasmid was cut with NotI to 
obtain the NotI-flanked IRES-hBirA-IRES-EGFP fragment and inserted into the NotI site 






A BglII-BAP-XbaI-BAP-NheI-BAP-MluI-SacII sequence was generated by 
annealing 4 overlapping oligos and inserted between the BglII and SacII sites of pDihBiE. 
The 4 oligos used were:  


















This plasmid with IRES-hBirA-IRES-EGFP was termed pBAP-DihBiE (Appendix 2.3a). 






polylinker XmaI-BamHI-XhoI used to relinearize the plasmid. This plasmid with IRES-
hBirA was termed, pBAP-DihB (Appendix 2.3b).  
The transmembrane region with its stop codon removed was PCR generated with 
the primers 5‟ ACTCCTGCTATGGGTACTGCT 3‟ and 5‟ 
TCACCATGGGACGTGGCTTCTTCTGCCAAAGCATGAT 3‟ and then SalI and NcoI 
digested. EGFP was excised from pCAG-ihBirA-iEGFP SV40Neo using NcoI and NotI. 
The SalI-NcoI flanked transmembrane region and the NcoI-NotI flanked EGFP was 
ligated simultaneously between the SalI-NotI site of pBAP DihB. This plasmid with the 
transmembrane intracellular EGFP was termed pBAP DihB TmE (Appendix 2.3c). 
pBAP –DihbiE was NotI digested and the ends ligated to remove both ires-hBirA 
and ires-EGFP. This plasmid with only the 3 BAP epitopes added was termed pBAP-D. 
The candidates for the second component of the sorting molecule were cloned 
between the MluI and SacII sites after, and in frame with the 3 BAP sequences, into all 4 
versions of the base vector, unless stated. They were PCR generated using the pMACS-
Lngfr-Neo template and the following primer pairs, which added a MluI and SacII site to 
the products‟ 5‟ and 3‟ end respectively: 
 
For Lngfr from the 26
th






TTTTACGCGT CTTGGAGGTGCCAAGGAGGC 3‟ and5‟ TTTTCCGCGG 
CCTCTTGAAGGCTATGT 3‟ 
For Lngfr from the 20
th
 a.a., including the transmembrane region: 5‟ TTTTACGCGT 
CTGCTTCTGGGGGTGTCCCTTGGAGGT 3‟ and 5‟ TTTTCCGCGG 
CCTCTTGAAGGCTATGT 3‟ 
For Lngfr from the 26
th
 a.a., excluding the transmembrane region: 5‟ TTTTACGCGT 
CTTGGAGGTGCCAAGGAGGC 3‟ and 5‟ TTTTCCGCGG 
CACCACGGGCTGGGAGCTGC 3‟ 
For Lngfr from the 20
th
 a.a., excluding the transmembrane region: 5‟ TTTTACGCGT 
CTGCTTCTGGGGGTGTCCCTTGGAGGT 3‟ and 5‟ TTTTCCGCGG 
CACCACGGGCTGGGAGCTGC 3‟ 
For the rabbit-heavy chain constant region: 5‟ 
TTTTACGCGTATGGGAAGCTTTAAGGCTCCATCAGTCTT 3‟ and  5‟ 
TTTTCCGCGG TTTACCCGGAGAGCGGG 3‟ 
For the extracellular EGFP: 5‟ TTTTTTACGCGT ATGGTGAGCAAGGGCGAGGA 
and TTTTTTCCGCGG CTTGTACAGCTCGTCCATGC 3‟. This particular 












6.2.2 Construction of pSBL targeting vectors 
To knock the two-component BAP-Lngfr molecule into the Sox9 locus, a targeting 
construct was made such that the Ig Leader Sequence – HA – 3xBAP-Lngfr-
Transmembrane region was inserted after the translational start codon, with 138bp of the 
first exon deleted as with pSox9 Lngfr Neo (Appendix 2.2b). This was followed by the 
LoxP-flanked PGK-gb2-Neo. two other plasmids were also made. One of them has the 
EGFP after and in frame with the transmembrane region and the other has an F2A peptide 
between the transmembrane and EGFP. Another 3 versions of plasmids were made, 
which were exactly the same as the 3 above, but with IRES-hBirA included after the stop 
codon of the transmembrane protein and before the LoxP-flanked PGK-gb2-Neo. 
A SacI-NheI-NotI-HindIII-FseI-NruI-KpnI polylinker was used to replace the 
MCS of pBlueScript II SK (+). The Sox9 left homology arm was PCR generated in two 
pieces, from the pSox9 Lngfr Neo plasmid template. The first was amplified with the 
primers 5‟ 
GGGAACAAAAGCTGGAGCTCGGCGCGCCGGCCGGCCTCGCGACGCCCTCTTA
GGTATCTG 3‟ and 5‟ GCCAATCACGGCTAGCTCTTGAGT 3‟, which added SacI-
AscI-FseI-NruI to the 5‟ end, and NheI to the 3‟, and cloned between the SacI and NheI 
of the polylinker. The second piece was amplified with the primers 5‟ 
TTTTTTTTGCTAGCCGTGATTGGCCCGAGGTATC 3‟ and 5‟ 
TTTTTGCGGCCGCGATATC ACGCGAGCCCGGGGCAGGGG 3‟, which added a 
NheI to the 5‟ end and EcoRV-NotI to the 3‟ end, and cloned between the NheI and NotI 






The LoxP-flanked PGK-gb2-Neo and right homology arm were cut out from 
pSox9 Lngfr Neo using NotI and HindIII and were cloned in between NotI and HindIII of 
the polylinker region.  
The Ig Leader Sequence – HA – 3xBAP-Lngfr-Transmembrane region or Ig 
Leader Sequence – HA – 3xBAP-Lngfr-Transmembrane region- EGFP was subcloned 
from the pBAP-DihBiE Lngfr or pBAP-DihB-TmE Lngfr and inserted between the 
EcoRV and NotI sites. These two plasmids were termed pSBL and pSBL-TmE 
respectively (Appendix 2.4b). 
The SacI – NotI flanked F2A-EGFP was taken from a pre-existing sequenced 
plasmid. The Lngfr-transmembrane region, flanked with MluI and SacI, were PCR 
generated from the pBAP-DihBiE Lngfr template, with the primers 5‟ 
TTTTACGCGTCTTGGAGGTGCCAAGGAGGC 3‟ and 5‟ 
TTTTTTGAGCTCCACGTGGCTTCTTCTGC 3‟. pSBL was cut with MluI and NotI and 
the intervening sequences replaced with the MluI-SacI flanked Lngfr-transmembrane 
region and the SacI – NotI flanked F2A-EGFP simultaneously, to obtain the plasmid 
pSBL-F2A.  
To subclone IRES-hBirA into the vectors, a NotI site was introduced at the ends 
of IRES-hBirA of the pBAP-DihB (Appendix 2.4c) plasmid with an XhoI-NotI-XhoI 
linker into its unique XhoI site and then the IRES-hBirA fragment isolated with NotI. The 
NotI-flanked IRES-hBirA was then subcloned into the unique NotI site just before the 






ihB and pSBL-F2A-ihB. pSBL-ihB, pSBL-TmE-ihB were linearized with AscI while 
pSBL-F2A-ihB with NruI for electroporation into ES cells. 
The same screening strategy was employed as described above (Section 5.2.5).  
6.2.3 Construction of hBirA expression vector 
Constructs were made to target the ROSA26 locus, in the intronic region between 
the first and second exon, with transgenenic sequences inserted into an endogenous XbaI 
site. Two separate constructs were made, both to express the humanized –BirA enzyme 
(hBirA) from the ROSA26 locus, but one with a beta-galactosidase (lacZ) reporter gene 
after the hBirA sequence, under the control of an Internal Ribosomal Entry Site (IRES), 
termed pROSA-hBirA-ILN, and the other one without, termed pROSA-hBirA-Neo. In 
order to express hBirA, a splice acceptor was placed just before the hBirA cDNA 
sequence. The lox-P flanked PGK-neomycin (Neo) resistance gene was placed behind, to 
confer G418 resistance. The expression of hBirA on the targeting construct depends on 
the endogenous ROSA26 promoter, thus it will not express unless integrated correctly, or 
after an active promoter. A third construct was later made, where the right homology arm 
of the targeting construct was extended by a further 9kb, termed pROSA26-hBirA-Neo-
Mn. 
pBluescript II SK(+)(pBS), GenBank/EMBL accession number X52328 
(Fermentas, USA), was digested with KpnI and SacI, and the polylinker „ SacI overhang– 
Xba I – EcoRI – BamHI – HindIII – SalI – SpeI – XbaI – KpnI overhang‟ was cloned in 






The splice acceptor was generated by PCR from a pre-existing sequenced 
template with the primers 5‟ TCTGAATTCATCTGTAGGGCGCAGTAGTCC 3‟ and 5‟ 
TCTGGATCC ACCGTCGATCCCCACTGGAAA 3‟, such that it was flanked with 
EcoRI and BamHI, enabling its insertion between the EcoRI and BamHI of the polylinker 
region of the modified pBS. 
hBirA was PCR generated with the primers 5' 
TCTGGATCCTTAATTAAGCCACCATGAAGGACAACACCGTGCC 3' and  
5' TCTAAGCTTTTAATTAA CTACTTCTCTGCGCTTCTCAGGGAGA 3' digested and 
cloned between the BamHI and HindIII sites of the polylinker region of the modified 
pBS. The hBirA template used was kindly provided by Ogryzko‟s group (Mechold, 
Gilbert et al. 2005). 
To generate the construct without IRES-lacZ, a SpeI-LoxP-PGK-Neo-LoxP-
polyA-SpeI fragment was cut out from a pre-existing sequenced plasmid with SpeI and 
inserted into the SpeI site of the polylinker region of the modified pBS. To generate the 
construct with IRES-lacZ, an XhoI – IRES-lacZ- PGK-Neo-LoxP-polyA-XbaI fragment 
was cut out from a pre-existing sequenced plasmid with XhoI and XbaI and inserted 
between the SalI and SpeI sites of the polylinker region of the modified pBS, thereby 
destroying the XhoI, XbaI, SalI and SpeI sites.  
At this point, the construct containing IRES-lacZ was termed pBS-hBirA-ILN and 
the one without was termed pBS – hBirA-Neo. The entire region flanked by the XbaI 






pBS-hBirA-Neo, and cloned into the unique XbaI site on the pROSA26-1 targeting 
vector, to produce pROSA-hBirA-ILN and pROSA-hBirA-Neo respectively (Appendix 
2.6). SacII was used to linearize this plasmid to generate the targeting construct 
electroporated into ES cells. pROSA26-1 contains a 1.1kb 5‟ left homology arm and a 
4.3kb 3‟ right homology arm to the ROSA26 locus. It does not include the ROSA26 
promoter site, but includes a diphtheria toxin gene after the 3‟arm for negative selection. 
To generate pROSA-hBirA-Neo-Mn, a NotI flanked PGK-gb2-Neo fragment was 
excised from a pre-existing sequenced plasmid, and cloned into the unique NotI site of 
pROSA-hBirA-Neo. The entire expression cassette was excised with HapI and NheI, gel 
purified, and used for RED/ET mediated BAC homologous recombination (Gene Bridges, 
Germany), to modify a BAC (RPCI-23-244D9) containing the ROSA26 locus. The 
modified BAC was then digested with MfeI and all the fragments shotgun cloned into a 
pBS vector with a SacII- SviI-MfeI-NsiI-SacI polylinker cloned between its SacII and 
SacI sites. Kanamycin-Ampicillin dual selection was used to select for only those vectors 
which took up the PGK-gb2-Neo containing region. NotI was used to remove the PGK-
gb2-Neo from this vector, to obtain pROSA-hBirA-Neo-Mn. SacII and MfeI was used to 
generate the targeting construct that contained the same short left homology arms as 
pROSA-hBirA-Neo and electroporated into ES cells. 
To screen for ES cells modified by the pROSA-hBirA- Neo, -ILN, Neo-Mn 
targeting constructs, the ES cells were screened by Southern Blotting, with gDNA 
digested with SpeI, and probed with Rosa5‟ Probe 2 (718bp) outside of the 5‟ short left 






10.1kb bands. EcoRI is also used to confirm the Southern Blot results, giving a wildtype 
band size of 15.6kb and a modified band size of 4kb. The probe was PCR generated using 
the primers 5‟ CGCCAGTCCGCCAACA 3' and 5' AAACCAGAGGAGAGGCGTTCA 
3' using the RPCI-23-244D9 BAC as a template. PCR conditions used were: 1x [95 C 5‟]
 40x [95 C 15”, 60  C 15”, 72  C 60”] 1x [72 C 10‟]. The 0.5x SSC stringent wash 
was done at 56˚C. Cre was transiently expressed to remove the LoxP-flanked Neo. 
Successful removal was detected through two rounds of G418-sensitivity screening of the 
clones picked.  
An internal probe, Rosa Int2 (620bp), was PCR generated with the primers 5' 
GTCACCCGAGTTTATACTCT 3' and 5' AATATCAGCCTGGCAATATGT 3 using the 
RPCI-23-244D9 BAC as a template'. PCR conditions used were: 1x [95 C 5‟] 40x 
[95 C 30”, 50  C 30”, 72  C 60”] 1x [72 C 10‟]. Genomic DNA cut with EcoRI gave a 
wildtype band size of 15.6kb and if the construct was integrated, a band size of 13.5kb 
was also obtained. The 0.5x SSC stringent wash was done at 43˚C. 
6.2.4 X-Gal staining for LacZ 
Adherent cells had their media removed and were rinsed with PBS three times. 
They were then fixed at 4˚C for 10 minutes with Fix solution, consisting of a final 
concentration of 2% formaldehyde, 0.2% glutaraldeyhyde, 0.02% NP-40, 0.01% NaDC 
made in PBS. They were then rinsed in PBS thrice again before the X-gal solution was 
added and left overnight at 37˚C to react with any LacZ in the cells to produce a blue 
color. The X-gal solution was made up to a final concentration of 5mM Kferro CN, 5mM 







6.2.5 MACS using the BAP tag 
MACS was carried out as described above in Sections 2.3, except that either 
magnetic-bead conjugated anti-Biotin was used, or magnetic-bead conjugated Strepavidin 
was used.  
6.2.6 Removal of cell-bound magnetic beads 
Cells that were bound to the column by magnetic-bead conjugated antibodies were 
given a final wash with calcium-, magnesium-, phenol red – free HBSS (Gibco, USA) 
and then eluted from the column with phenol-red-free 1ml 1x Tryple Express (Gibco, 
USA). Cells were nutated with Tryple Express at 37˚C for 5 minutes and then 100ul FBS 
was added to inhibit the reaction. Cells were then pelleted and washed with PBE. The 
Dead Cell Removal Kit (Miltenyi Biotec, Germany) was used to remove dead cells and 
the live cell fraction was then subjected to a second round of MACS.  
6.2.7 Zebrafish injection and dissociation 
Zebrafish were mated and the freshly fertilised eggs were collected and injected 
with 100-200pg of plasmid DNA per embryo within the first hour.  
Zebrafish embryos were maintained in petridishes of Egg Water (60 µg/ml 
"Instant Ocean" Sea Salts in distilled water with methylene blue) in a humidified 28˚C 






To perform MACS on the embryos, the petridishes were first placed on ice until 
the fish embryo movement was minimal. Egg water was removed and the embryos 
washed with ice-cold HBSS. About 50 embryos are transferred into a 1.5ml tube 
containing 500ul of Liver Digest Media. A pestle was used to break up the embryos. They 
were then pipette up and down with a 1ml pipette tip, until they were mostly single cells. 
The cell suspension was filtered through a single cell filter. The cells were pelleted, 
washed with HBSS and MACS performed as described for mice cells.  
6.2.8 Confocal imaging 
Cells were grown on Lab-Tek Chamber Coverglass (Nunc, USA) until 80% 
confluent. Media was aspirated and PBS was used to wash the cells three times. Cells 
were fixed in 4% Paraformaldehyde (PFA) for 10min at 4˚C, permeabalized with 
0.1%TritonX-100/ PBS for 3min and washed three times with PBS. Prolong Gold 
(Invitrogen, USA) with DAPI was used to mount the samples and cured for 24 hours in 
the dark before viewing. If antibodies were used, cells were blocked in 1%BSA/PBS after 
permeablization and then incubated with antibodies in 1%BSA/PBS. Imaging was done 
using the Carl Zeiss LSM 5 Duo Inverted Microscope, operated by the Biopolis Shared 






Section 6.3 Results  
  
Because a single round of MACS could not purify rare cell populations 
sufficiently when their proportion approached that of background levels, we designed a 
Two-Step MACS strategy. Here, a two-component transgenic cell-surface protein we 
designed, BAP-Lngfr, is co-expressed with the gene of interest, so that cells expressing 
this gene can be subjected to two rounds of MACS, one round against each component. 
This was successfully developed and found to be sufficient for our analyses. 
6.3.1 Optimisation of the two-component surface protein design 
To create a plasmid for the expression of our two-component cell surface sorting 
molecule, we used the pDisplay (Invitrogen) plasmid vector as our starting base vector, 
because the pDisplay vector already contains the required components to express the 
protein of interest and transport it to the extracellular cell surface. It contains the CMV 
promoter to drive the expression of the expression cassette. The Start codon, ATG, is 
followed by the Murine Ig kappa-chain V-J2-C signal peptide, which serves as the Leader 
signal for the nascent polypeptide to be transported across the ER membrane and to be 
eventually transported to the extracellular cell surface. After the nascent polypeptide is 
transported across the membrane, the signal is cleaved off. The plasmid contains the 
PDGFR transmembrane domain, which anchors the protein into the membrane, so that a 
transmembrane protein at the cell surface is created. Between the Leader sequence and 
the transmembrane domain, there is the Multiple Cloning Site which is flanked by the 
Hemagglutinin A (HA) epitope at the 5‟ and the myc epitope at the 3‟. The plasmid 
contains the kan/neo expression cassette controlled by the SV40 promoter and a bacterial 






mammalian cell cultures.  
To enable Two-step sorting, we cloned in two components into the Multiple 
Cloning Site (Fig. 6.2). For first round sorting by the biotin-tag component, we cloned in 
3 BAP tags in succession at the 5‟ end, closer to the N-terminus than the other 
component. 
For the second round of sorting, we used the Lngfr. There were two 
considerations to be made as the BAP-Lngfr would be an artificial protein and we did not 
know how its folding and expression pattern would be affected. The folding was 
important as the Lngfr must still be recognised by the anti-Lngfr antibodies and the BAPs 
must be recognised by hBirA. The expression was important as the cell surface molecule 
had to be expressed at sufficient levels at the cell surface, yet it must not be lethal to the 
cells or be degraded too quickly by the cells. 
 The first consideration to be made was whether or not to retain the 
transmembrane region of Lngfr, since the pDisplay vector contained the PDGFR 
transmembrane region. We were uncertain if having two transmembrane regions would 
enhance its stability at the cell surface or if it would reduce its cell surface expression 
instead. Also, the transmembrane of Lngfr region might affect the way the extracellular 
portion was folded.  






wanted to remove the Lngfr Leader sequence. This was very critical because the Leader 
portion of a protein precursor that enables its export across the ER membrane would be 
cleaved off in the mature protein. If we retained this cleavage site, the N-terminal 3 BAP 
tags would be cleaved off as well. Thus we had to start the Lngfr component only after 
this cleavage site.  




 a.a. of the mouse 
LNGFR (NCBI protein database ACCESSION  Q9Z0W1; swissprot: locus 




 a.a) of the human LNGFR, used in 
our system). However, when we aligned the mouse and human LNGFR protein sequence 
(Fig 6.3.1.1 ), we identified a conserved a.a. sequence from the 16
th
 a.a. to the 25
th
 a.a. of 
the human Lngfr. We rationalised that functionally important sequences have a tendency 
to be conserved through evolution and so this conserved region might be functionally 
important. The key functionally important sequence following the Leader sequence is the 
cleavage site. Furthermore, the conserved sequence contained a stretch of Leu, a nonpolar 
a.a., a typical characteristic of the Leader sequence. Hence we speculated that the 




 a.a. instead.  
Given the uncertainty, we decided to create 4 versions of BAP-Lngfr to identify 
empirically the optimal one to use. These 4 versions were made up of the 4 different 
combinations of either having the Lngfr transmembrane region or not and either including 




 a.a. of the Lngfr (Fig. 6.3.1.2). In addition to the 4 BAP-
Lngfr versions tested, we also made constructs using EGFP and constructs using the 






used, well established transgenic marker and could serve as a molecule for FACs or 
imaging purposes. The Rabbit Fc region was used because we had earlier found the anti-
rabbit antibody to give the lowest background.  
Each of these candidate second components were cloned into a pDisplay vector 
that had already been modified to contain the 3x BAPs, as well as the IRES-hBirA and 
IRES-EGFP inserted between the STOP codon of the PDGFR transmembrane region and 
the poly(A) coding sequence.  
The plasmid constructs were transfected into both HEK293 and NIH3T3 cells and 
MACS performed after 24 hours of transfection. A single-step MACS was performed 
using antibodies against the second component i.e. against the Lngfr, EGFP and Rabbit 
Fc components of the cell surface molecule . This was because the Two-step MACS was 
yet to be optimised. We included as positive control, a single-round MACS that used the 
Lngfr single component cell surface molecule only.  
We found that the best sorting (Fig. 6.3.1.3) was achieved with the HEK293 cells, 
using the Lngfr without the Lngfr transmembrane region and excluding Lngfr a.a. 20 – 
25. The Lngfr-only control achieved a recovery of 33.63% while the best performing 
BAP-Lngfr, 90.01%. The BAP-Lngfr achieved a purity of 84.1% against 77.5% of the 
Lngfr-only control.  










sorting purity; both versions achieved sorting purities above 80%. BAP-Lngfr versions 
that excluded the Lngfr transmembrane region performed the best in terms of recovery.  
The MACS performed very poorly with the NIH3T3 cells in contrast, once again 
underscoring the differences in expression of the cell surface molecules between different 
cell types. Compared to the control, which achieved a purity of 91%, the BAP-Lngfr 
without the Lngfr transmembrane and without a.a. 20 – 25 achieved a purity of only 
26.1%. This was the best performer in terms of purity, compared with all the other 
candidate second components. In terms of recovery, it was the second best performer, 
giving 13.11% recovery against the 100% recovery for the Lngfr-only control. The best 
performer was the BAP-Lngfr version with no Lngfr transmembrane but with the a.a. 20 
– 25, with a recovery of 15.08%. However, because our primary objective was to obtain 
pure sorts and because the difference in recovery was very slight, we considered the best 
performing candidate second component when NIH3T3 cells were used, to be the BAP-
Lngfr version with neither Lngfr transmembrane nor a.a.20 – 25, as well.  
In summary, we analysed the Lngfr sequence and postulated that the Leader 
sequence might be cleaved off 6 amino acids downstream of the published theoretical 
cleavage site. We tested this in HEK293 and NIH3T3 cells, using versions of Lngfr that 
excluded only the published theoretical cleavage site (includes a.a.20-25), or versions of 
Lngfr that excluded both the published cleavage site and the cleavage site we postulated 
(excludes a.a. 20-25). We found that in both cell lines, MACS performed better when 
both the published and our postulated cleavage sites were excluded (a.a. 20-25 excluded). 






actually 6 amino acids downstream of the publisehd theoretical one. Our analysis and 
approach successfully identified the best BAP-Lngfr version for use as our two-
component cell surface protein for Two-step MACS. This was the BAP-Lngfr version 
without the endogenous Lngfr transmembrane, and without both the published and our 
hypothetical cleavage site (excluding a.a. 20-25). Henceforth, this was the only second 
component that we used.  
From this best performing BAP-Lngfr, we made 3 different versions of the 
plasmid (Fig. 6.3.1.4): The first contained IRES-EGFP and IRES-hBirA following the 
BAP-Lngfr. We named the plasmid pBAP-DihBiE-Lngfr. The second contained no 
IRES-EGFP. We named this plasmid pBAP-DihB-Lngfr. The third encoded a BAP-Lngfr 
– EGFP fusion protein, instead of the IRES-EGFP. The EGFP was fused to the C-
terminus on the transmembrane domain of the BAP-Lngfr. Hence it was in the 
intracellular part of the cell membrane. We named this plasmid pBAP-DihB-TmE-Lngfr. 
These different variations of the plasmid were made to allow various experimental 
strategies to characterise the synthetic BAP-Lngfr cell surface molecule and to optimise 
the Two-step sorting strategy.  
To visualise and ensure our cell surface molecule was folded correctly 
(recognisable by its antibodies) and that it localised properly, we performed confocal 
imaging on the transfected cells using various antibodies. Fig 6.3.1.4 shows HEK293 
cells expressing the cell surface molecule consisting of the components HA-3xBAP-myc-
transmembrane domain (Lngfr has not been included). PE-conjugated anti-HA shows this 






stained nucleus (in blue). Cells were permeabalized prior to antibody staining. No green 
fluorescence is detected as EGFP is absent. HEK293 cells expressing a cell surface 
molecule with all the same components, plus the additional EGFP fused to the C-terminus 
of the transmembrane domain on the intracellular side of the cell surface, confirms that 
the molecule is localised on the cell surface and cytoplasm but not in the nucleus (blue). 
Fig. 6.3.1.4 shows the overlap between the HA (red) and EGFP (green). HEK293 cells 
that express the same cell surface molecule, but with EGFP under the IRES control rather 
than being fused to the transmembrane domain, express EGFP (green) throughout the 
whole cell, including the nucleus (blue), where no HA is detected (red). Thus we were 
confident that our base expression vector successifully coded for the main components of 
the cell surface protein that we wished to use and that they were appropriately expressed, 
folded and translocated. 
To ensure that with the inclusion of the selected Lngfr component, proper protein 
folding and localisation still took place, we also stained pBAP-DihB-TmE-Lngfr-
transfected HEK293 cells with PE-conjugated anti-HA and DAPI. Fig 6.3.1.5 shows cells 
expressing the cell surface molecule consisting of the components HA-3xBAP-Lngfr-
myc-transmembrane domain- fused EGFP. To determine if the cell surface molecule was 
properly translocated to the extracellular side of the cell surface, we did not permeabalize 
the cells before antibody staining, as we did earlier. Thus the HA detected (red) by the 
anti-HA antibody could only be the HA epitopes on the extracellular surface of the cell 
and not those on the intracellular side or the cytoplasm. The green fluorescence from the 
fused EGFP shows that the molecule is also expressed throughout the cytoplasm, but not 






0.1%Triton-X-100 permeabalization and hence still stains the nucleus (blue). Thus we 
concluded that our two-component extracellular cell surface BAP-Lngfr was indeed 
exposed on the cell surface, for the cell to be labelled by bead-conjugated anti-biotin or 




































6.3.2 Gene targeting for the in vivo Two-step MACS 
  
BAP-Lngfr knock in to the Sox9 locus 
Similar plasmids were made to express the selected Bap-Lngfr in Sox9-expressing 
cells in mice tissue. We used the same Sox9 gene targeting constructs used to generate the 
single component Lngfr knocked-in ES cell lines earlier. This time, the first Sox9 exon 
was partially replaced with either BAP-Lngfr, BAP-Lngfr with EGFP cloned in frame 
with BAP-Lngfr to express a BAP-Lngfr-EGFP fusion protein, or BAP-Lngfr-F2A-
EGFP. F2A (Foot and mouth virus 2A peptide) (Chinnasamy, Milsom et al. 2006) is a 
viral sequence that enables the cleavage of the peptide within itself. Hence BAP-Lngfr 
and are expressed in the same cells, but as independent proteins. F2A has been shown by 
various groups (Ibrahimi, Vande Velde et al. 2009) ; (Chinnasamy, Milsom et al. 2006; 
Trichas, Begbie et al. 2008), including our own (unpublished data), to allow higher and 
equal levels of gene expression across multiple cistrons compared to IRES and has been 
shown to work in transgenic mice as well (Trichas, Begbie et al. 2008).  
These 3 construct variants were made so that the same in vitro experiments can be 
replicated with animal cells. Another 3 constructs were also made from these 3 variants, 
where IRES-hBirA was added just before the polyA tail of the expression cassette. Mice 
generated from these plasmids would not need to have hBirA knocked-in to other loci for 
biotinylation of BAP to occur.  
These Sox9-targetting constructs with their various transgenenic sequences were 






were picked and expanded. They were screened in the same manner described for theES 
cells with a single component Lngfr knocked-in to the Sox9 locus. Until the time of 







hBirA knock in to the ROSA26  locus  
In order for the Two-step sorting to work with animal tissue, the BAP-Lngfr 
needed to be biotinylated by hBirA in the cells of interest. hBirA is expressed in trans and 
need not be under the same promoter control as the BAP-tagged protein. We chose to 
knock hBirA into the ROSA26 locus to generate mice capable of expressing hBirA in all 
their tissues so that all Sox9-expressing cells could be isolated.  The BAP tag sequence 
used was optimized by Schatz‟s group and found to be MAGGLDNIFEAQK* IEWHE 
for N-terminus tags and  GGLDNIFEAQK* IEWHEstop for C-terminus tags, where the * 
indicates the lysine being biotinylated (Schatz 1993; Beckett, Kovaleva et al. 1999). Any 
transcription factor to be biotinylated by hBirA should contain one of these sequences. To 
ensure that our hBirA protein would be functional before creating the hBirA transgenic 
mice lines, we created a plasmid encoding an N-terminus BAP tagged EGFP. This vector 
was transiently co-transfected into cells with pBS –hBirA (expressing hBirA only) and 
pDihBiE (one of the intermediate plasmids in the construction of our two-component 
BAP-Lngfr overexpression and targeting constructs, expressing hBirA, EGFP and part of 
the cell surface protein). StrepAvidin-HRP Western Blotting against biotinylated BAP-
EGFP proved our hBirA functional (Fig. 6.3.2.6).  
The ROSA26 locus was chosen for its ubiquitous and constitutional expression 
throughout mice development from the four-cell embryonic stage on (Kisseberth, 
Brettingen et al. 1999). Previous studies involving the knock-in of lacZ at the ROSA26 
locus achieved widespread prominent X-gal staining (Zambrowicz, Imamoto et al. 1997). 
Such an expression pattern of hBirA is necessary to biotinylate the widest possible 






and tissue type.  
The pROSA26-1 was created by Soriano‟s (Soriano 1999) group for targeted 
homologous recombination at the mouse ROSA26 locus. This consisted primarily of a 
1.1kb left and 4.3kb right arm and unique XbaI RE site for introducing the transgene 
between the first and second exons (Fig. 6.3.2.8). Using the pROSA26-1 targeting 
construct, we cloned a splice acceptor followed immediately by the hBirA gene. We also 
added a neomycin resistance gene run by a PGK promoter and flanked by loxP sites, after 
the splice-acceptor and hBirA sequence to enable G418 selection ES cells transfection. 
We also created another variation of the plasmid construct, this one with an IRES-
lacZ cassette between the hBirA and neomycin resistance gene cassettes. Eventually we 
wanted to have two transgenic mice strains; one with the lacZ reporter to reflect hBirA 
expression (pROSA-hBirA-ILN) and the other without (pROSA-hBirA-Neo) (Appendix 
2.6).  
We knocked in both gene cassettes into the ROSA26 locus of V6.4 ES cells by 
homologous recombination. After electroporation of the targeting construct into the 
ESCs, the LacZ allowed us to screen for our desired mutants, as the ROSA26 locus was 
active in ES cells. Colonies arising from cells where homologous recombination took 
place turned blue when fixed and treated with the X-gal substrate (Fig. 6.3.2.7). Random 
integrations into other active loci can also give rise to blue colonies. Of all the G418-
resistant colonies picked, 1 in 10 reacted positively with X-gal. These were screened and 






contain the desired knock-ins. Altogether, 57 clones were identified.  
 4 of these colonies were expanded in culture and then electroporated again to 
transiently express Cre from a circular expression construct. The resulting colonies were 
screened for G418 sensitivity to detect for the loss of the loxP-flanked PGK-Neo cassette. 
About 12- 40% of the picked colonies had neo removed.  
We picked two of these clones, ILN2b and ILN21a to transiently transfect BAP-
tagged EGFP into and confirmed by Western Blotting that BAP-EGFP could be 
biotinylated (Fig. 6.3.2.6). These 2 clones were karyotyped and ILN2b was found to be 
normal, while ILN21a had chromosomes with Robertsonian translocations and grew 
significantly slower. This may explain why ILN21a has a significantly lower level of 
biotinylated BAP-EGFP compared to ILN2b ─ most of the protein material was 
contributed by the feeder cells which tended to overgrow the culture. 
Clones, ILN2 and ILN7, containing neo still, were used for microinjection for the 
purposes of generating mice transgenic for hBirA and lacZ. At the time of writing, we 
had obtained 2 chimeric mice (35% and 25% chimerism by coat color) from 2 

























6.3.3 Optimising the Two-step MACS protocol 
Having ensured that the BAP-Lngfr or BAP-Lngfr-EGFP fusion proteins used 
were optimal and that the folding and localisation was correct, we proceeded to optimise 
each step of the MACS protocol to isolate the Lngfr-expressing cells. Very briefly giving 
an overview of our strategy, four main steps are involved: Firstly, live single-cell 
populations from animal tissue are obtained for use as the starting input material for 
MACS. Next, the first round of MACS selects for cells with the 3 BAPs displayed on the 
extracellular cell surface. Thirdly, the beads from the first round of MACS are removed, 
to enable a second round of sorting, which is the second round of MACS and the final 
main step. Finally, the second round selects for cells expressing the Lngfr epitopes on the 




We investigated the effects that different cell dissociation solutions had on the cell 
viability. After NIH3T3 cells were dissociated with different dissociation solutions, they 
were stained with Propidium Iodide and FACS analysed (Fig. 6.3.3.1a). Typsin- and 
TrypLE dissociated (approximately 5-10 minutes at room temperature) cells were very 
similar, with 93.4% and 93.3% viability respectively. Liver Digest media from Invitrogen 
had 95% cell viability while a similar homemade collagenase- dispase solution (200U/ml 
Collagenase I, 200U/ml Collagenase II, 2.5U/ml Dispase in HBSS, 10min incubation at 
room temperature) had 96.4% cell viability. Cells that were incubated with PBS alone 






cell viability (Fig. 6.3.3.1b). This underscored the importance of not leaving the cells 
exposed to the wash solutions for extended periods. We also decided to use HBSS as the 
wash solution for all steps prior to any antibody incubation steps, rather than PBS. This 
included the steps immediately after removing teratoma or embryos from the mice, where 
the tissue was immediately washed and stored in ice-cold HBSS. Trypsin, TrypLE and 
Liver Digest were commercial (Invitrogen) solutions were based in HBSS and we 
prepared our homemade collagenase-dispase solution in HBSS as well.  
We also investigated which dissociation solution was most effective and less toxic 
to the cells when embryonic tissue was dissociated to single cells (Fig. 6.3.3.1a). Trypsin 
and TrypLE dissociated the 12.5 d.p.c mouse embryonic tissue very poorly when 
incubated and mechanically agitated for 10min. When incubated longer, the tissue did not 
dissociate to single cells but formed huge masses of degraded tissue. Collagenase 
dissolved in either HBSS or Leibovitz media digested the tissue to single cells when 
incubated on a nutator for 3 hours at 37˚C. However, the long duration may have altered 
gene expression and cell biochemistry. When the incubation was reduced to 10min with 
mechanical agitation (pipetting repeatedly with a 1ml pipette tip) there was partial 
dissociation. Viability of the cells was 84% when digested in HBSS and 87.7% when 
digested in Leibovitz. The homemade collagenase-dispase solution was able to dissociate 
the tissue almost completely within 10min with mechanical agitation. Cell viability was 
88.3%. Invitrogen‟s Liver Digest media was able to dissociate the tissue just as well and 
viability was 82.5%. Dead cells tended to bind antibodies non-specifically, affecting the 
purity of the Eluted fraction. Hence, following the dissociation of tissue to single cells, 






bead-conjugated antibodies against various proteins displayed on cells undergoing 
apoptosis and necrosis, to bind and retain the dead cells on the MACS column. Dead cells 
were bound to the various antibodies in the kit‟s cocktail antibody mix and retained on 
the column. The cells that flow through or that were washed out were the live fractions 
that were subsequently used for the Two-step MACS. Dead cell debris was also removed 
when dissociated cells were pelleted gently as the debris tended to remain in the 
supernantant that was discarded (Fig. 6.3.3.2). Alternatively, the Dead Cell Removal kit 
was applied after the first round of MACS, as dead cells tended to make up a significant 
proportion of the eluted cells. Enzymatic removal of the beads bound to the cells also 
results in cell death, which was removed for increased purity of the second round of 
MACS.  
The next aspect of the dissociation solution we investigated was its effect on the 
recovery of cells. HEK293 cells transfected to express BAP-Lngfr- fused with EGFP 
were dissociated with trypsin, TrypLE, homemade collagenase-dispase or Liver Digest 
solution. MACS was performed with either anti-Lngfr or anti-biotin. (Fig. 6.3.3.1a). As 
expected, recovery was very low when anti-biotin was used for MACS of cells 
dissociated by trypsin or TrypLe because the BAP portion would have been cleaved off. 
The lower recovery obtained from TrypLE-dissociated cells showed that it was more 
efficient at cleaving the trypsin-sites. Because a significant amount of epitope sites were 
cleaved off by trypsin and TrypLE, even the recovery when anti-Lngfr was used was 
significantly lower than when collagenase-dispase or Liver Digest media was used. 
Collagenase and dispase - also the major components of the Liver Digest media - had no 






biotinylated BAPs recognised by anti-biotin, compared to Lngfr with epitopes along its 
entire length, the recovery using anti-Lngfr was significantly higher.  
Both the homemade collagenase-dispase and Liver Digest solutions were suitable 
for dissociating tissue to single cells for MACS, because tissues were well dissociated 
into sufficiently viable single cells that could be recovered efficiently after MACS. As the 
Liver Digest was the most convenient to use, requiring no preparation on our part, we 


















Magnetic- bead removal 
Between the first round of MACS using the anti-biotin antibody and the second 
round of MACS using anti-Lngfr, the beads needed to be cleaved off, so that the non-
specifically bound cells from the first round could be washed off. While protocols to strip 
all antibodies away from cells completely using acetic acid exists, such a method was 
very harsh; we wanted to use a method where the cells are kept at physiological 
conditions as far as possible.  
We investigated two possible ways to achieve this. The first way was to make use 
of the 14 trypsin cleavage sites along the Lngfr component of BAP-Lngfr (Fig. 6.3.3.3a). 
Because the anti-Lngfr antibody is a polyclonal antibody, complete trypsin digestion 
would have still left a sufficient portion of Lngfr epitope sites. Both trypsin and TrypLe 
(Invitrogen) recognise these cleavage sites, but we chose TrypLe because it conveniently 
works optimally at room temperature, is gentler on the cells and so does not need to be 
stopped. When trypsin was used, large dead cell clumps formed; this was less of a 
problem when TrypLe was used.  
The other way of removing the beads was to use Miltenyi‟s Anti-Biotin Multisort 
kit. The bead-conjugated Multisort anti-biotin antibody has a proprietary cleavage site 
that will be cleaved to remove the beads when treated with the accompanying Multisort 
Release Reagent (Fig. 6.3.3.3b).  






fraction after MACS, using either the usual bead-conjugated anti-biotin or the Multisort 
anti-biotin, was collected. The cells were incubated with either TrypLE or the Multisort 
Release Reagent (as directed by the manufacturer). These cells were put through another 
MACS column. The flow-through and Unbound fraction together contained the cells with 
sufficient beads cleaved off to be released from the column. The bound fraction, which is 
then eluted mechanically with the plunger, contains the cells with insufficient beads 
cleaved off and are hence retained on the column. We found that with TrypLE, the ratio 
of released cells to retained cells was 20:1, whereas with the Multisort Kit, this ratio was 
5:2. Hence we decided to continue with TrypLE to remove the magnetic beads that bound 
to the cell surface molecule via the antibody. Hence, TrypLE, as the better approach, was 













We wanted to ensure that antibody-cell incubations used were optimal. Thus we 
investigated MACS recovery of cells after incubating the cells with the bead-conjugated 
antibodies for differing concentrations of antibody and for differing periods and 
temperatures (Fig. 6.3.3.4). While there was only a single anti-Lngfr antibody available 
for the second round of MACS, there were 3 possible options for MACS using the 3 
BAPs in the first round: Strep-Avidin, anti-biotin or the Multisort Kit anti-biotin 
(described earlier). Under all the different antibody incubation conditions tested, the anti-
biotin consistently outperformed both Strep-Avidin and Multisort Kit anti-biotin. This 
was despite Strep-Avidin having the highest known non-covalent binding affinity for 
biotin in nature. Perhaps the conjugation of the magnetic bead to Strep-Avidin decreases 
its affinity for biotin. In the same way, even though the Multisort Kit Anti-biotin is made 
from the same antibody as the anti-biotin, but with an addition Multisort Release Reagent 
cleavage site for bead-removal, that addition seemed to have somehow decreased its 
binding affinity for biotin. As expected, anti-Lngfr produced the highest recovery rate 
consistently, likely because it has more epitope sites on the BAP-Lngfr.  
For anti-biotin, a shorter incubation (40min) at room temperature rather than a 
longer (2hours) incubation at 4˚C seemed to work a little better (59.2% vs. 47.4%), and so 
did doubling the antibody concentration used from 20% v/v as recommended to 40% v/v. 
However, because the difference was slight (59.2% vs. 66.9%) and the second round of 
MACS would decrease the non-specific background, we decided to keep with the 20% 
v/v recommendation because we did not want to increase the cells exposure to the sodium 






however, doubling the antibody concentration doubles the recovery as well (14.9% vs. 
36.5%). For anti-Lngfr the best recovery was achieved with the recommended 20% v/v 
antibody concentration (94.1% vs. 78.5%), incubated for a shorter duration at room 












Surface expression of BAP-Lngfr 
Using the percentage of cells expressing EGFP within each fraction to determine 
recovery and purity can be misleading, as it assumes that all the transfected cells have 
equal distribution of the BAP-Lngfr across their cytoplasm and extracellular surface. 
Confocal images of cells expressing the BAP-Lngfr fused with EGFP (Fig. 6.3.1.5) 
showed that this may not be the case. When the non-permeabilized cells were stained 
with PE-conjugated anti-HA antibody, some green-fluorescing cells showed more 
extracellular red staining than others.  
When we performed MACS on input HEK293 cells with a large percentage 
successfully transfected with the pBAP-DihB-TmE-Lngfr construct and stained each 
fraction with PE-conjugated anti-HA antibody, without permeabilization, we found that 
most of the cells found in the Unbound fraction did not localise their cell surface 
molecule on the extracellular surface, while most cells in the Eluted fraction did 
(Fig.6.3.3.5). FACS analysis showed that 82.3% of the starting input cells had green 
fluorescence. When the input cells were stained with PE-conjugated anti-HA, 35.1% of 
the cells had both green and red fluorescence and another 54% were green only. 17.5% 
were unstained and 0.4% were red only. Because the cells were not permeabilized, only 
cells that expressed the BAP-Lngfr- EGFP fusion protein on the extracellular surface 
would be bound by the PE-conjugated anti-HA antibody, as previously shown (Section 
6.3.1).  






MACS, the Unbound fraction had 70.8% green cells and 25.9% untransfected, colorless 
cells (Fig. 6.3.3.5). 3.3% were both green and red. In contrast, the Eluted fraction had 
86.7% of cells expressing the BAP-Lngfr-EGFP fusion protein on its extracellular cell 
surface. 12% were green only and 1.2% were colorless. When bead-conjugated anti-Lngfr 
was used for a single round of MACS, recovery was higher. 44% of the Unbound fraction 
were green only, 54% were untransfected colorless cells and only 1.6% had the BAP-
Lngfr EGFP fusion protein on the extracellular cell surface. In the Eluted fraction, 54.9% 
of cells had the BAP-Lngfr EGFP fusion protein on the extracellular cell surface, while 
37.1% were green only, indicating that the anti-Lngfr was a lot more sensitive than the 
anti-biotin antibody or anti-HA antibody. This explains the higher recovery rate seen with 
MACS using anti-Lngfr compared to anti-biotin. However, its specificity was lower, as 
the Eluted fraction was less pure, with 7.8% of the cells being untransfected. This is 
consistent with previously described observations that MACS with HEK293 cells using 












6.3.4 Two-step MACS 
At this point we had optimised the following parameters: the Two-component 
BAP-Lngfr extracellular surface molecule design for MACS: the tissue dissociation 
conditions: the BAP-Lngfr cleavage conditions: and the conditions for bead-conjugated 
antibody labelling of the target cells. Thus we proceeded to test out the entire Two-step 
MACS protocol using dissociated 12.5 d.p.c wildtype mice embryo cells spiked with 
HEK293 cells expressing the BAP-Lngfr-EGFP extracellular fusion protein. The cells 
used for the spike-in were isolated by MACS of HEK293 cells transfected with the 
pBAP-DihB-TmE-Lngfr plasmid. The anti-biotin was used and the positive eluted cells 
collected. 12.5 d.p.c wildtype embryos were dissociated using Liver Digest media and 
passed through a single-cell filter.  
In our first protocol attempted (Protocol 1, Fig. 6.3.4.3a), the single cells were 
spiked with the transfected HEK293 cells at 2% by cell count. Dead cells were then 
removed. . The remaining cells formed the starting input cell population. They were 
incubated with bead-conjugated anti-Biotin and the first round of MACS performed. 
FACS analusis showed that  the resulting Eluted fraction had a purity of 41.6%. The 
Unbound fraction had 1.6% GFP+ cells.  
Because the carrier solution used to resuspend and wash cells for MACS 
contained 0.5% BSA, the trypsin cleavage may have been compromised. Hence for the 
third and final wash before eluting the cells bound to the MACS column, we used HBSS 






agitation for 10min at 37˚C. Fetal Bovine Serum was added to 20% concentration to stop 
the reaction. The cells were washed in PBE (D-PBS/0.5%BSA/5mM EDTA pH8.0) and 
the incubated with the bead-conjugated anti-Lngfr antibody for the second round of 
MACS. The purity of the cells after the second round was 70.4%, and the wash had 
21.2% GFP+ cells. In both the first and second rounds, the recovery was nearly 100% by 
cell count.  
We then made a next attempt using a slightly modified protocol (Protocol 2, Fig. 
6.3.4.3a), which improved the Two-Step MACS performance substantially. This time, 
TrypLE was used instead of trypsin, and the Dead Cell Removal Kit was applied after 
TrypLE cleavage between the first and second rounds, rather than at the point 
immediately after dissociation and spike-in. This time, the cells were spiked in at 1% by 
cell count (1.1% GFP+ by FACS analysis). The eluted cells from the first round of 
MACS had a purity of 37.9%, which was increased to 84.4% after the second round. The 
Unbound fractions in both rounds had 0.2% GFP+ cells.  
We also made an attempt using this same protocol to isolate cells expressing this 
2-component cell surface molecule when spiked at a 0.15% level by cell count (0.1% 
GFP+ by FACS analysis). Purity of the eluted cells following the first round of MACS 
was 17% and 40.3% after the second round.  
We did a negative control MACS using this same protocol, where we used cells 
from the Unbound fraction from the MACS of transfected HEK293 cells. We spiked them 






analysis). Because the Unbound fraction also contained EGFP, they could still be tracked 
to see if enrichment occurred as well. In the earlier section, we had shown that the 
Unbound fraction contains cells that express the cell surface molecule as well, but not in 
sufficient amounts on the cell surface as would be found on cells of the Eluted fraction. 
Purity of the eluted cells following the first round of MACS was 0.6% and 2.2% after the 
second round.  
The FACS analysis itself “affects” the proportion of cells fluorescing in each 
fraction. This is because it is up to the user to set the gates and cut off points for 
fluorescence. Cell cultures tend to give rise to fairly homogenous single-cell populations, 
with respect to their side and forward scatter characteristics. Cells dissociated from 
complex tissues tend to be very heterogeneous (Fig. 6.3.4.1a left). Unlike blood tissue 
where there are a small number of different cell types, giving rise to distinct cell 
populations identifiable on a forward and side scatter plot, cells dissociated from either 
embryos or teratoma do not. Under the haemocytometer, this can be observed (Fig. 
6.3.4.1a right) ─NIH3T3 produces fairly uniformly sized large cells, whereas embryos 
produced cells of all sizes. Because we want to know what the characteristics of the entire 
cell population within each fraction are, we tried to set the scatter gates as wide as 
possible with tissue dissociated cells, to ensure that all the cell types are taken into 
account. The downside of such a wide scatter gate is that a lot of cell debris also gets 
counted as cells, which can skew the percentage of fluorescing cells.  
Setting the cut-off point for GFP fluorescence is also a challenge with tissue-






usually used as the reference population for non-fluorescence. Cells from culture e.g. 
NIH3T3 are expected to have a uniform level of autofluorescence, but in practice, 
autofluorescence falls along a narrow bell-shaped normal curve. Any GFP fluorescence 
would shift this curve significantly. Hence it would be logical to set the cut-off point at 
the extreme right tail, where the GFP just registers 0% on the FACS Analyser.  
This same principle cannot apply if the fluorescence is not strong and the shift in 
the normal curve has significant overlaps with the background (Fig. 6.3.4.2a), resulting in 
an underestimation of the proportion of fluorescent cells in the area of the overlap (green 
box, Fig. 6.3.4.2b). This can mean that the purities of the Eluted fractions are 
underestimated (red circle, Fig. 6.3.4.2b). This can happen when the antibody to the cell 
surface molecule is very sensitive and able to retain cells even when the BAP-Lngfr and 
EGFP expression is weak. It also cannot apply to complex cell populations, however, 
because it is made up of many different subpopulations of different cell types, each with 
its own level of background autofluorescence. The bell-shaped curve is very wide and is 
an accumulated effect of many smaller bell-shaped curves. A particular cell population of 
interest may have a very low level of autofluorescence. When it fluoresces because of an 
introduced gene, the fluorescence might be masked by cells with very high levels of 
autofluorescence, even though there is a significant difference for that particular 
subpopulation of interest (Fig. 6.3.4.1b). Setting the GFP cut-off points overly stringent, 
where the wildtype cells register 0% GFP+ may underestimate the actual populations of 
fluorescing cells. Vice versa, non-stringent cut-off points give rise to false positives and 






To illustrate with Protocol 2 (Protocol 2, Fig. 6.3.4.3a) of our optimised Two-step 
MACS, setting the gates less stringently increases the purity of the first round of MACS 
to 49.4% instead of 37.9% (Fig. 6.3.4.3b) and the purity of the second round to 86.6% 
instead of 84.4%. The proportion of fluorescent cells in the first round wash increases 
slightly from 0.2% to 0.3%, and that in the second round wash increases slightly as well 
from 0.2% to 0.5%.  However, lowering the stringency of the cut-off point would also 
mean that the starting input cells would have 2% spiked in cells instead of 1.1%. Because 
we spiked in the cells at 1% by cell count, we decided to use the more stringent cut-off 
point, since the 1.1% GFP+ in the input cell population was much closer to the actual 
numbers compared to the 2% GFP+. With spike-in experiments where the proportion of 
GFP cells are known, this can be means of setting the cut-offs. However where this is 
























6.3.5 Reservations  
One of the main concerns we have about our method is the effect of introducing 
the transgenic cell surface molecule on certain cell types, tissues or even entire animals.  
 
Poor NIH3T3 cell viability 
Protein expression of the cell surface molecule differed between cell types (Fig. 
6.3.5.1a ). In HEK293 cells the single-component Lngfr cell surface molecule performed 
poorly with MACS done 24 hours after transfection, having a recovery rate of only 
33.63% and an elute purity of 77.55%. The two-component BAP-Lngfr cell surface 
molecule performed significantly better, with a recovery rate of 90.01% and an elute 
purity of 84.1%. The opposite was true with NIH3T3 cells however. The single-
component Lngfr cell surface molecule performed very well with MACS done 24 hours 
after transfection, having a recovery rate of 100% and an elute purity of 91%. The two-
component BAP-Lngfr cell surface molecule performed significantly worse, with a 
recovery rate of 13.11% and an elute purity of 26.1%.  
 These differences may be a result of differences in the way the two proteins are 
folded in these two cell types. These proteins may also have an effect on the viability of 
the cells; this seems to be very pronounced when BAP-Lngfr is expressed in NIH3T3 
cells. NIH3T3 cells transfected with pBAP-DihB-TmE-Lngfr express BAP-Lngfr fused to 
EGFP. By 12 hours, they fluoresced and continued to do so until 24 hours. The 
fluorescent cells began to die and by 36 hours, half the fluorescent cells were alive and 






fluorescent “cells” were the debris of the dead cells (Fig. 6.3.5.1c). The non-fluorescent 
cells grew normally.  
This phenomenon was not observed when the same construct was transfected into 
HEK293 cells, or when the pBAP-DihBiE-Lngfr (to express BAP-Lngfr and EGFP 
independently in the same cells) was transfected into NIH3T3 cells. In both these 
instances, fluorescence was observed in live cells past 72 hours, even though expression 
was decreased, as expected over time following any transient transfection (Fig. 6.3.5.1b). 
However MACS was still significantly poorer with the NIH3T3 cells.  
When we cultured NIH3T3 cells transfected with either pBAP-DihBiE-Lngfr or 
pBAP-DihB-TmE-Lngfr or pBAP-DihB-Lngfr in G418 selection media for 6 weeks, the 
cells continued to grow normally. A no-DNA control transfection was lethal after 2 
weeks. After 6 weeks, pBAP-DihBiE-Lngfr transfected cells continued to fluoresce very 
weakly, compared to untransfected, unselected cells as well as the pBAP-DihB-Lngfr 
transfected cells on G418-media. pBAP-DihB-TmE-Lngfr cells looked normal. However, 
there were occasionally one or two rare single fluorescent live cells. There were also a 
few large clumps of dead cells that fluoresced weakly. This was noticed even after cells 
were passaged and these dead cell clumps from earlier passages washed away. When we 
did a Western Blot on these cells, similar levels of expression of cell surface molecule for 
all 3 transfection variations were observed. Their levels were, as expected, significantly 
lower than the 24 hour transfections (Fig. 6.3.5.2). When probed for EGFP, degradation 
of the BAP-Lngfr EGFP fusion protein was observed on the Western Blot, consistent with 






dead cells, where perhaps the degradation mechanism had ceased to function, allowing 
EGFP to fluoresce.  
The fact that gene expression from the transfected expression constructs seemed 
to continue, as evidenced by the cell viability in G418 selection media for 6 weeks, the 
continued EGFP fluorescence in the pBAP-DihBiE-Lngfr transfected cells and the similar 
protein levels detected by Western Blot, seemed to suggest that it was the protein 
expression or folding that was being affected in NIH3T3 cells. Cell viability was also 
affected. Cells expressing the BAP-Lngfr fused with EGFP seem to either not fluoresce; 
only dead cell debris seem to fluoresce.  
Because the main difference between the single-component cell surface molecule 
and the two-component one was the addition of the 3 BAPs and because biotinylated 
proteins are not usually found on the extracellular surface of cells, we investigated if 
biotinylation affected the protein folding and localisation, or perhaps even the cell 
viability.  
We made a construct from the pBAP-DihB-TmE-Lngfr vector encoding the BAP-
Lngfr-EGFP fusion protein, which had the ires-hBirA removed. MACS was performed 
with NIH3T3 cells transfected with 1) pBAP-DihB-TmE-Lngfr that had ires-hBirA, the 
construct without ires-hBirA and 2) the hBirA-less construct with hBirA on a separate 
plasmid transfected together. We found that when anti-Lngfr was used for the MACS, 
there was no difference in the performance of MACS (Fig. 6.3.5.3), indicating that 






anti-Biotin was used, there was insignificant enrichment of fluorescent cells when the 
hBirA-less construct was used, indicating that enrichment required the biotinylation of the 
BAP-Lngfr.  
In fact, what we found was that increasing the biotinylation improved the MACS 
performance. The purity of MACS doubles when HEK293 and NIH3T3 cells were grown 
in media with Biotin addition to a final concentration of 100uM (Fig. 6.3.5.3a). This 
hinted that the poor performance of MACS using NIH3T3 might be because the BAP-
























Zebrafish developmental abnormality 
We wanted to know if our Two-Step MACS could be applied to developmental 
model organisms other than mice. Attempts to express the cell surface molecules in 
zebrafish embryos for MACS gave rise to fish with developmental abnormalities.  
Genes can be expressed in zebrafish embryos by injecting plasmid expression 
constructs at the one cell stage, within the first hour. We injected embryos with pBAP-
DihBiE- Lngfr to express the two-component BAP-Lngfr cell surface molecule and 
EGFP, pBAP-DihB-TmE-Lngfr to express the two-component BAP-Lngfr with the fused 
transmembrane EGFP, pMACS-Lngfr-Neo to express the Lngfr alone and pEGFP to 
express EGFP alone as a positive control.  
While 80-90% of pEGFP-injected or control embryos tend to survive past the first 
24 hours, those injected with the other plasmids have a high death rate of about 50- 90%. 
Amongst the survivors, injected embryos tend to be developmentally slower (Fig. 
6.3.5.4). By 60 hours, the uninjected zebrafish had hatched but not the injected ones. 
Fluorescing embryos tended to be deformed (Fig. 6.3.5.5). Only the EGFP control had 
obvious fluorescence. By Day 6, amongst the survivors, about 10% or less of pEGFP-
injected or uninjected embryos would be deformed. Amongst those expressing the BAP-
Lngfr molecule, about 20% were deformed. Amongst those expressing the BAP-Lngfr 
molecule with EGFP fused at the transmembrane, about 80% of the surviving embryos 
tended to be deformed. Most survivors were not fluorescent. MACS did not result in any 






These observations suggest that the transgenic cell surface molecule affected the 


















Section 6.4 Discussion  
To circumvent the difficulty of isolating specific cell populations from dissociated 
complex tissue when their proportions reached levels similar to that of the background, 
we developed a Two-step MACS strategy. These rare cells (1%) are defined by their 
expression of a particular gene of interest rather than their cell surface markers or size. A 
two-component transgenic cell surface protein is expressed under the promoter control of 
the endogenous gene of interest by means of gene targeting and the generation of 
transgenic tissue. We have used the BAP-Lngfr as the two-component cell surface 
molecule because the first component, BAP, can be biotinylated in specific subsets of 
cells expressing a particular gene, by expressing the biotinylating enzyme, hBirA under 
the promoter control of another gene defining the specific subpopulation. Using insight 
from our observations of our pilot in vitro experiments and our single-step MACS 
optimisations described in chapters 4 and 5, we optimised the Two-step protocol and 
achieved a MACS Eluted fraction of 84.4% from a starting Input fraction of 1.1% desired 
cells. From a 0.1% starting Input fraction, we achieved an Elute fraction of 40.3% purity. 
This is a substantial improvement upon our previous approaches and was sufficient for 
downstream analysis.  
Lngfr was used as the second component for the second round of MACS, because 
we have previously shown that sufficiently pure samples of rare cells can be isolated from 
cell cultures using Lngfr. We tested several different variations of Lngfr. We found that 
excluding amino acids 20 – 25 of the human Lngfr and excluding the Lngfr 






also hints that the Leader signal of Lngfr span up till amino acid 25 rather than 20, as was 
previously thought. We have also shown that this BAP-Lngfr is appropriately folded and 
can be located on the extracellular cell surface in HEK293 cells. Thus the time invested in 
optimisation and development of the protocol resulted in an approach that could 
successfully isolate specific cells of interest from complex cell mixtures. At this point we 
were confident that our approach could be used on our target gene, Sox9. Here, we have 
chosen to knock hBirA into the ROSA26 locus for ubiquitous expression, and BAP-Lngfr 
into the Sox9 locus.  
Previous attempts have been made to isolate cartilaginous and osteogenic 
progenitors by MACS. Those cell isolations were made by identifying the cells by a 
particular known cell surface marker. Isolating chondrogenic or osteogenic cells based 
upon expression of an internal protein or transcription factor has not been described to 
date. Precartilaginous stem cells were MACS purified from rat perichondrium using an 
antibody against FGFR3, to a purity of 93-99%, of which about 80 – 85% were viable 
(Cheng, Chen et al. 2006). Osteoprogenitors were isolated from human bone marrow 
using an antibody against STRO-1, a stromal cell surface marker (Encina, Billotte et al. 
1999).  The drawback to defining cells of interest by their cell surface markers is that 
these markers may not be expressed at the earliest stages of differentiation. Onset of stem 
cell differentiation down a particular lineage is often defined by a transcription factor 
functioning as a master regulator. In the case of cartilaginous cells, Sox9 is this master 
regulatory transcription factor. Sox9-expressing cells later also differentiate into the 
osteogenic lineage. Our MACS strategy allows the isolation of cells from the earliest 






under the promoter control of Sox9. Thus gene expression events at the earliest stages of 
chondrogenic differentiation, when Sox9 is first expressed, can be observed. 
At the earliest stages of differentiation, the numbers of precursors to a particular 
lineage are usually very small, before they enter the proliferative phases. This makes it 
important for the strategy to be able to isolate these rare cells of interest to sufficient 
purity. In the last chapter, we showed that a single round of MACS does not yield 
samples of sufficient purity when the proportion of the cells of interest approaches the 
level of the background or false positives. This background tends to be high in a complex 
cell population. Here, we show that doing two consecutive rounds of MACS significantly 
improves this purity. 
The first round of MACS was capable of enriching for rare cells (~1-2%) to a 
purity of about 50%. With this significant fold-enrichment, the second round of MACS 
was capable of enriching the desire cell population up to 84% purity. Ultra rare cells 
(~0.1%) could be enriched to about 17% purity after the first round and about 40% after 
the second round. This enrichment was achieved using mouse embryonic tissue-
dissociated cells spiked with HEK293 cells expressing extracellular BAP-Lngfr. The 
negative control, where cells expressed BAP-Lngfr only within the cytoplasm but not on 
the cell surface, did not yield any significant enrichment, even after the second round of 
MACS. This level of enrichment was achieved because each of the major steps was 
optimised.  






populations, our optimisation experiments were carried out by spiking BAP-Lngfr-
expressing HEK293 cells into embryo-dissociated cells. These cells were also made to 
express EGFP for FACS analysis of each MACS fraction. Spike-in experiments offer two 
advantages. Firstly, because the positive cells have already been pre-characterised and 
enumerated, we had a basis for evaluating the performance of MACS. If either embryo or 
teratoma were used, the uncertainty of the exact proportion and fluorescence would make 
it difficult to evaluate and optimise each step of MACS. The second advantage is that this 
is a much faster way of optimising the MACS as long durations may be required for 
wholly transgenic animals or tissue to be obtained. This is especially so with Sox9, where 
the transgenic animals die in utero.  
We optimised the tissue-dissociation; this is important as live cells are desired at 
the end of the MACS for more representative samples, or even for subsequent cell 
culture. Dead cells also tend to bind antibodies non-specifically, hence adversely impacts 
the purity of the Eluted fraction. We found that the homemade dissociation solution of 
collagenase and dispase worked as well as the commercially available Liver Digest 
solution, also primarily made up of collagenase and dispase. For ease of use, we used the 
Liver Digest solution. These solutions performed significantly better than trypsin or 
TrypLE, in terms of dissociation effectiveness, recovery of desired cells and viability of 
the dissociated cells. This may be because the extracellular matrix of tissues is primarily 
made up of collagen and glycoproteins. Cells also require cell surface ligands and 
receptors to be intact to prevent apoptosis, and this may be disrupted by trypsin. 






bead removal is unnecessary for Miltenyi‟s products due to their small bead size (50nm) 
and biodegradability. However, removal is still necessary as a subsequent round of 
MACS is to be done, in order to select only a specific subset of the originally selected 
population. Partington et al. tackled this issue by combining the use of both Miltenyi‟s 
beads with Invitrogen‟s Dynal beads. Dynal beads come in three sizes 1 µm, 2.8 µm and 
4.5 µm ( http://www.invitrogen.com/site/us/en/home/brands/Dynal.html), which are 
significantly larger than Miltenyi‟s beads. The first positive selection is carried out using 
Miltenyi‟s high gradient magnetic cell separation, which can retain cells labelled with the 
50nm magnetic beads. The Eluted fraction is then labelled with another antibody to target 
only a specific subset which expresses another cell surface marker. This time the larger 
Dynal beads are used, which does not make use of a high gradient magnetic cell 
separation (HGMS) method, but relies on a strong cobalt-samarium magnet placed 
directly outside the tube of labelled cell suspension. Cells with only the 50nm beads 
attached are weakly magnetised relative to cells labelled with the larger Dynal beads. 
Because the Dynal system is not a high gradient magnetic cell separation system, it can 
only capture cells that are more strongly magnetised and allows the cells labelled only 
with 50nm beads to be removed in the non-retained fraction. Due to their large size, 
Dynal beads still had to be removed and this was done by trypsin treatment. The final cell 
sample had a 97% purity of the cells desired (Partington, Jenkinson et al. 1999).  
In our case, we wanted to use the HGMS method throughout, especially since 
using Partington el al.s‟ method did not remove the need for bead removal. Our cell 
surface molecule was made up of a single polypeptide and cleaving off the 1
st
 component 






along any of these would remove the bead, while leaving sufficient peptide to serve as 
polyclonal anti-Lngfr antibody epitopes.  We have found TrypLE to be the best means of 
removing the magnetic beads bound to the cells, as it cleaves Lngfr along Trypsin 
cleavage sites. Trypsin is the other alternative enzyme to use. Both of these methods, 
however, result in a certain amount of cell death. Also, after the first round of sorting, the 
dead cells would have been enriched because they tend to bind the antibodies non-
specifically.  
Dead cells were removed using Miltenyi‟s Dead Cell Removal Kit. We found that 
removing the dead cells just prior to the second round of MACS was better than removing 
them at the start, just before the first round of MACS. While differences like this seem 
subtle, the similar levels of background non-specific cells and our cells of interest meant 
that a significant difference in Eluted fraction purity would result. By using TrypLE 
instead of trypsin and by postponing the dead cell removal step, the final Eluted fraction 
purity increased from about 70% to about 84%.  
The antibodies used and incubating conditions were optimised as well. The 
specificity and sensitivity of the antibodies used are the primary determinants of the 
purity and recovery respectively. Evaluating the recovery is fairly straight forward as long 
as the number of positive eluted cells and input cells are known. Evaluating the 
proportion of fluorescent cells in each fraction and hence the purity of the Eluted fraction, 
is trickier. This is due to the uncertainty involved in gating the single cell population and 
setting the fluorescent cut-off point. Due to heterogeneity of cell types, gates are set as 






extreme right tail of the unlabelled cell population, where the GFP just registers 0% on 
the FACS Analyser.  With complex cell populations, however, there is always a 
significant overlap between the size of some cell debris and small cells, as well as 
between the auto-fluorescence of some cells with the true EGFP- fluorescence of others. 
For this reason, the purity and recovery observed in these experiments should be taken 
qualitatively. For example, the difference in the purity of eluted cells between each round 
of MACS, or when compared to the negative control is very large (84.4% vs 2.2%), so we 
can confidently conclude that enrichment of the desired cells have been made. If 
downstream biological studies were to be done on the isolated cells, we recognise that 
more biological replicates would be needed in order to get statistically significant 
quantitative estimates of purity and recovery.  
One of our main areas of concern is that the protein expression, localisation or 
folding of the cell surface molecule seems to differ between cell types and seems to affect 
cell function and viability. Normal function and cell viability was observed in HEK293 
cells. NIH3T3 cells were normal when expressing Lngfr but not BAP-Lngfr or BAP-
Lngfr fused with EGFP. Both Lngfr- chimeric male and female mice seemed normal. 
Lngfr-transgenic teratomas contain cartilage tissue indicating normal Sox9 expression and 
cell function in cells where the transgenic Lngfr is expressed. A study by Tannous et al., 
reported the use of a biotinylated cell surface receptor used for in vivo magnetic 
resonance and fluorescence tomographic imaging in glioma-derived tumours; there was 
no report of cell or tissue abnormalities (Tannous, Grimm et al. 2006). On the other hand, 
cell function and viability seemed to be adversely affected in NIH3T3 cells - seem to 






development seemed to be compromised.  
This has a few implications for our MACS strategy. Firstly, the transgenic animal 
may either not survive or the survivors could be developmentally abnormal, preventing us 
from studying our desired cells under developmentally normal conditions. Furthermore, 
nothing is known about the mechanism through which their development is compromised. 
While we have been able to generate chimeric adult male and female mice from V6.4 ES 
cells transgenic for the single-component Lngfr, and while cartilage can be found in 
transgenic teratoma, no fully transgenic embryos have yet to be obtained after screening 
over 300 embryos from the matings of these chimeric males to wildtype females. This 
could be because transgenic embryos die at a much earlier stage that the 10.5 – 13.5 d.p.c 
that we screen them at, or that transgenic spermatozoa or their progenitors are not viable 
or functional. While characterising these mutants is important, it was outside the scope of 
this thesis. 
Another implication of the protein expression of the cell surface molecule being 
different in different cell types is that the cells of interest may not all be enriched by 
MACS. Even when teratomas are used and the issue of viability is circumvented, the cells 
that are unaffected by the cell surface molecule may be over-represented in the enriched 
fraction. For example, many different cell types express Sox9. The cell types whose 
viability is affected by the transgenic proteins would not be represented in the Eluted 
fraction.  






rare cells from dissociated animal tissue, means that it is a good strategy to use for 
isolating sufficiently pure samples for sensitive downstream studies like transcriptome 
analysis. This strategy can potentially isolate any cell based on the expression of any gene 
of interest. The precaution that needs to be taken, however, is that not all cells are 
compatible with the BAP-Lngfr two-component cell surface molecule design. Depending 
on the cell type and animal under study, the BAP or Lngfr component may need to be 
replaced, and this requires empirical observation. We have already generated the targeting 
constructs to knock the BAP-Lngfr or BAP-Lngfr with EGFP fused into the Sox9 locus. 
When transgenic mice embryos, adult mice or teratoma are made from the transgenic ES 
cells, we would have a better idea of how suitable the BAP-Lngfr is for all the mice 
tissues. Mice generated from the transgenic ES cell lines with hBirA-lacZ knocked into 
the ROSA26 locus would also be a convenient tool for any future work where in vivo 






Chapter 7. Transcriptome Profiling of 
 MACS-isolated cells: Sox9-related gene 






Section 7.1 Introduction  
7.1.1 Experimental goals and set up 
Isolation of cells of interest has historically been determined by expression of 
specific cell surface molecules. However, many important genes do not code for surface 
proteins. Our overall aim was to develop an strategy though which cells could be isolated 
based on their expression of an internal gene of interest. Addressing this we developed a 
Two-step MACS-based cell isolation strategy, which could isolate rare cells to high 
purity defined by the expression of a gene of interest coding for an internal protein. This 
was achieved by linking the expression of a two-component transgenic cell surface 
protein with the expression of the gene of interest, Sox9. In this chapter I assess the 
suitability of MACS-isolated cells for downstream analysis. I show how Sox9-expressing 
cells could indeed be isolated and that the microarray data obtained as a result can 






7.1.2 Illumina Bead-Chip Array 
The aim of developing our MACS-based cell isolation strategy was to prepare cell 
samples from complex tissue that were sufficiently homogenous for sensitive downstream 
applications like transcriptome profiling.  
We set out to establish whether MACS provides representative cell samples from 
dissociated complex tissue, whether they are of sufficient quality and quantity to perform 
downstream transcriptome profiling, whether an accurate transcriptome map could be 
elucidated and whether this map could then be used to identify novel genes related to our 
gene of interest, Sox9.  
We performed gene expression microarrays on the RNA isolated from the Sox9-
expressing cells. These cells were isolated to ~60% purity from Sox9
+/Lngfr
 teratoma tissue 
by the single-step MACS. Details of the isolation have been described in Chapter 5.  The 
Two-step MACS was not done on tissue as the BAP-Lngfr transgenic ES cell lines 
required have not yet been established. 
DNA microarray technology made its debut in 1995. Since, it has been used to 
expression profile diseased tissue, effects of toxicants and delineate molecular pathways 
(Walker and Hughes 2008). Clinical variables, tissue variability, RNA quality and 






(Atz, Walsh et al. 2007) Clinical variables and tissue variability determines the variability 
of the input cDNA. The input cDNA material is the single most important factor that the 
end user has to take care of. The samples must be obtained or treated in a reproducible 
manner, which can be difficult if heterogeneous tissues are used, as any variation in the 
proportions of the different cell types can have a very large effect on the microarray, 
which is highly sensitive (Walker and Hughes 2008).When the quality of the biological 
samples is taken care of, several other factors affect the reliability of microarray assays of 
gene expression: RNA quality, RNA amplification, cDNA labelling efficiency, 
microarray hybridization efficiency and image acquisition quality (Muyal, Singh et al. 
2008). Most of these factors have been optimized by the companies developing the 
microarray platforms, if commercial platforms are used. The only factor that the user has 
to ensure is the RNA quality, which has a great, direct impact on the array results. The 
Agilent 2100 Bioanalyzer is the recommended system of choice to determine the quality 
of the RNA. The user software that uses an algorithm to describe the integrity (extent of 
preservation from degradation) of the RNA with the RNA Integrity Number (RIN) that 
ranges from 1 – 10, where 1 is low and 10 is highest in integrity. The 260/280 optical 
density ratio of >1.8 also indicates pure RNA samples.   
Microarray platforms need to be tested for their reproducibility, sensitivity, 
accuracy of amplification, accuracy of measurements of differential expression (Viale, Li 
et al. 2007). The Illumina Beadchip platform is one of the best (Debey-Pascher, Eggle et 
al. 2009). Gene expression differences are not based on single measurements but are a 
statistical calculation from several dozen identical probes (Wong, Loh et al. 2008). The 






binding of the cDNA to these probes would produce different signal intensities, 
depending on the level of gene expression. The 30x feature redundancy ensures high-
confidence results. (http://www.illumina.com/pages.ilmn?ID=51).Up until the mid-2000s, 
microarrays required large starting quantities of 5 – 10ug (Viale, Li et al. 2007), making it 
difficult and tedious to obtain sufficient material from rare cell populations from tissue. 
Currently, Affymetrix claims to require 100ng 
(http://www.affymetrix.com/support/help/faqs/gene_1_0_st/faq_2.jsp). Nimblegen 
requires 20ug (http://www.nimblegen.com/products/exp/index.html). Illumina claims to 
require only 50ng of starting RNA, which can be obtained from only approximately 10^5 
cells. Our institute‟s in-house microarray technology group evaluated the performance of 
several microarray platforms and RNA amplification kits for accurate gene expression 
profiling starting from only 50ng of RNA. They found that Illumina performed the best 
when starting RNA samples were small. They validated Illumina‟s claim that accurate 
profiling can be done with a minimum of 50ng RNA and that Epicenter‟s TargetAmp 
Nano-g Biotin-aRNA Labelling Kit for the Illumina System gave the highest yielding and 
accurate RNA amplification. Hence the Illumina Beadchip was our microarray platform 






7.1.3 Sox9 Transcriptome profiling 
Gene expression profiles describe the total transcriptional output of the cells, the 
key determinant of protein expression and hence cellular phenotype (Walker and Hughes 
2008). To understand the molecular mechanisms behind cellular phenotypic changes that 
occur during the development of embryos and tissues, we need to elucidate the gene 
regulatory pathways that occur as a result of the effects of certain master regulators. 
SOX9 is one such master regulatory transcription factor that is involved in a range of 
developmental events (reviewed in Chapter 2). However, transcriptome mapping of tissue 
cells defined by their expression of Sox9 has never been done, to our knowledge. Because 
tissue samples for transcriptome profiling were defined by their phenotype, what were 
studied instead, were developmental processes where Sox9 was involved or implicated in. 
The transcriptome maps obtained as a result were taken to represent the Sox9 gene 
regulatory networks. The two main Sox9-related developmental processes studied were 
chondrogenesis and gonadal development.  
To understand how chondrogenesis occurs, transcription profiling studies used 
both cell lines and tissue material. Both established cell lines and primary cultures, were 
used for their convenience because of their scalability and their homogeneity. ATDC5, 
other cell lines (Olney, Wang et al. 2004; Wahl, Shukunami et al. 2004; Chen, Fink et al. 
2005; Shinomura, Ito et al. 2006) and primary cultures like chondrosarcoma derived 
primary cultures (Dailey, Laplantine et al. 2003) were used. ATDC5 is an embryonic 






expression changes of chondrocytes as they differentiate (Shukunami, Shigeno et al. 
1996) (Shukunami, Ishizeki et al. 1997) (Akiyama, Hiraki et al. 1996). Unlike most other 
chondrogenic cell lines, they grow on a monolayer and do not have to be grown in ultra-
dense hanging-drop cultures, making them very easy to use.  
Gene profiling studies that used chondrogenic tissue material used different 
protocols for isolating the cells of interest. The different zones of a 14-day old mouse 
femur – resting, proliferative, pre-hypertrophic and hypertrophic chondrocytic zones – 
were isolated through the microdissection of each zone (Belluoccio, Bernardo et al. 
2008). The microdissected articular cartilage and growth plates of 3 day old mice were 
also used (Yamane, Cheng et al. 2007). Mouse calvariae was digested was collagenase 
and dispase digested. After the first 7 minutes of digestion at 37˚C, the single cells were 
collected as the mesenchymal cell fraction. After the next 4 rounds of 7 minute 
digestions, the single cells were collected as the osteoblast fraction (Ichida, Nishimura et 
al. 2004).  Yet other studies made use of whole tissue. Tibiae, femurs, humeri, central 
metatarsals of 15.5 day mouse embryos were dissected out (Sugars, Karner et al. 2006; 
James, Ulici et al. 2007). Here, entire bones are digested and RNA extracted from the 
heterogeneous mix of cells. Adult articular cartilage was also used to study secondary 
cartilage formation (Hayman, Blumberg et al. 2006). As reviewed in Chapter 2, whole 
tissue or even microdissected tissue samples contain other irrelevant cell types that can 
potentially distort and confound data of sensitive downstream assays. 
Our study uses a fundamentally different approach to obtain cells to study Sox9. 






these tissue, we isolated cells from tissue that expressed Sox9. When ES cells are injected 
into the flanks of SCID mice, they differentiate randomly to form teratoma tissue. The 
random, complex mix of cell and tissue types is representative of animal tissue types 
found at all normal spatio-temporal developmental stages. By isolating cells expressing 
Lngfr on the cell surface, we were isolating cells of all spatio-temporal developmental 
stages that express the transcription factor Sox9. Hence we hope to get a complete picture 
of all genes that are co-expressed with Sox9. The availability of these published 
transcriptome profiles enables us to have  reference data to validate our cell isolation 






7.1.4 Limitations of microarrays 
A major limitation of microarray analysis is its inability to distinguish between 
direct and indirect targets of the transcription factor under study (Walker and Hughes 
2008). In order to address this limitation we attempted Sox9 chromatin 
immunoprecipitation (ChIP) to identify the DNA sequences that the transcription factor 
directly binds to. Compared against the gene expression profile, three distinct subsets can 
be identified: First, the genes whose regulatory elements are occupied by the transcription 
factor and whose altered expression level is correlated with this occupancy; Second, the 
genes whose regulatory elements are occupied by the transcription factor, but whose gene 
expression is unaltered despite the occupancy; Third, genes whose expression level is 
altered, but whose known regulatory elements are unoccupied by the transcription factor 
of interest.  
Traditionally the number of cells required for ChIP has been on the order of 10^8. 
Hence cultured cell samples were usually used. Recent protocols have been developed 
that use significantly less material, meaning that rare cell populations isolated from tissue 
can be used for ChIP assays (Collas) Recent work (manuscript in preparation) by our 
laboratory has demonstrated that ChIP assays can be successfully used to identify Sox9 
binding sites when limbs and tails, but not whole embryonic material is used as starting 
material, showing that enrichment of Sox9-expressing cells does influence its success. 
These tissues are obtained from 13.5 d.p.c wildtype mice and material from at least 25 






The benefit of using wildtype, whole tissue is that time does not have to be spent 
modifying ES cells and generating transgenic tissue material. Also, antibody selection of 
the transcription factor means that ChIP is less susceptible to contaminating cells, as 
compared to gene expression profiling. However, we chose to perform ChIP on the cells 
isolated in the same fashion as for transcriptome profiling.This was better because both 
assays would be comparing the same cell populations and would eliminate the variations 
introduced by having two different cell sampling methods.   
The ability to parallel process with MACS-based cell isolation strategies means 
that sufficient amounts of highly pure cell populations for ChIP can be isolated in a short 
time.  Furthermore, by using a Two-step MACS strategy, specific Sox9-expressing cell 
subsets can be isolated, which is impossible when using whole tissue. By being able to 
separate out different subsets of cells expressing the same transcription factor, the 
different transcription factor regulatory networks that are responsible for the differences 






Section 7.2 Methods 
7.2.1 ATDC5 G418 titration 
Untransfected, wildtype ATDC5 cells and ATDC5 cells transfected with a vector 
carrying PGK-gb2Neo, were selected in parallel, in media containing G418 at 
concentrations ranging from 50 – 400 ug/ml, at 50ug/ml increments. The lowest G418 
concentration that completely killed untransfected ATDC5 cells while allowing the 
proliferation of transfected cells was used as the G418 selection concentration.  
7.2.2 ATDC5 differentiation 
ATDC5 cells were differentiated by growing the cells to 90% confluency, then 
treating with Insulin-Selenium-Transferrin (Roche) 10ug/ml for at least 3 days and then 
either 0.2 ug/ml of BMP4 for 24 hours (Wahl, Shukunami et al. 2004) or 50ng/ml BMP2 
for 10 days (Akiyama, Shukunami et al. 2000) ml media per 6-well well or 40ml of media 
per 10cm plate was used.  
Differentiation was confirmed by TaqMan (Applied Biosystems, USA) Arrays 
using inventoried probes against Agc, Hapln1, Matn1, Col2A1 and other Sox9-regulated 
genes. Total RNA was first extracted using the RNAeasy kit (Qiagen, USA) and reverse 
transcription was done using the High Capacity cDNA Archive Kit (Applied Biosystems, 






7.2.3 Generation of ATDC stable-transfected lines 
12.5ug of circular plasmid DNA was added to 2.5 ml of Optimem, followed by 
30ul of FugeneHD, and incubated for 20min. 2.5ml of the mix was then added dropwise, 
with gentle swirling, to the cells grown in 10ml of normal ATDC5 media (Section 3.4) on 
a 10cm dish. 48 hours later, the media was changed with 200ug/ml G418 added for 
selection. A negative control with water used in place of DNA for transfection was done 
in parallel. After 2 weeks, untransfected cells are dead, leaving colonies of surviving 
cells. Over 6 weeks, the surviving colonies grow to a confluent 10 cm dish, which is then 
passaged to a 15 cm dish. Up to this point, cells are maintained in G418 selection media. 
At confluency, the cell stocks are frozen or cultures are maintained for subsequent 
experiments.  
7.2.4 CAG, CMV, PGK promoter test 
To replace the CMV promoter of pBAP-EGFP (Appendix 2.1a), pBAP-EGFP was 
cut with AseI and XhoI to remove the CMV fragment. AseI-SalI flanked CAG promoter 
was excised from pCAG-IRES-hBirA-IRES-EGFP-SV40-Neo (Appendix 2.7) and used 
to replace the CMV, to form pCAG BAP-EGFP. AseI-XhoI flanked PGK promoter was 
PCR generated with the primers 5‟ TTAATTATTAATATTCTACCGGGTAGGGGAGG 
3‟ and 5‟ AATTCCACTCGAGCTGCAGGTCGAAAGGCCCGG 3‟, and used to replace 






7.2.5 pCAG-NSox9 and pCAG-CSox9  
To overexpress Sox9 epitope-tagged at either its N or C terminal with a BAP-HA 
or HA-BAP tag respectively, we started with a pre-existing sequenced expression vector 
made in our laboratory, pCAG-IRES-hBirA-IRES-EGFP-SV40Neo (Appendix 2.7). 
Either the N or C terminal tagged Sox9 cDNA sequence was cloned into the SalI site of 
the vector, between the CAG promoter and the IRES sequence.  
The N –terminal tag was made by annealing the two oligos 
5‟GAATTCTGCAGTCGAGCCATGGGCGGCCTGAACGACATCTTCGAAGCCCAG
AAAATCGAATGGCACTACCCCTACGACGTGCCCGACTACGCCCTCGAGGTCG




The Sox9 fragment was PCR generated from an IMAGE clone containing the 
Sox9 cDNA sequence (MGC: 18772; IMAGE: 4165469; Clone Sequence: BC034264.1; 
Corresponding RefSeq mRNA: NM_011448.2. Ordered from ATCC, USA), using the 
primers 5‟ GAATTCTGCAGTCGACATGAATCTCCTGGACCCCTT 3‟ and 5‟ 
TATCGATACCGTCGACTCAGGGTCTGGTGAGCTGTG 3‟. The oligos and Sox9 
fragment were cloned into the SalI site of pCAG-IRES-hBirA-IRES-EGFP-SV40Neo to 






The C-terminal tag was made by annealing the two oligos 
5‟AATTCTGCAGTCGACTACCCCTACGACGTGCCCGACTACGCCGGCGGCCTG
AACGACATCTTCGAAGCCCAGAAAATCGAATGGCACGAATGATCGACGGTAT




The Sox9 fragment, inclusive of 200bp of the 3‟UTR (we could not clone in the 
Sox9 fragment terminating at the STOP codon successfully), was PCR generated from the 
same IMAGE clone template, with the primers 5‟ 
TTTTCTCGAGATGAATCTCCTGGACCCCTT 3‟ and  5‟ 
TTTTCTCGAGCGGCCATTTGCAATATGT 3‟. The oligos and Sox9 fragment were 







7.2.6 pNBAP-  and pCBAP-  Sox9 targeting vectors 
To express Sox9 with a BAP and HA tag at either the N or C terminal, two 
separate targeting constructs were made to replace the endogenous Sox9 with the tagged 
version. For the N terminal tagging, the BAP sequence, followed by the HA sequence 





 base before the start codon, a LoxP-flanked neo was inserted. For the C 
terminal tagging, the HA sequence followed by the BAP sequence was placed between 
the second last and final stop codon. 4 bases after the stop codon, the Lox-P flanked neo 
were inserted.  
RED/ET mediated BAC homologous recombination (Gene Bridges, Germany) 
was carried out to modify the BAC RP24-248D4, containing the Sox9 locus. To generate 
the PCR fragments for homologous recombination, three sequential rounds of PCR was 
done, in order to add the epitope tag sequences and the 50bp homology arm 
(approximately 170bp) to one end of the amplified PGKgb2Neo and the 50bp homology 
arm to the other end. The PGKgb2Neo which had been cloned into a sequenced plasmid 
was used as the template. For the N terminal tagging, the epitopes were added to the 3‟ 
end of the PCR product and for the C terminal tagging, the epitopes were added to the 5‟ 
end.  






the three sequential rounds of PCR for the N terminal tagging, which were:  
The forward primer:   
5‟ CCGCCGCGGCTTCTCGCCTTT CCC 
GGCCACCCGCCCCCTGCCCCGGGCTCATAACTTCGTATAGCATACA 3‟ 
First round:  
5‟GGCGTAGTCGGGCACGTCGTAGGGGTAGTGCCATTCGATTTTCTGGG
CTTCGAAGATGTCGTTCAG 3‟ 






Three forward primers were used sequentially with the same reverse primer for 














Third round:  
5‟ACAGCCCGCAGCACTGGGAACAACCAGTCTACACACAGCTCACCAG
ACCCTACCCCTACGACGTGCCCGA 3‟ 
The reverse primer: 
5‟TCTTTAAAAAAAAAAAAAAAAAAGATCAGCTCTGTCACCATAGCTTT
TCTATAACTTCGTATAATGTATG 3‟ 
The modified BAC was then digested with HindIII and shotgun cloned into the 
HindIII site of a pBS vector. Kanamycin-Ampicillin dual selection was used to select for 
only those vectors that took up the PGK-gb2-Neo containing region. It was linearized at 
the unique XhoI site and electroporated into ES cells. The Sox9 gene targeting construct 







To screen for modified ES clones by Southern Blot, the same probes were used as 
described earlier (Section 5.2). The N terminal tagged clones were digested with either 
BamHI with SpeI to give a wildtype band of 12.2kb and a mutant band of 3.7kb, or EcoRI 
to give a wildtype band of 7.2kb and a mutant band of 4.4kb. The C terminal tagged 
clones were digested with BamHI and SpeI to give a wildtype band of 12.5kb and a 
mutant band of 6.6kb.  
7.2.7 RNA isolation 
Cells were homogenized in Trizol (Invitrogen, USA) at a concentration of 10^7 
cells or less per ml of Trizol. A minimum of 200ul of Trizol was used. Samples in Trizol 
were stored at -80˚C long term until ready to be processed for expression analysis.  
0.2ml of chloroform was added per ml of sample in Trizol. These were shaken, 
vortexed and left to stand for 2-3 min. The phases were then separated at 12,000g 15min 
at 4˚C. Phase-lock gel (Eppendorf, USA; later bought over and marketed as MaxExtract, 
Qiagen, USA) was used. The aqueous phase was added to an equal volume of 100% 
ethanol, vortexed and applied to either an RNeasy mini or micro kit, depending on the 
cell number. The RNA Cleanup protocols from the respective kit manuals were used. On-
column DNAseI treatment was done. RNA was quantified by Nanodrop1000. Integrity 






Technologies, USA), according to the manufacturer‟s instructions. Appropriate aliquots 
were made for downstream processing and samples were stored at -80˚C until use.  
7.2.8 Illumina Bead-Chip Array 
Biotinylated cRNA was made using the TargetAmp Nano-g Biotin-aRNA 
Labelling Kit for the Illumina System (Epicentre Biotechnologies, USA) and the integrity 
qualified on the Agilent 2100 Bioanalyzer RNA 6000 Pico chip.  
The Illumina MouseWG-6 v2.0 Expression BeadChips (Illumina, USA) 
microarray platform was used. 45,200 transcripts and six samples profiled simultaneously 
on a single MouseWG-6 BeadChip.  
7.2.9 Microarray Analysis 
GenespringGX 9 (Agilent Technologies, USA) was used for microarray data 
analysis. The call for present was set at 0.9 and absent below 0.6. Anything between the 
two was a marginal call. A raw signal threshold of 5 was used. Normalisation was 
performed using the Median Shift algorithm. Median shift was set to the 75
th
 percentile 
and the baseline to the median of all samples. Probe sets were filtered by expression level 
with a lower percentile cut-off of 20 in at least one sample. Probe sets were then further 
filtered by Flags. Present and Marginal calls were accepted, Absent calls were rejected. 






was shortlisted. Samples were sorted based on two parameters: MACS fraction and 
genotype. Subsequent analysis was performed using the Fraction-Genotype Interpretation. 
Hierarchical clustering was done with the Pearson Centered distance metric and Centroid 
linkage rules. 2-way ANOVA statistical analysis with asymptomatic P-value correction 
was used to analyse the gene expression level, while a p<0.05 was used to identify the 
differentially expressed genes. The Benjamini Hochberg False Discovery Rate algorithm 
was applied for multiple testing correction at p<0.05.  
Gene ontology was described using PANTHER 
(http://www.pantherdb.org/genes/batchIdSearch.jsp)  
Protein interactions were described using iHOP  
(http://www.ihop-net.org/UniPub/iHOP/) 
7.2.10 Chromatin Immunoprecipitation 
Crosslinking was carried out by adding 270ul of 37% formaldehyde per 10ml 
culture media to 15cm-dishes of cells placed on an orbital shaker swirling at 100rpm for 
10 min. Glycine was added to a final concentration of 0.2 M to quench the crosslinking 
reaction. Plates were continuously swirled for another 5 min. The cells were then washed 
with ice-cold PBS twice. 2ml of cell lysis buffer (10 mM Tris.HCl pH 8.0; 0.25% 
TritonX-100; 10 mM EDTA; 0.1 M NaCl + protease inhibitors) was used to lyse the cells. 






rinse the plate and pooled with the previous lysate. After nutating at 4˚ for 15min, the 
lysate was pelleted at 700g for 10min at 4˚. The supernatant was discarded and the pellet 
lysed with 3 pellet volumes of SDS Lysis Buffer from the EZ ChIP kit (Upstate, USA). 
They were sonicated with the Bioruptor (Diagenode, USA); set to „High‟, at 4˚C, for 15 
cycles of 30s-On-30s-Off, in 300ul aliquots in 15ml-polypropylene Falcon tubes. The 
sonicated samples were pelleted at 15,000g at 4˚ for 10min and the supernatant saved. 
This formed the „Chromatin‟. Chromatin was pre-cleared with 5ug/200ul chromatin of 
normal Ig from the animal the primary antibody was developed in. This was incubated 
with 60ul of EZ ChIP Kit Protein G Agarose Beads with 600ul of 1x Dilution Buffer from 
the One-Day ChIP Kit (Diagenode, USA) for 1 hour at room temperature. These Beads 
have been pre-blocked with BSA and Salmon sperm DNA. In the meanwhile 5ug of 
specific antibody against the protein of interest was attached to 60ul of Beads in 200ul of 
1x Dilution Buffer for 1 hour at room temperature. The pre-cleared chromatin was then 
added to the specific antibody-conjugated Beads. After 16 – 20 hours nutating at 4˚C, the 
Beads were pelleted and washed for 5 minutes each in the following order at room 
temperature: thrice with 1x Dilution Buffer, once with EZ ChIP Kit Low Salt Buffer, 
once with EZ ChIP Kit High Salt Buffer, EZ ChIP Kit LiCl Wash Buffer and twice with 
Tris-EDTA pH 8.0. The Beads were pelleted at 5000g for 1min every time a change of 
solution was required. The antibody-protein-DNA complexes were eluted from the beads 
with 200ul of freshly prepared Elution Buffer (20ul 10%SDS, 20ul 1M NaHCO3, 160ul 
water) at 68˚C for 1 hour at 1400rpm on the Eppendorf Thermostat Plus (Eppendorf, 
USA) heat block. The supernatant was removed and de-crosslinking carried out by 
addition of 8ul of 5M NaCl and incubation at 67˚C overnight. To remove RNA, 1ul 
RNAseA (10ug/ul) was added and samples incubated for 30min at 37˚C. Proteins were 






(10ug/ul) at 45˚C 2 hours. The DNA was purified by phenol-CIA extraction. To ensure 
maximum yield of DNA, 1ul of 20mg/ml glycogen and 50ul of 4M LiCl was added to the 
extracted aqueous phase before ethanol precipitation. The final ChIP DNA was dissolved 
in 50ul TE. 1 ul was used for real-time PCR using the Power- SYBR-Green (Applied 
Biosystems, USA) system in 10ul reactions on a 364-well plate, according to the 
manufacturer‟s instructions. The 7500 Real-Time PCR System (Applied Biosystems, 
USA) was used. Fold-difference between ChIP DNA and the input Reference DNA was 
manually calculated from the Ct values. The tables in Appendix 5 describe the primers 
used against putative Sox9-binding regions. Additionally primers against non-Sox9-
binding regions were also included. 2 primer pairs against GAPDH were used; the first 
pair was „5‟ CTCCCACTCTTCCACCTTCGATGC 3‟‟ with 5‟ 
GGAGGCCATGTAGGCCATGAGGTC 3‟‟, and the second pair was 5‟ 
CCTGGAGAAACCTGCCAAGTATGATGAC 3‟‟ with 5‟ 
GCTGTTGAAGTCGCAGGAGACAACC 3‟. A pair of primers against actB was also 
used: „5‟ GGCAACGAGCGGTTCCGATG 3‟‟ with 5‟ 






Section 7.3 Results 
The purpose of developing a good MACS strategy was to isolate rare cells from 
complex tissue for sensitive downstream assays. We needed to test if isolated cells are of 
sufficient purity, quality and quantity for microarray analysis. To this end, teratoma tissue 
was generated from Sox9
+/Lngfr
 modified ES cells. After harvesting the tissue, we digested 
them to single cells and MACSorted them. The isolated cells had their RNA extracted. 
This was used for microarray assays using the Illumina Beadchip platform. The data was 
used to evaluate the suitability of the single-step MACS for downstream microarray 
application. The Two-step MACS strategy has not yet been tested this way, as modified 
ES cell lines must first be obtained. In addition, we also generated ES cell lines modified 
with either N or C terminally BAP-HA-tagged SOX9, to be used for generating 
transgenic embryonic tissue for ChIP. As will be described, our approach resulted in 
isolation of RNA samples from Sox9-expressing cells, which were successfully analysed 
by microarray, revealing novel information about Sox9 gene expression pathways. 
7.3.1 Microarrays of MACS fractions 
Teratoma tissues were generated and sorted through a single-step MACas 
described in Chapter 5 to provide isolated Sox9-expressing cells from tissue. These cells 
were eluted off the column at the end, in the Eluted fraction. Only the Lngfr, and not the 
Two-step Bap-Lngfr surface molecule were used for MACS, although the cells were put 
through two columns to improve their purity. Teratoma was used for two reasons. Firstly 






availability of the tissue material was significantly more reliable than embryos. Secondly, 
since the entire teratoma is ES derived, there was also no need for screening.  
Because detailed gene expression information was being mined from the 
microarray data of the Eluted fraction, we used 6 biological replicates to ensure that our 
data would be very statistically accurate. Each biological replicate came from an 
independently derived Sox9
+/Lngfr
 ES cell clone. Three biological replicates came from the 
V6.4 ES cell line and another three from the R1 ES cell line. For each parent ES cell line, 
there is one clone that had the neo inserted after the Lngfr sequence, while another two 
clones have had their neo removed by Cre mediated excision of the LoxP flanked neo. 
For the microarray analysis, these samples were grouped together to form the mutant 
eluted samples (mt). The R^2 value for biological replicates were above 0.95.  
In parallel, we had two biological replicates from teratomas derived from each of 
the two wildtype ES cell lines. The amount of cells that were eluted in this case was very 
small, so we pooled the Eluted fraction from several teratomas into each microarray 
sample. In this case, each biological replicate came from two distinct groups of pooled 
teratomas, from different mice. Collectively, this group of samples formed the wildtype 
Eluted fraction samples (wt). In this group, we also included the Eluted fraction from the 
sorting of a wildtype 13.5 d.p.c embryo.  
We also made use of the previously derived Sox9
EGF/EGFPP
 ES cell line to make 
teratomas. This was a single clone derived from the V6.4 cell line. We had three 






teratomas from different mice. These formed the knock-out Eluted fraction samples (ko).  
Cells from the Unbound fraction were also used for microarray. Cells were also 
removed from the wildtype and knock-out samples before the MACS, which formed the 
„input‟ (i) fraction. Because the Sox9+/Lngfr input cells were essentially the same as those 
from the wildtype, we did not see the need to also perform microarrays on the Input 
fraction and decided instead to maximise the yield we could get from those teratomas. We 
expected the input cells from teratomas of all genotypes to be very similar and the 
Unbound fraction to be very similar to the input cells as well, because the majority of 
cells would actually be found in the wash. The summary of the samples used is given in 
Fig. 5.3.3.1. 
Teratomas were harvested when they grew to about 1 cm in diameter, after 2 – 4 
weeks of injecting the ES cells into their flank and are shown in Fig. 5.3.3.2b. After 
digesting them to single cells, removing the debris and cell or tissue clumps with a 40um 
single-cell strainer, we typically get around 1 – 4 x 10^7 cells. Out of this starting input 
material, between 10 – 22% of that cell number made up the eluted Eluted fraction after 
MACS of the Sox9
+/Lngfr
 teratomas. In contrast, only 0.275 – 0.4% and 0.42 – 1.1% of the 
input material ends up in the Eluted fraction after MACS of the wildtype and the Sox9 
null teratomas respectively. The RNA yield from the Sox9
+/Lngfr
 Eluted fractions ranged 
between 2 – 10ug, while the yield from the wildtype and Sox9-null  Eluted fractions 
ranged between 0.5 – 2ug. The RIN ranges from 7.7 – 9.7 (only 2 samples fall below 8, 
the recommended cut-off for microarrays). The RIN obtained after RNA amplification 






This shows that cells isolated from MACS are capable of yielding sufficient RNA, of 
sufficient quality, for downstream microarray assays.  
Since the Lngfr-expressing cells did not express any fluorescent proteins, we 
labelled the cells with anti-Lngfr-FITC to have an idea of the percentage of positive cells 
there were in Input and Eluted fractions, to assess the level of enrichment taking place. 
However, because there are cells expressing endogenous LNGFR and dead cells that 
tended to bind antibodies non-specifically, this method was not as accurate at accessing 
the level of enrichment as when EGFP-expressing cells were used in Chapter 4. As seen 
in Figure 5.3.3.2a, the input Sox9
+/Lngfr
  samples had less than 30% of their cells labelled, 
while most of the Eluted fraction had at least 40% of the cells labelled. The purity of the 
Eluted fraction ranged from 32% to 95%, with most being about 60 – 80 % pure. Less 
than 20% of the cells of the wildtype or Sox9-null input (wt-i and ko-i) samples were 
labelled and less than 40% of the cells of their Eluted fraction were labelled. Despite such 
a high percentage of the cells of the wildtype or Sox9-null  input (wt-I and ko-i) samples 
being labelled, the percentage of cells actually being eluted out, compared to the input, is 
very low. Many of the labelled cells may be dead cells or cells that bind antibodies non-
specifically. These cells may bind sufficient FITC-conjugated antibodies to be visualised 
on the cytometer, but insufficient bead-conjugated antibody to be retained on the MACS 
column.  
The Input and Unbound fractions of all genotypes – Sox9+/Lngfr (mt), wildtype(wt) 
and knockout (ko) cluster together on the PCA plot, supporting our hypothesis that cells 






order to have maximal statistical strength without doing too many microarray replicates, 
we decided to treat all the Unbound fraction and Input fraction samples as a single group, 
„input (i)‟ for the microarray analysis.  
The elute (e) fractions from teratomas of the 3 distinct genotypes – wildtype, 
mutant and knockout – form 3 distinct clusters on the PCA plot (Fig. 7.3.1.1). This shows 
that the MACS isolation of these different cell populations were indeed isolating specific 
cell populations with distinct and defined transcriptome profiles. Amongst the Eluted 
fractions of the Lngfr-expressing and Lngfr-negative genotypes – representing Sox9-
expressing cells and MACS background cells respectively –  the samples form distinct 
clusters as well. The samples also cluster with their biological replicates. The wildtype 
and knockout samples cluster together, and the mutant samples cluster separately.  
The differences between Sox9
+/Lngfr
 and wildtype or Sox9-null teratoma in terms of 
their  proportion of input cells eventually eluted, the differences in the proportion of anti-
Lngfr-FITC labelled cells in each fraction between the different genotypes, as well as the 
clustering of biological replicates on the PCA plot, provides the first hints that the MACS 
has isolated a specific surface-Lngfr-expressing population of cells. The quality control 
checks performed at each step from the isolation of RNA to the completion of the 
microarrays showed that samples obtained from MACS of teratoma tissue were capable 
of producing RNA of satisfactory integrity. This is a significant advance in the specific 











7.3.2 Elucidation of candidate Sox9-related genes 
The next step would be to compare the gene expression profiles of the eluted 
Sox9-expressing cells against that of the background cells (non-specifically bound wt-e 
and ko-e cells) and also against that of the Input fraction cells. We hypothesised that the 
differentially regulated genes would be Sox9 related and this forms the transcriptome map 
we are aiming to elucidate.  
660 genes out of the total list of 45,281 entities analysed were found to be at least 
2-fold differentially expressed between the samples compared. When the Eluted fraction 
from Sox9
+/Lngfr
 samples was compared to the Input fraction, 66 genes were upregulated, 
and 395 downregulated.When this same gene list from the Sox9
+/Lngfr
  Eluted fraction was 
compared against the Eluted fraction from the wildtype and Sox9-null teratomas, 59 and 
42 genes were upregulated respectively, and 407 and 331 genes were downregulated 
respectively. Between these 3 different sample comparisons (Fig. 7.3.2.1), 28 genes were 
common to all 3 upregulated gene subsets and 295 common to all 3 downregulated gene 
subsets. Even when only the genes with at least 5-fold differential expression were 
analysed, there was substantial overlap of more than 90% between the downregulated 
gene subsets (169 genes overlapped all 3). Amongst the upregulated genes, only 18 
showed at least a 5-fold difference in total.  Since the differentially expressed genes 
identified were very similar, whether the cells of interested were compared against the 
starting input complex cell mixture or against the background non-specifically bound 
cells, we had confidence that our data was Sox9-specific.  
To determine which of these differentially expressed genes were due to the cells 






comparisons too, shown in Fig. 7.3.2. 2. Comparing the Eluted fraction of wildtype and 
Sox9-null teratomas with the Input fraction (wt-e vs I, and ko-e vs i) at a 2-fold cut-off, 
408 upregulated and 118 downregulated genes were identified.There were no 5-fold 
differentially regulated genes. 3 upregulated and 11 downregulated genes (<10%) were in 
common with the comparison between Sox9
+/Lngfr
  Eluted fraction and the Input fraction 
(mt-e vs i). These genes were subsequently subtracted from the list and the resulting gene 
lists were termed „Sox9+/Lngfr Elute vs Input‟ Upregulated (56 genes >2-fold; 12 genes >5-
fold) or Downregulated (396 genes >2-fold; 178 genes >5-fold) genes.  
To serve as a negative control comparison for the differentially expressed genes 
between the Eluted fraction of the Sox9
+/Lngfr
 and the wildtype and Sox9-null fraction (mt-
e vs wt-e and mt-e vs ko-e), we compared the Eluted fraction of the Sox9-null against that 
of the wildtype. We found few 2-fold differentially expressed genes – 20 upregulated and 
33 downregulated, which we subtracted from the former comparison. There were no 5-
fold differentially expressed genes. Genes, which by then were still differentially 
expressed when the Sox9
+/Lngfr
 Eluted fraction was compared to both the Sox9-null and 
wildtype Eluted fraction, formed the resulting gene list „Sox9+/Lngfr  Elute vs wt/ Sox9-null 
Elute‟ Upregulated (30 genes >2-fold; 0 genes >5-fold) or Downregulated (320 genes >2-
fold; 232 genes >5-fold) genes (Fig. 7.3.2.2). The clear distinction between the gene 
expression profile of the cells of interest and these negative controls reinforces our case 
that a Sox9-specific cell population was selected for.  
We used PANTHER, which groups gene expression data into biological pathways 
and processes, to describe the biological processes that the genes in the different fractions 
were involved in and found stark contrasts between gene lists from the negative control 






were genes involved in developmental processes and immunoregulatory processes, as 
Sox9 is known to be part of these gene regulatory networks.  
When the gene profiles of the eluted Sox9-expressing cells were compared against 
either the input cells (mt-e vs i) or the background cells (mt-e vs wt-e and mt-e vs ko-e), 
developmental genes made up 15 – 22% of both the >2-fold upregulated and 
downregulated gene lists. All the immunoregulatory genes, however, were downregulated 
(13-15% of downregulated genes, 0% of upregulated genes). The opposite was true in the 
negative control comparisons where the background cells were compared against the 
input cells (wt-e vs I and ko-e vs I). Here, all the immunoregulatory genes were 
upregulated. This shows that immunoregulatory gene expression pathways are 
significantly repressed when Sox9 is expressed, while different developmental pathways 
are being up or downregulated in these cells.  
The majority of these differentially regulated developmental and 
immunoregulatory genes were differentially expressed whether the Sox9-expressing cells 
were compared against the input cells or the background cells (mt-e vs I, mt-e vs wt-e and 
mt-e vs ko-e). Developmental genes, for example, made up 15-22% of the genes 
differentially expressed in all 3 gene lists (mt-e vs I, mt-e vs wt-e and mt-e vs ko-e), but 
only 3-6% of that in only 2 gene lists. Both the developmental and immunoregulatory 
genes were also more highly upregulated than other genes; they were 25% over-
represented in the >5-fold differentially expressed genes compared to the >2-fold ones. 
These observations increased our confidence that these differentially expressed 
developmental and immunoregulatory genes played a specific and significant role in 
Sox9-expressing cells. Since the „Sox9+/Lngfr Elute vs Input‟ and „Sox9+/Lngfr Elute vs wt/ 






approximations to the Sox9-related genes, we examined these 2 gene lists and identified 
the genes common to both. We hypothesized that this list would be made up primarily of 
Sox9 related or co-expressed genes, and would also be a source of novel Sox9-related or 
regulated genes. 25 upregulated and 288 downregulated genes were identified. These 
genes are likely to be regulated in the same direction (up or down) when Sox9 is 
expressed. Amongst the upregulated gene list 19% were involved in developmental 
processes and none in immunoregulatory processes. Amongst the >2-fold and >5-fold 
downregulated gene list, 18% and 20% respectively were involved in immunoregulatory 
processes, 19% and 24% respectively in developmental processes. We termed this gene 
list „Candidate Sox9-related genes‟ (Fig. 7.3.2.3). 
We wanted to test our hypothesis that the „Candidate Sox9-related gene list‟ was 
an accurate representation of Sox9 regulated or co-expressed genes. We used iHOP 
(www.ihop-net.org) to determine which other proteins these genes interacted with at the 
protein level, to establish which gene regulatory networks they were involved in and 
which genes they might be co-expressed with. iHOP is an internet application that 
collates all literature to identify  gene-process relationships and protein-protein 
interactions to be identified. 
Out of the 25 upregulated Candidate Sox9-related genes, there was iHOP 
information on 10 of them.9 of them are known to encode proteins that either directly or 
indirectly interact with members of the Sox9 regulatory networks. These 9 genes are Tle1, 
Rfx4, Zfp354c, Zfp354a, Ncor1, Wnt3, Apop-1, Bcat1, and Rln1. The list of proteins 
known to interact with each them at the protein level are listed in Appendix 4 Table1. 
Direct or indirect interaction partners are in bold. Direct interaction partners are known, 






directly, or whose expression is directly regulated by the SOX9 transcription factor. 
Indirect interactions here refer to the genes on the list whose protein interacts with 
another protein either known to be part of the Sox9 regulatory network, or which interacts 
with such a protein. 
Out of the 288 Candidate Sox9-related downregulated genes, 165 were 
downregulated by more than 5-fold. Out of this 165 genes, information was obtained for 
82 of them. 75 of these (91%) are known to have direct or indirect interactions with 
members of the Sox9 gene regulatory networks and we have considered them putative 
Sox9-related genes. These 75 genes can be broadly categorised into those related to 
developmental and immunoregulatory processes. 49 of them are related to 
developmentally regulated gene pathways involving Sox9 and 43 of them are related to 
the immunoregulatory regulated ones. 21 genes are represented in both groups. We could 
not find Sox9 and some of the genes classically known to be Sox9 regulated within the 
chondrogenic pathways like col2A1 and aggrecan. These genes were not part of the 660 
genes that were differentially regulated amongst all the samples. Further analysis revealed 
that there was insignificant difference in gene expression level between all the samples 
























7.3.3 Comparison of data set with existing literature 
We compared our „Candidate Sox9-related genes‟ with published Sox9 related 
transcriptome profiles. We compared this list between published transcriptome profiles of 
tissues known to express Sox9: chondrocytic and male gonadal tissue. Fig. 7.3.3.1 shows 
that there is very little overlap between the chondrocytic („Chondrocyte‟) and male 
gonadal („Male Gonad‟) tissues. Amongst the upregulated genes, 14 are common to both 
chondrocytic and male gonadal tissue and none to our list obtained from the Sox9
+/Lngfr
 
eluted cells („Eluted Cells‟). Amongst the downregulated genes, none are common 
between the 2 published lists, and 3 are common between the chondrocytic sample and 
ours. These 3 genes are pappa2, csf1r and samhd1.  
We also compared our samples with published transcriptome profiles of 
differentiated ATDC5 cells and micromass cultures (Fig.7.3.3.2). Both of these are 
accepted cell culture models for chondrogenic differentiation, for which Sox9 is the 
master regulator. Again, there is very little overlap between any of the samples. Between 
our Sox9
+/Lngf
 eluted cells and the ATDC5 cells, only Sox4 was upregulated in both and 
Emp3 downregulated in both. There were no genes in common with our list and the 
micromass genelist.  We then aggregated the ATDC5 and micromass culture gene lists, so 
that we could compare the profiles of chondrocytic tissue and chondrogenic cell culture 
models, with our cells. While the overlap between our gene list and all the published ones 
remain extremely small, the overlap between the tissue and cell culture models increased 
























7.3.4 Preparations for in vivo ChIP 
Transcriptome profiling reveals genes that are co-expressed with Sox9. In order to 
distinguish genes that are merely co-expressed, from genes that are directly regulated by 
Sox9, a ChIP needs to be done, followed by a PCR, microarray or sequencing step to 
identify the DNA sequences bound by Sox9. ChIP requires a large amount of starting 
material so cell cultures are normally used, although the binding sites may differ from 
that in vivo. Previous work done in our lab showed that whole embryos could not be used 
for ChIP; some form of enrichment e.g. using the limbs and tails for ChIP only, was 
needed (manuscript in preparation). Due to its scalable nature, MACS would be an 
excellent enrichment method for preparing homogenous samples for ChIP on animal 
tissue material. Using the Two-Step MACS, specific subsets of cells expressing a 
particular gene of interest can also be isolated.  
To further improve the identification of DNA sequences bound by Sox9 directing 
the fate of different cell types, we tagged SOX9 with BAP. This way we could control the 
biotinylation of different subsets of SOX9 by expressing the hBirA under the control of 
different lineage markers. When used with the Two-Step MACS, the ChIP would not be 
affected by the cell isolation, which utilizes the BAP as well, because the 3xBAP on the 
cell surface is cleaved after the first round of sorting. Any residual ones picked up during 
the ChIP would not affect the bound – sequence identification as the extracellular 
molecule does not bind DNA. We also included a HA tag as that is a well-established 






al. 2004) (Kohzaki and Murakami 2007)  to be suitable for ChIP due to the sensitivity and 
specificity of their available antibodies. Having both the BAP and HA tag, SOX9 could 
be immunoprecipitated using antibodies against either biotin, HA or SOX9 itself. As 
different antibodies bind non-specifically to different extents to different background 
proteins, using different antibodies to address the same question will give us more 
confidence that we are looking at true positives if the same DNA sequence is pulled down 
by all three antibodies. 
To tag SOX9, plasmid constructs were made for specific targeting of the genomic 
Sox9. The same homology arms used to target Sox9 to knock-in Lngfr was used here. The 
BAP sequence was placed furthest from Sox9, followed by the HA sequence and then a 
loxP-flanked PGK-gb2-Neo (Fig. 7.3.4.1) This allows for Kanamycin and G418 selection 
in bacterial and mammalian cells respectively, and allows for the Cre removal of the 
loxP-flanked sequence. Two constructs were made, one for targeting Sox9‟s N-terminus 
and another for targeting the C-terminus, so that any effect the tagging had on Sox9 
function would be controlled for. 160 G418 resistant colonies each from the 
electroporation of N- and C- terminus targeting of Sox9 were screened by PCR and 
Southern Blotting (Fig7.3.4.2). 1 successfully targeted clone was identified each, for the 
N- and C-terminus tagging of Sox9. The LoxP-flanked neo was also removed by transient 
expression of Cre. To date, however, chimeric mice have not been obtained from these 


















7.3.5 Preparations for in vitro ChIP 
Because the ATDC5 is one of the most convenient models for chondrogenic 
differentiation, it has been used for high throughput studies of gene expression changes 
during chondrogenesis. Having compared this in vitro model with in vivo results, there 
could be value in also comparing the primary SOX9 targets in the ATDC5 and in vivo 
models. Having a cell culture model would also enable us to do preliminary optimisation 
of the ChIP protocol before performing ChIP on MACS-isolated cells. For this purpose, 
we needed to express HA-BAP tagged SOX9 in ATDC5 cells. Attempts to specifically 
target the endogenous SOX9 using the same constructs for ES cell gene targeting did not 
succeed - G418 resistant colonies did not form at all. We then explored the possibility of 
overexpressing the tagged Sox9. We first compared 3 promoters commonly used for 
overexpression in cell lines: pCAG, pCMV and PGK. ATDC5 cultures transfected with 
pCMV had 4-fold more fluorescent cells than PGK and those transfected with pCAG had 
10-fold more fluorescent cells than pCMV.  EGFP was used as the reporter gene. Next we 
made overexpression constructs driven by pCAG, followed by the Sox9 cDNA (RefSeq 
mRNA: NM_011448.2) sequence with either the tag sequences on its 5‟ or 3‟ end. This 
was followed by IRES-EGFP and IRES-hBirA (Fig. 7.3.4.1). EGFP serves as a reporter 
gene as a quick means of determining the lipid transfection efficiency and hBirA is 
needed for the BAP to be biotinylated.  
5% of the ATDC5 cells were transfected within the first 48 hours judging by the 






weeks of G418 selection, only about 5 colonies were obtained. A mock transfection done 
in parallel yielded no colonies after 2 weeks. The G418 resistant cells were scaled up 
under drug selection. Very little tagged SOX9 could be detected in these stably 
transfected lines (detectable by Western Blot only with overnight exposure, with very 
high background). We speculated that the cells were regulating the expression of tagged 
SOX9 and keeping its level very low or shutting it off. Attempts to perform ChIP on 
either the transiently transfected cells or the stably transfected cells were unsuccessful.  
We attempted to perform ChIP using antibodies against SOX9 directly with 
BMP4-differentiated ATDC5 cells. To identify the sequences of the ChIP DNA to 
determine if it was sucessful, we employed the PCR method. One of the pre-requisites of 
using PCR is that some information about the transcription factor‟s binding sites is 
known. In the case of Sox9 literature is available, and this was one of the key reasons why 
we chose to work with Sox9. The tables in Appendix 5 describe the primers we used. 
Many of these positive control binding sites for PCR were identified through gel-shift 
mobility assays in published studies. 
While we managed to identify antibodies that could successfully 
immunoprecipitate SOX9, we were unable to see any enrichment of known SOX9 
binding sequences. There are several explanations that could help refine future 
experiments. Detection of binding sites requires efficient cross-linking and de-cross-
linking between the transcription factor and DNA. If the transcription factor is very 
loosely bound to the DNA, or is indirectly bound through other protein partners and 






other binding partners to affect their regulatory functions (reviewed in Chapter 2.3). 
Although we did attempt to optimise the cross-linking and de-cross-linking, this could be 
an area for future refinement. Subsequent to cross-linking, the sonicated size of the DNA 
fragments is also important because the sizes must be large enough to span the amplicon 
size of the PCR primers used, yet at the same time, must be of a sufficiently small size 
such that non-binding regions would not be precipitated along with the transcription 
factor. This is so that the difference in copy number in the precipitated fraction between 
bound and unbound DNA regions would be significant enough to confidently indicate 
which regions were bound.  
In the absence of other proteins interacting with SOX9, the binding properties of 
SOX9 might be different and hence these experiments might not accurately reflect the in 
vivo binding sites. Also, SOX9 binds to different sites in different cells, thus binding sites 
identified in other cell and tissue types might also not be good positive controls for 
another cell type. Our laboratory has previously observed that the binding sites of Col2A 
differ in embryos compared to what was claimed in the literature. To circumvent the 
potential problem of identifying the wrong binding sites for positive controls, the entire 
population of ChIP DNA could be identified either through microarray analysis or 
sequencing. While promoter arrays are often employed for this purpose, in the case of 
SOX9, genomic tiling arrays or custom arrays may be required, because SOX9 tends to 
bind within introns – especially the first intron, in addition to promoters. Going forward, 












Section 7.4 Discussion 
The purpose of developing MACS-based strategies of isolating rare cells from 
tissue was to prepare samples for sensitive, purity-dependant applications like 
transcriptome-profiling. We showed in the previous chapters that a single-step MACS is 
capable of isolating rare cell populations to about 50% purity and Two-step MACS to 
over 85% purity. In this chapter, we used Illumina Beadchip microarrays to assess the 
suitability of single-step MACS for such downstream applications and to map out gene 
regulatory pathways involving our gene-of-interest. The results showed that single-step 
MACS successfully isolated Sox9-expressing cells from Sox9
+/Lngfr
 teratoma. The cells 
were microarray-profiled and generated gene lists were heavily populated (~90%) with 
Sox9 related genes. Only single-step MACS was assessed as we had successfully 
generated modified ES cell lines where Lngfr was knocked-in to the Sox9 locus. These 
cell lines were used to generate teratoma where Sox9-expressing cells also expressed 
Lngfr on its extracellular cell surface. Similar ES cells expressing the two-component cell 
surface BAP-Lngfr protein were yet to be obtained, and hence assessment of Two-step 
MACS for tissue remains part of future work.  
MACS has been shown to affect downstream applications of sorted samples, such 
as with fluorescence in situ hybridization where the hybridization efficiency is 
significantly reduced (Kuo and Guo 2001). In our case however, the RNA integrity and 
Illumina Beadchip Arrays quality controls show that RNA isolated from cells of all 
fractions following MACS were of sufficient quality to perform downstream microarray 






90%, according to both our experience and published reports (Medina, Segundo et al. 
2004). Our cells were isolated from the dissociation of teratomas, a very complex 
heterogeneous tissue, using the single-step MACS. MACS was performed using magnetic 
bead-conjugated anti-Lngfr antibodies, to isolate cells expressing the transgenic Lngfr on 
the cell surface. Lngfr expression is controlled by a Sox9 promoter and mirrors Sox9 
expression. Our isolated cells of interest - Sox9
+/Lngfr
 cells from the MACS  Eluted 
fractions - show a differential gene expression profile that is very distinct from the input 
starting complex cell suspension and that is very distinct from the cells eluted after 
MACS of wildtype or Sox9-null teratomas. We identified genes that are differentially 
expressed regardless of which of these 3 reference populations were used and subtracted 
from this gene list those which were also differentially expressed in the same direction 
(up- or down- regulated) in negative control comparisons. The resultant gene list 
„Candidate Sox9-related genes‟ consists largely of genes that are known to interact 
directly or indirectly with Sox9-related genes at the protein level. Together, these 
observations support our case that Sox9-expressing cells were being isolated from our 
Sox9
+/Lngfr
 teratomas by MACS, but not from wildtype or Sox9-null teratomas.  
The transcription factor SOX9 is well-known as the master regulator of 
chondrogenesis. However, as reviewed earlier, Sox9 is involved in many other 
developmental processes as well, including sex determination, heart valve development, 
pancreatic, intestinal crypt cell development, neurogenetic developmental processes such 
as notochord maintainance, oligodendrocyte formation, gliogenesis etc. It is also found to 
be expressed in the developing lungs, teeth, and skin cells (Reviewed in Section 2.3). 






some of these developmental processes. Our observations were consistent with this 
expectation. Genes involved in developmental processes were overrepresented in the list 
of differentially expressed genes when the profile of MACS eluted Sox9
+/Lngfr
 cells were 
compared to the different control cell fractions. Developmental genes also formed a 
higher proportion amongst the >5-fold differentially regulated genes compared to the >2-
fold ones. Amongst the „Candidate Sox9-related genes‟ we identified, most were not only 
developmental genes, but also had direct or indirect relation to Sox9. These observations 
validated our approach and provided a list of possible Sox9-related genes for future 
analysis by our group. Our „Candidate Sox9-related genes‟ represent genes that are 
expressed in Sox9-expressing cells and are likely to be involved with processes where 
Sox9 plays a functional role. However, these genes are not necessarily directly or even 
indirectly regulated by, or regulators of, Sox9. To estimate the likelihood of these Sox9-
co-expressed genes having a role in Sox9-related gene regulatory networks, protein-level 
interactions with various players of Sox9-related developmental processes can be 
examined. We postulated that many of these genes are co-expressed with Sox9 as they 
have protein-level functions in these Sox9-related regulatory processes. 9 of the 10 known 
upregulated candidate Sox9-related genes that iHOP identified as having protein-level 
direct or indirect interactions with other known members of the Sox9 regulatory pathways 
(Tle1, Rfx4, Zfp354c, Zfp354a, Ncor1, Wnt3, Apop-1, Bcat1, and Rln1). 5 of the 9 genes 
have direct interactions and 4 have indirect ones. Many of these interacting proteins are 
also involved in developmental processes that Sox9 is involved in, or are expressed in 
similar tissuesSox9. Tle1 is a transcription factor involved in neuronal and epithelial 
differentiation and is expressed in bone tumors (Kosemehmetoglu, Vrana et al. 2009). It 
is known to be part of the Wnt and Notch signalling pathways, which also regulate Sox9 






which Sox9 is downstream of (Ashique, Choe et al. 2009). It also regulates gene 
transcription during spermatogenesis and is highly expressed in the testis (Wolfe, 
Vanwert et al. 2008). The zinc-finger transcription factor Zfp354c gene contains response 
elements for the transcription factors Runx2, NFkappaB, Smads, Sp1, and Ets1, all 
known members of Sox9 gene regulatory networks (Jheon, 2003) The zinc-finger 
transcription factor Zfp354c gene contains response elements for the transcription factors 
Runx2, NFkappaB, Smads, Sp1, and Ets1, all known members of Sox9 gene regulatory 
networks (Jheon, Suzuki et al. 2003).  Zfp354c itself has been implicated as a 
chondrogenic related transcription factor in ATDC5 cells (Narukawa, Suzuki et al. 2007). 
Zfp354a is involved in epithelial development in the kidney (Witzgall, Obermuller et al. 
1998). Ncor1 is a transcriptional repressor implicated in breast cancer, which Sox9 has 
also been implicated in (Afonja, Raaka et al. 2002). Wnt3 is involved in Shh and Bmp 
signalling, both known to regulate Sox9 (Robertson, Braun et al. 2004). Apop-1is 
involved in apoptosis (Sun, Yasuda et al. 2008). Bcat1is a cytosolic branched-chain 
aminotransferase expressed in developing oligodendrocyte where Sox9  is known to be 
expressed in (Sweatt, Garcia-Espinosa et al. 2004). Rln1 is implicated in recurrent 
largyngeal neuropathy (Dixon, Hahn et al. 2009). Appendix 4 Table 1 provides more 
detail about these 9 genes. Under each gene are all its known interacting protein partners. 
In bold are genes that are either known to be part of Sox9 gene regulatory networks or 
have interactions with such proteins. There were 288 downregulated candidate Sox9-
related genes. Due to the length of the list, we decided to focus on the shorter list that as 
downregulated by at least 5-fold. There were 165 such genes, for which 82 had iHOP 
information. These genes fell into 2 main categories: 49 of them are related to 






immunoregulatory regulated ones: 21 genes are represented in both groups.  
In adult cartilage tissue, pro-inflammatory cytokines are expressed and involved 
in osteoarthiritic tissue. The pro-inflammatory cytokines IL-1 and TNFalpha have been 
shown to dedifferentiate chondrocytes and downregulate genes like Sox9, Col2 and 
integrins, through the NFkappaB pathway (Murakami, Lefebvre et al. 2000). IL-1 effects 
can be countered by IGF-1, TGF-beta1, BMP2 and BMP9 to induce chondrogenic 
differentiation (Kolettas, Muir et al. 2001; Majumdar, Wang et al. 2001; Roman-Blas, 
Stokes et al. 2007; Seifarth, Csaki et al. 2009). IL-6 is involved in the repair of arthrodial 
cartilage by suppressing the differentiation of chondrocytes while upregulating the 
expression of matrix proteins and pro-chondrogenic surface signalling receptors like the 
BMP-receptors (Namba, Aida et al. 2007). In mouse embryonic limb buds, 
chondrogenesis requires the upregulation of Sox9 and its downstream genes, as well as 
the inhibition of IL1-beta (Takahashi, Nuckolls et al. 1998). Disruption of 
immunoregulatory pathways by the use of anti-inflammatory drugs have been known to 
cause skeletal side effects leading to growth retardation in children and reduced bone 
quality in adults (James, Ulici et al. 2007; Fernandez-Cancio, Esteban et al. 2008). Thus 
published literature supports our observation that immunoregulatory genes are 
downregulated in our Sox9-expressing cells of interest and that more than half of the 85 
genes on our >5-fold downregulated „Candidate Sox9-related genes‟ list were involved in 
IL1, IL6, TNFalpha, or NFkappaB signalling pathways. These pathways have to be 
repressed for Sox9-directed chondrogenesis to occur. Amongst the downregulated 
developmental genes, Tgfb1 and Igf1 feature prominently. Tgfb1 and Igf1 acts upstream 






increases, these early regulators of Sox9 expression are downregulated. Amongst the 
indirect interacting proteins are a group that acts upstream of Sox9 or are still expressed in 
the early part of Sox9 expression. Such proteins include Runx1, Runx2, Fgf2, Shh, Bmp2 
Wnt3A (Yamashiro, Wang et al. 2004; Yamashita, Andoh et al. 2009)  (Majumdar, Wang 
et al. 2001). Another group is expressed in the later part of Sox9, mainly because they are 
target genes upregulated by Sox9, transcription factor. Such proteins include Acan, Sox5, 
Runx2 and Runx3 (Akiyama, Chaboissier et al. 2002; Soung do, Dong et al. 2007).  
It was interesting that when cells eluted from the MACS of wildtype and Sox9-
null teratoma, all the immunoregulatory genes were upregulated. In terms of cell 
numbers, about 1% of the input cells would be found in this Eluted fraction, as compared 
to ~10% with the Sox9
+/Lngfr
  teratomas. Most of these cells that represents the 
background of the MACS would either be cells that express endogenous LNGFR on its 
surface, had cell surface proteins that bound non-specifically with the anti-Lngfr 
antibody, or were dead or dying cells. Dead and dying cells tend to make up the majority 
of this fraction, and these cells may express high levels of pro-inflammatory or 
immunoregulatory genes. Cells that express endogenous LNGFR did not seem to make 
up a problematic proportion of the background, likely because endogenous LNGFR is not 
as highly expressed as Sox9 and its levels produced too few LNGFR for the cells to be 
retained on the column. Despite the correlation that our „Candidate Sox9-related genes‟ 
had with Sox9 gene regulatory networks, there was very little overlap when compared 
with published transcriptome profiles of Sox9-expressing tissue. Two genes were 
upregulated in both our data and the ATDC5 genelists, Sox4 and Emp3. Sox4 is known to 






(Lioubinski, Muller et al. 2003; Hong and Saint-Jeannet 2005; Ezura, Sekiya et al. 2009). 
Emp3 is not known to be associated with Sox9 gene regulatory networks, but has been 
implicated in neuroblastomas and gliomas(Kunitz, Wolter et al. 2007; Li, Pang et al. 
2007; Scrideli, Carlotti et al. 2008) . Sox9 has been shown to be involved in glial cell 
differentiation, and Emp3 is a putative a novel candidate gene to study further in this 
process (Pompolo and Harley 2001). Between the published chondrogenic downregulated 
genes and ours, 3 genes are common: Pappa2, an enzyme which cleaves IGFBP-5, a 
stimulator of bone-formation (Christians, Hoeflich et al. 2006) ; Csf1r, which has a low 
level of expression in diseased glomeruli where Sox9 is highly expressed (Bennett, Czech 
et al. 2007) ; and Samdh1, a regulator of the innate immune response (Rice, Bond et al. 
2009) . Between the published transcriptome profiles, there was also very little overlap. 
Several explanations exist for this small number of overlapping genes. Apart from the fact 
that microarrays are known to be very susceptible to inconsistencies, between platforms, 
or even on the same platforms within the same laboratories, or when different 
interpretation methods and algorithms are used to analyze the data (Walker and Hughes 
2008), other factors are likely to be at play as well. 
One major factor may be the difference in sample type, which once again 
underscores the importance of having suitable, representative samples for the question 
being investigated. Between chondrogenic tissue and male gonadal tissue, little overlap 
can be expected because these are two entirely difference developmental processes even 
though Sox9 plays a major role in both. Between the ATDC5 cell culture and micromass 
culture though, the lack of common genes was a surprise, since both are often used as 






together, we see a 4-20% overlap with the chondrogenic tissue gene expression profile. 
This underscores how cell culture models can differ from each other and with in vivo 
processes to produce misleading results. Chondrogenic tissue samples used to obtain the 
chondrogenic tissue gene lists used here were prepared through several means. Clancy et 
al. induced ectopic formation of endochondral bone in mice quadriceps with Bmp2 
(Clancy, Johnson et al. 2003).Yamane et al. obtained surface and resting chondrocytes 
from postnatal proximal humeri using laser capture microdissection (Yamane, Cheng et 
al. 2007). Belluoccio et al. microdissected different maturation zones from 14-day old 
mouse femur growth plate cartilage (Belluoccio, Bernardo et al. 2008). Sugars et al. 
removed metatarsal long bones from 15 and 19 d.p.c mous embryos (Sugars, Karner et al. 
2006).These studies used the traditional definition of chondrocytic tissue: the expression 
of classical Sox9 downstream target genes like Col2aI, Aggrecan, Alcian Blue staining, 
Alkaline Phosphatase positivity. By their very definition, these cells are already in the 
later stage of Sox9 expression, when Sox9 exerts its effects to upregulate its targets. 
Regulatory pathways, which act upstream of Sox9 to increase its expression, may or may 
not be detectible at this stage. Our methodology defines our cells of interest by the 
expression of Sox9 as the Sox9 endogenous promoter controls Lngfr expression. What 
would determine the kind of cells we isolate are a) the period which the Sox9 promoter is 
active b) the half-life of Lngfr c) the level of Sox9 promoter activity and Lngfr translation 
in each particular cell type.  
The period that Sox9 is actively transcribed may or not correspond to the same 
period during which Sox9 exerts its transcriptional effects, due to post-transcriptional 






expressing cell types. By defining cell types by the expression of markers downstream of 
the gene of interest, a different picture might be obtained from defining the cell types by 
the expression of the gene of interest itself. In our case, the marked absence of many 
classical Sox9 chondrogenic downstream markers, and the large representation of 
upstream genes, hint that cells in the early Sox9-expression phase are being isolated. The 
presence of downstream targets like Acan and Sox5 show that cells in the later phase are 
also represented. The half life of the reporter gene makes a difference as well. EGFP is 
known for its stability, and may still fluoresce 24 hours (Wahlers, Schwieger et al. 2001) 
after the transcription of the gene of interest is switched off. Often, this may correspond 
to the period where the expression of downstream target genes may be high, once again 
giving that same picture of the cells of interest, if FACS based on EGFP-expression was 
used for sample preparation. One interesting question to answer in future would be the 
half-life of the transgenic Lngfr and BAP-Lngfr in different cell types and their 
relationship to the gene of interest. The fact that there is no significant difference in gene 
expression levels of Sox9 between the test and control samples, indicates that Lngfr may 
have a longer half-life such that the Lngfr protein is still available at the cell surface for 
MACS selection even after  Sox9  is no longer expressed. The level of Sox9 promoter 
activity in different Sox9-expressing cell types may differ. This means that different cell 
types may be isolated to different degrees of efficiency, affecting the final representation 
of that particular cell type in the sample. With the development of our Two-step MACS 
strategy, it would be possible to isolate specific Sox9-expressing subpopulations in the 
future. That would allow us to compare the absolute spatio-temporal differences in Sox9 






The fact that with teratomas, different cell types tend to be present in more 
random, and, hence, probably more equal levels, may also explain differences between 
our study and those published. The published studies looked at a particular tissue type and 
that was represented by their transcriptome profile. Even if whole embryos were used for 
the isolation of all Sox9-expressing cells, the sample would still be skewed towards the 
more abundant lineages. The large amount of chondro-skeletal cells in embryos would be 
expected to mask genes downstream of Sox9 of cells of other lineages, from the gonads, 
neuroprogenitors, heart valve etc. With teratomas, the representation may be more equal, 
although it will be affected by the Sox9 expression level of each type as explained above, 
as well as the survivability of having a single allele knocked out in the different cell 
types. For example, Sox9+/- mice tend to die of heart failure due to defective valves 
(Lincoln, Kist et al. 2007), while conditional Sox9+/- mice can develop chondrocytic 
tissue normally, as we have observed. Future work using Sox9+/+ genotypes would 
address this issue and subpopulation isolation with the Two-step MACS would also 
prevent the averaging of gene expression levels across cell types and the masking of less 
abundant ones.  
The contaminating, non-Sox9-expressing cells in the different samples may also 
explain the difference between the gene sets obtained. This is especially true for tissue-
derived samples, including ours. On average, our samples were about 60% pure, as 
determined by anti-Lngfr-FITC staining that also stains some cells non-specifically. That 
nearly half of our samples were not Sox9-expressing would have tremendous effects on 
the transcriptome profile. This was the primary challenge our Two-step MACS was 






Sox9-related genes gives us confidence that our Two-step MACS would be even better. 
The diluting effects of contaminating cells and non-chondrogenic Sox9-expressing cells 
may further explain the under-representation of classical Sox9 chondrogenic markers in 
our differential gene expression profile. It may also explain why the magnitude of 
differential gene expression was small: most were less than 10-fold differentially 
regulated. In the case of the published studies, using whole bone would include non-
chondrogenic, non-Sox9-expressing cell types, although the microdissected samples 
would be purer. 
One point of concern we had, which might also contribute to the differences in the 
transcriptome profiles of different sample types, is the effect that the various sample 
preparation methods has on gene expression. Hayman et al. (Hayman, Blumberg et al. 
2006) reported significant changes in expression levels of chondrogenesis-related genes 
such as Col2 and Aggrecan, as a result of enzymatic dissociation of cartilage tissue into 
single cells. Other studies report that MACS has no significant effect on the gene 
expression profiles of cells. However, for certain cell lines, enzymatic exposure to make 
single cell suspensions and antibody incubation seems to have an effect on a small subset 
of genes. The genes tend to be involved in extracellular matrix remodelling, repair, signal 
transduction, replication and transcription (Woelfle, Breit et al. 2005).  
While we cannot rule out any gene expression changes as a result of our isolation 
protocol, we have attempted to minimize this by keeping the tissue dissociation and cell 
isolation time to the minimum. Hayman‟s group used cartilage explants from slaughtered 






dissociated to single cells. Hayman et al. compared a 6-hour collagenase digest, a 22-hour 
collagenase digest, a 45-minute trypsin digest followed by a 3-hour collagenase digest 
and a 1.5-hour pronase digest followed by a 3-hour collagenase digest. They found that 
the digest utilising trypsin resulted in primary cell culture morphology that was distinct 
from the others. Trypsin digest tends to result in the cleavage of many cell surface 
proteins which might affect intracellular signalling and hence cell function and 
morphology. Collagenase on the other hand, digests collagens specifically, which is 
primarily a supportive extracellular matrix protein. Thus we chose to use the Liver Digest 
media which digests mainly the extracellular matrix structural support proteins. Our 
dissociation was usually completed within 1 hour. However, we recognise that even 
within this short duration, some mRNA transcripts might be more susceptible to 
degredation than others during the cell isolation procedure, and this may account for why 
there does not seem to be any significant difference in the expression levels of Sox9 or 
other chondrocytic genes between the test and control samples.  
We do not think that the magnetic field applied during MACS would have 
significant effects on gene expression. Cell proliferation and growth was previously 
shown not to be affected by exposure to constant magnetic fields of up to 0.05T. Fields of 
up to 11T also have been shown to have no effect on DNA content or replication, or cell 
differentiation (Swann, Dealtry et al. 1992). MACS selected cells also do not alter their 
electrophysiological properties (Greenfield, Sun et al. 1997). In terms of cell function, 
there are conflicting reports where some claim MACS affects the function of isolated 
eosinophils (Casale, Erger et al. 1999) (Malm-Erjefalt, Stevens et al. 2004) and cord 






was a better method of preserving eosinophil (Munoz and Leff 2006), megakaryocyte 
(Schmitz, Radbruch et al. 1994) and natural killer cells (Leung, Iyengar et al. 2005). More 
work in future is required to investigate the effects that our one- and Two-step MACS has 
on Sox9-expressing cells, or any other cells of interest isolated.  
One major limitation of our current experiments is that it identifies the major 
genes and pathways that are co-expressed with Sox9, without providing information on 
which are directly related, or whether there is any cause-and-effect relationship with 
Sox9. In fact, there might be a set of genes that are co-expressed with Sox9-expressing 
cells that have nothing to do with Sox9 at all. These genes, in particular the 
downregulated ones, may represent genes that are wholly unrelated to Sox9  function but 
are specifically expressed in some other cell type, eg.  genes involved in the immpune 
response could simply be expressed more highly  in many other cell types eg those of the 
haematopoetic system, rather than in Sox9-expressing cells. We attempted to optimize a 
ChIP protocol that could be applied to our isolated cells of interest, so that Sox9 primary 
targets could be identified. Unfortunately, we were unable to do so successfully. This 
would be an important future piece of work to pursue. To this end, we have also created 
transgenic ES cell lines where the endogenous Sox9 has been tagged, so that ChIP can be 
performed on isolated transgenic tissue-derived cells, with antibodies against these tags. 
This will have to be pursued by other members of our group in future. 
Our Sox9-related genes were identified by comparing the eluted Sox9
+/Lngfr
 
teratoma cells with the eluted wildtype or Sox9-null cells or with the Input fraction. These 






address –that is, whether MACS is suitable for isolating cells of interest for transcriptome 
mapping. This experiment elucidated genes that are co-expressed with Sox9 but not 
necessarily directly involved in Sox9-related pathways. This is because many other gene 
expression differences are a result of simply being a different cell type and that confounds 
the information gleaned about Sox9-related genes. However, by demonstrating the 
suitability of our MACS strategy for isolating rare cell samples, other experiments can 
now be done in future to elucidate genes directly within the Sox9 gene regulatory 
network. Another such experiment that can better elucidate genes that regulate or are 
regulated by Sox9 would be to compare MACS isolated cells from Sox9+/+, Sox9+/- and 
Sox9 -/- tissue. The gene expression of the cells compared would be identical, except for 
the genes that are affected as a result of the Sox9 dose-dependent differences, which are 
highly likely to be direct players in Sox9 gene-regulatory pathways.  
Finally, to confirm if any of the genes identified have a direct role to play in Sox9 
upstream or downstream gene regulations, functional studies can be be done. Mechanistic 
studies will also elucidate how they exert their effects. In such cases, cell culture models 
would provide a convenient platform for overexpression or knockdown assays, which can 
later be confirmed in vivo. Two-step MACS isolations can also be done using these 
putative Sox9-related genes to define the cell population of interest. By elucidating the 
gene regulatory networks of these different genes, a clearer, larger picture of how 
different networks determine the phenotype and function of different cells in embryos and 















Sensitive assays for transcriptome profiling, proteomics and other biological 
processes require starting cell samples of high purity, as the data is easily distorted by 
contaminating irrelevant cell types. This need is most keenly felt when developmentally 
regulated processes, like the control of gene expression pathways by key developmentally 
regulated transcription factors, are being investigated. Such studies require samples that 
are representative of the spatiotemporal cell-specific events occurring in vivo. The 
samples must be of sufficient quantity and quality for the sensitive downstream assays to 
produce reliable data. However, current technologies commonly used fall short in one 
way or other (reviewed in Chapter 2). Using whole organs or tissue introduces irrelevant 
cell types into the sample, which distorts the data, e.g. gene expression profiles of all the 
cell types on average are obtained, rather than that of any particular cell type. 
Microdissected samples are purer, but they are laborious and technically challenging to 
prepare, hence sample quantities are small. Thus nucleic acid amplification is often 
needed downstream, a step that introduces bias. Cultured cells are homogenous, cheap 
and convenient to use, but the cells are taken out of their in vivo microenvironment, 
which affects spatiotemporally regulated developmental processes and gene expression 
greatly. FACS has thus far yielded the most suitable samples, in terms of its sample 
purity, quality and ease of preparation. The drawback of FACS, however, is its high start-








To address these needs and challenges, we set out to develop a sample preparation 
strategy that met the following criteria: 
(i) able to isolate specific cell populations or cell types from animal 
tissue 
(ii) able to isolate the desired cells even when they were rare, with 
proportions approaching that of the background non-specific cells  
(iii) able to isolate desired cells defined by the expression of one or two 
genes of interest rather than cell surface marker(s) 
(iv) able to isolate the desired cells to sufficient purity and quality for 
sensitive downstream assays 
(v) cheap, fast and scalable so that sufficient quantities of cell sample 
can be obtained for assays without the need or option of further 
amplification 
 
We found MACS to be a suitable method on which to base our cell isolation 
strategy. In principle, MACS is very similar to FACS, except that the start-up costs are a 
hundred times lower and it is hence scalable. It has routinely been used in the clinical 
setting to isolate cells from large volumes of blood, based on the cell surface markers of 
the desired cells. A number of research studies have also utilised MACS to isolate desired 
cells from various other tissues, again based on cell surface marker expression (reviewed 






We developed the Two-Step MACS cell isolation strategy to isolate desired rare 
cell populations from dissociated solid animal, not defined by the cells‟ surface marker 
expression, but by the expression of a gene of interest. This is a generic isolation method 
that can be applied to all cell types of interest defined this way, e.g. to study any 
transcription factor of interest within its in vivo environment.   
In developing our isolation strategy, we have shown that cells of interest can be 
isolated from cell cultures to high (nearly 100%) levels of purity and recovery by 
expressing a transgenic cell surface protein molecule, Lngfr, and performing a single 
round of MACS after labelling these cells with magnetic bead-conjugated anti-Lngfr 
antibody. The Lngfr is a truncated version without the intracellular domain needed for 
downstream signalling. We applied this single-round MACS strategy to animal tissue, by 
generating teratomas from modified mouse ES cells.  These ES cells have part of one 
Sox9 allele replaced with the Lngfr coding sequence, so that the Lngfr expression mirrors 
that of Sox9. We chose Sox9 as our model gene of interest to develop our cell isolation 
strategy because of Sox9‟s biological importance as the chondrogenic master regulator 
transcription factor, and because its well-studied expression pattern gives us a reference 
point to use as positive control. Teratomas were generated reliably and quickly and were 
capable of developing Sox9-expressing tissue.  
Using the tissue dissociation and single-round MACS protocol we optimised, we 
isolated Sox9-expressing cells to a purity of 60% on average. We also spiked known, 
defined amounts of Lngfr-expressing transfected cells into cells dissociated from wildtype 
embryos to ~1% and found that a single round of MACS produced samples, which was 
nearly half made up of contaminating cells. Since this was unlikely to be satisfactory for 






protein, BAP-Lngfr, for the purpose of doing two consecutive rounds of MACS. We 
termed this novel strategy „Two-Step MACS‟. The first MACS round targets the first 
component, biotinylated-Biotin Acceptor Peptide, and the second round targets the 
second component, Lngfr. In between both rounds, the two-component molecule is 
cleaved at its trypsin sites to remove the beads labelling the cells. After optimising the 
Two-step MACS protocol, we managed to isolate the ~1% spiked-in cells to a purity of 
~85%, and the 0.1% spiked-in cells to a purity of ~40%. Our design of the two-
component cell surface molecule also allows the isolation of specific subsets of Sox9-
expressing cells. The Biotin Acceptor Peptide requires the expression of humanised-BirA 
in trans for biotinylation. The magnetic bead-conjugated antibody targets biotin. For our 
current work, we have knocked hBirA into the ubiquitously expressed ROSA26 locus. If 
a specific subpopulation is desired in future, hBirA can be expressed under the control of 
another gene that defines this subpopulation eg. Bapx1 for chondrogenic subpopulations. 
This way, MACS can isolate a population of cells defined by the co-expression of two 
genes. This strategy can be applied to any cells of interest, other than Sox9-expressing 
cells, for very precise analysis. Other two-component cell surface molecules can also be 
tested, if they can serve the functions required for Two-step MACS. These alternatives 
may improve the sorting efficiency and have less effects on the cell functioning and 
viability.  
We have also elucidated Sox9-related genes and gene regulatory networks that can 
now be functionally and mechanistically investigated for future work. This showed that 
MACS isolated cell samples were of sufficient quantity and quality for downstream 
microarray analysis. Despite the ~60% purity of the single-round MACS samples we used 






gene regulatory networks. Gene expression activity related to both the early and late 
phase of Sox9 expression were elucidated. Both gene expression pathways regulating 
Sox9 and those regulated by Sox9 could be identified. Our data also concurred with 
growing evidence that downregulation of immunoregulatory gene activity takes place just 
prior to the upregulation of Sox9-related developmentally regulated gene activity e.g. 
chondrogenic gene expression. Additionally, our use of teratoma rather than embryo 
samples enabled the detection of Sox9-related gene networks involved in other 
developmental processes apart from chondrogenesis. These genes may not have 
previously been known because most Sox9 gene regulatory studies concentrate on 
chondrogenic, sex determination or neurogenic networks. However, Sox9 has been 
reported to be expressed in many other cell types as well, where their gene regulatory 
networks might involve any one of the novel interactors we have identified. Based on our 
Sox9 data, future experiments could include ChIP to identify any primary Sox9 targets, 
gel shift assays to see if these proteins bind Sox9 regulatory regions, overexpression and 
knock down assays to determine their functional effects and other similar experiments. 
Apart from microarrays, the Two-Step MACS can be used to prepare samples for 
other sensitive downstream assays such as TaqMan assays and  high-throughput 
sequencing for transcriptome profiling, or ChIP, proteome arrays and mass spectrometry 
to study key protein functions. The scalability of Two-Step MACS has reduced the need 
to depend on cell cultures or nucleic acid amplification and the purity of tissue-derived 
cell samples ensures an accurate representation of in vivo biological processes are being 
studied.   
Our work has some limitations and raises some questions that can be answered by 






Two-step MACS was tested using spiked-in cells. Although spike-in experiments allow 
us to accurately determine the purity and recovery of the sorting method, since the 
number of cells of interest are pre-defined, we would also like to know if cells from tissue 
can express, fold and translocate this protein appropriately and at suitable levels for 
sorting. We would also like to generate embryos to test both the one- and Two- step 
MACS. This would allow us to see if viable embryos can be obtained, especially since 
our tests on zebrafish gave rise to developmental abnormalities. Teratomas also have their 
limitations since tissues may not be in their natural microenvironment, which may affect 
their gene expression differently.  Since we are developing a generic method that is meant 
to be applicable to all cell types, defined by any desired gene of interest, we would also 
like to apply these strategies to other genes. Genes expressed in cells of post-natal and 
adult animal organs can also be studied, by dissociating organ tissue to single cells. The 
embryonic lethality of Sox9 knockout mice and low viability of heterozygous may 
account for our difficulty in obtaining embryonic material; investigating other genes may 
not present this problem. 
In conclusion, we have contributed to the available options for isolating rare cell 
populations from animal tissues by developing this Two-step MACS strategy. Compared 
to current available options, our strategy is fast, low cost, technically simple and scalable 
to produce quantities as required. It is capable of isolating specific cell populations or 
subpopulations as defined by the expression of one or two genes of interest, thus 
eliminating the need to have prior information on the cells size, density or surface 
markers available. Our successful transcriptome profiling shows that isolated cells of 
sufficient quality and quantities can be used for downstream sensitive biological assays. 






proteomes are now being mapped, with the advent of fast, high throughput sequencing 
and array technologies. Protein interactions, protein-nucleic acid interactions and micro-
RNA expression profiles are other areas of interest enabled by technological advances in 
profiling methods. The development of a strategy to provide spatiotemporally specific 
animal tissue samples will cater to these downstream technologies so that information 


















Appendix 1  
Survey of Sample Types used for Quantitative Gene Expression 
Profiling 





Expression profile of total VEGF, VEGF splice variants 
and VEGF receptors in the myocardium and arterial 
vasculature of diabetic and non-diabetic patients with 
coronary artery disease 
Human artery biopsies  (Zygalaki, 
Kaklamanis et 
al. 2008) 
The mouse and human Liprin-alpha family of scaffolding 
proteins: Genomic organization, expression profiling and 
regulation by alternative splicing 
Human and mouse whole 




Gene expression profiling reveals similarities between the 
in vitro and in vivo responses of immune effector cells to 
IFN-alpha 
Human density gradient 
purified immune cell subsets 
(Zimmerer, 
Lesinski et al. 
2008) 
Expression profiling of hepatic genes associated with lipid 
metabolism in nephrotic rats 
 
Rat whole liver (Zhou, Zhang et 
al. 2008) 
A microfluidic processor for gene expression profiling of 
single human embryonic stem cells 
Human embryonic stem cell 
cultures 
(Zhong, Chen et 
al. 2008) 
Response of the adipose tissue transcriptome to 
dihydrotestosterone in mice 
 
Mouse whole adipose tissue (Zhang, Calvo 
et al. 2008) 
Stemness gene expression profile of human adipose 
derived stem cells in long-term culture 
Human adipose tissue derived 
stem cell cultures 
(Zaman, 
Makpol et al. 
2008) 
Protein expression profiling of cytokines and cytokine 
receptors on purified chronic lymphocytic leukemia cells 
from patients with favourable prognostic indicators 
Human density gradient and 
MACS purified immune cell 
subsets 
(Yu, Sun et al. 
2008) 
Global relationship between the proteome and 
transcriptome of human skeletal muscle 
Human whole tissue (Yi, Bowen et 
al. 2008) 
Quality assessment of cross-species hybridization of CHO 
transcriptome on a mouse DNA oligo microarray 
 
Hamster established cell line (Yee, Wlaschin 
et al. 2008) 
Effect of ovarian steroids on gene expression profile in 
human uterine microvascular endothelial cells 
 
Human endothelial cell 
derived primary cell cultures 









Gene expression profiling related to the enhanced 
erythropoiesis in mouse bone marrow cells 
Mouse FACS purified 
immune cells, Human bone 
marrow derived primary cell 
cultures  
(Yang, Jeong et 
al. 2008) 
Murine Spinal Cord Transcriptome Analysis Following 
Reduction of Prevalent Myelin cDNA Sequences 
 
Mouse whole spinal cord 
derived cDNA libraries 
(Yan, Lathia et 
al. 2008) 
Neuropeptide receptor transcriptome reveals unidentified 
neuroendocrine pathways 
 
Silk worm whole brain, 
transfected human established 
cell line 
(Yamanaka, 
Yamamoto et al. 
2008) 
DNA methylation profile of tissue-dependent and 
differentially methylated regions (T-DMRs) in mouse 
promoter regions demonstrating tissue-specific gene 
expression 
Mouse whole organs (Yagi, 
Hirabayashi et 
al. 2008) 
Simultaneous isolation of DNA and RNA from the same 
cell population obtained by laser capture microdissection 
for genome and transcriptome profiling 
Human LCM purified tissue (Xu, Houck et 
al. 2008) 
Gene expression profile of 2058 spermatogenesis-related 
genes in mice 
Mouse whole testis (Xiao, Tang et 
al. 2008) 
Integrated genomic and transcriptional profiling identifies 
chromosomal loci with altered gene expression in cervical 
cancer 
Human cervical biopsies (Wilting, de 
Wilde et al. 
2008) 
Gene expression profiling of a mouse model of pancreatic 
islet dysmorphogenesis 
Mouse whole pancreas (Wilding 
Crawford, 
Tweedie Ables 
et al. 2008) 
Gene expression profiling of human oocytes at different 
maturational stages and after in vitro maturation 
 
Human oocytes (Wells and 
Patrizio 2008) 
Temporal gene expression profile in hippocampus of mice 
treated with D-galactose 
 
Mouse whole hippocampus (Wei, Cai et al. 
2008) 
Transcriptome-wide identification of novel imprinted 
genes in neonatal mouse brain 
Mouse whole brain (Wang, Sun et 
al. 2008) 
Gene expression profiling reveals putative HOXA10 
downstream targets in the periimplantation mouse uterus 
 
Mouse whole uterus (Vitiello, Pinard 
et al. 2008) 
Temporal profile of estrogen-dependent gene expression 
in LHRH-producing GT1-7 cells 
 
Mouse neuronal established 
cell line 
(Varju, Chang et 
al. 2008) 
Expression profiling of a high-fertility mouse line by 
microarray analysis and qPCR 
 
Mouse ovarian established cell 
line 
(Vanselow, 
Nurnberg et al. 
2008) 
Gene expression profile comparison of Barrett's 
esophagus epithelial cell cultures and biopsies 
 
Human epithelial primary cell 
culture and biopsy 
(van Baal, 







Combined effect of gender and caloric restriction on liver 
proteomic expression profile 
 
Rat whole liver (Valle, Silvestri 
et al. 2008) 
Gene expression profiling of methapyrilene-induced 
hepatotoxicity in rat 
 
Rat whole liver (Uehara, 
Kiyosawa et al. 
2008) 
Analysis of the retinal gene expression profile after 
hypoxic preconditioning identifies candidate genes for 
neuroprotection 
Mouse whole retina (Thiersch, 
Raffelsberger et 
al. 2008) 
Expression profiling of apoptosis-related genes in 
megakaryocytes: BNIP3 is downregulated in primary 
myelofibrosis 
 
Human LCM purified 
megakaryocytes 
(Theophile, 
Hussein et al. 
2008) 
Protein expression profile characteristic to hepatocellular 
carcinoma revealed by 2D-DIGE with supervised learning 
 
Human liver carcinoma 
biopsies 
(Teramoto, 
Minagawa et al. 
2008) 
Comprehensive gene expression profiling of Peyer's patch 
M cells, villous M-like cells, and intestinal epithelial cells 
Mouse purified microfold 
cells 
(Terahara, 
Yoshida et al. 
2008) 
Gene expression profiling of human mesenchymal stem 
cells for identification of novel markers in early- and late-
stage cell culture 
Human mesenchymal stem 
cell cultures 
(Tanabe, Sato et 
al. 2008) 
Gene expression profiling identifies lobe-specific and 
common disruptions of multiple gene networks in 
testosterone-supported, 17beta-estradiol- or 
diethylstilbestrol-induced prostate dysplasia in Noble rats 
Rat whole prostate tissue (Tam, Szeto et 
al. 2008) 
Gene expression profile of dorsal root ganglion in a 
lumbar radiculopathy model 
 
Rat dorsal root ganglion (Takeuchi, 
Kawaguchi et 
al. 2008) 
Accurate molecular characterization of formalin-fixed, 
paraffin-embedded tissues by microRNA expression 
profiling 
 
Human and mouse formalin-
fixed and paraffin –embedded 
whole tissue 
(Szafranska, 
Davison et al. 
2008) 
Cardiomyogenic gene expression profiling of 
differentiating human embryonic stem cells 
 
Human embryonic stem cell 
cultures 
(Synnergren, 
Adak et al. 
2008) 
Broad profiling of DNA-binding transcription factor 
activities improves regulatory network construction in 
adult mouse tissues 
Mouse whole tissues (Sun, Zhang et 
al. 2008) 
A global view of gene activity and alternative splicing by 
deep sequencing of the human transcriptome 
 
Human embryonic kidney and 
B-cell established cell lines 
(Sultan, Schulz 
et al. 2008) 
Global gene expression profiling of human embryonic 
stem cell derived cardiomyocytes 
 










A Novel Method of Obtaining Prostate Tissue for Gene 
Expression Profiling 
Human whole prostate tissue, 
visually selected 
(Sooriakumaran, 
Henderson et al. 
2008) 
Gene profiling of keloid fibroblasts shows altered 
expression in multiple fibrosis-associated pathways 
 
Human keloid derived primary 
cell culture 
(Smith, Boone 
et al. 2008) 
Gene expression profile of prostate cancer cell lines: effect 
of nerve growth factor treatment 
 
Human prostate epithelial 
established cell line 
(Sigala, Bodei et 
al. 2008) 
Gene expression profile analysis of primary glioblastomas 
and non-neoplastic brain tissue: identification of potential 
target genes by oligonucleotide microarray and real-time 
quantitative PCR 
Human glioblastoma derived 
primary cell cultures and 
whole brain white matter 
(Scrideli, 
Carlotti et al. 
2008) 
Transcriptome analysis in primary B lymphoid precursors 
following induction of the pre-B cell receptor 
 
Mouse FACS and MACS 
purified immune cells  
(Schuh, Meister 
et al. 2008) 
Gene expression profiling of two distinct neuronal 
populations in the rodent spinal cord 





Characterizing the mouse ES cell transcriptome with 
Illumina sequencing 
 
Mouse embryonic stem cells (Rosenkranz, 
Borodina et al. 
2008) 
Novel insights into the relationships between dendritic cell 
subsets in human and mouse revealed by genome-wide 
expression profiling 
Mouse and human FACS 
purified immune cell subsets 
and culture derived immune 
dendritic cells 
(Robbins, 
Walzer et al. 
2008) 
Expression profile of Lgi1 gene in mouse brain during 
development 
 
Mouse dissected regions of 
brain tissue 
(Ribeiro, 
Sbragia et al. 
2008) 
Transcription profiling of lung adenocarcinomas of c-
myc-transgenic mice: identification of the c-myc 
regulatory gene network 




Novel glioblastoma markers with diagnostic and 
prognostic value identified through transcriptome analysis 
 
Human glioblastoma biopsies (Reddy, Britto 

































































                                                                           
                Tryps_(100%)                                               
          Tryps_(100%)     |    Tryps_(82%)    Tryps_(100%)                
 
                     |     |              |               |                
              MGAGATGRAMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGAN 
          1   ---------+---------+---------+---------+---------+---------+   60 
                           
                              
                    
                                                                           
                          Tryps_(4.9%)            Tryps_(100%)             
 
                                     |                       |             
              QTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTG 
         61   ---------+---------+---------+---------+---------+---------+   120 
                   
                 
                                         
                                                                           
        Tryps_(100%)                                        Tryps_(100%)   
   Tryps_(100%)    |  Tryps_(75.5%)                      Tryps_(100%)  |   
 
              |    |              |                                 |  |   
              RCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLREC 
        121   ---------+---------+---------+---------+---------+---------+   180 
                        
                           
                          
                                                                           
                    Tryps_(100%)                                           
                Tryps_(100%)   |                                           
    Tryps_(100%)           |   |                                           
 
               |           |   |                                           
              TRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQ 
        181   ---------+---------+---------+---------+---------+---------+   240 
                                                 
                    
 
                              
       Tryps_(100%)               Tryps_(82.5%)  
 
                  |                           |  
              PVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR 
        241   ---------+---------+---------+----   274 
 
 
Legend : „Tryps‟ indicates the trypsin cleavage site (R or K) , and the percentage 
figure in brackets denotes the cleavage probability. Bold, underlined: 
Transmembrane domain. Blue: Intracellular domain .  
Trypsin cleavage prediction was made using the ExPASy PeptideCutter tool: 
Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A.; Protein 
Identification and Analysis Tools on the ExPASy Server; John M. Walker (ed): The Proteomics Protocols 
Handbook, Humana Press (2005). http://www.expasy.ch/tools/peptidecutter/ 
Protein annotation for transmembrane domain was based on NCBI protein database ACCESSION  















 Upregulated Candidate Sox9-related Genes Identified by Microarray 
Symbol Name 
  Tle1   
Aes amino-terminal enhancer of split 
Foxg1 forkhead box G1 
Runx1 runt related transcription factor 1 
Six3 sine oculis-related homeobox 3 homolog (Drosophila) 
Tle3 transducin-like enhancer of split 3, homolog of Drosophila E(spl) 
Tle4 transducin-like enhancer of split 4, homolog of Drosophila E(spl) 
Tle6 transducin-like enhancer of split 6, homolog of Drosophila E(spl) 
Arx aristaless related homeobox 
Gnrh1 gonadotropin releasing hormone 1 
Hlf hepatic leukemia factor 
Nkx2-2 NK2 transcription factor related, locus 2 (Drosophila) 
Nodal Nodal 
Notch1 Notch gene homolog 1 (Drosophila) 
Tcfe2a transcription factor E2a 
Tle2 transducin-like enhancer of split 2, homolog of Drosophila E(spl) 
Cxcl1 chemokine (C-X-C motif) ligand 1 
Runx3 runt related transcription factor 3 
Pax2 paired box gene 2 
Wt1 Wilms tumor homolog 
Usp14 ubiquitin specific peptidase 14 
Zfp423 zinc finger protein 423 
  Rfx4   
Rfx2 regulatory factor X, 2 (influences HLA class II expression, expressed in spermatocytes) 
  Zfp354c   
Bmp7 bone morphogenetic protein 7 
Runx2 runt related transcription factor 2 
Zfp354a zinc finger protein 354A 
Zfp426 zinc finger protein 426 
Sox9 SRY-box containing gene 9 
Zfp60 zinc finger protein 60 
Dlx5 distal-less homeobox 5 
Msx2 homeobox, msh-like 2 
Myod1 myogenic differentiation 1 
Pparg peroxisome proliferator activated receptor gamma 






Sp7 Sp7 transcription factor 7 
Acan Aggrecan 
Ecm1 extracellular matrix protein 1 
  Zfp354a   
Zfp354b zinc finger protein 354B 
Zfp354c zinc finger protein 354C 
Klk6 kallikrein 6 
  Ncor1   
Ncor2 nuclear receptor co-repressor 2 
Pparg peroxisome proliferator activated receptor gamma 
Hdac3 histone deacetylase 3 
Pik3ca phosphatidylinositol 3-kinase, catalytic, alpha polypeptide 
Ncoa1 nuclear receptor coactivator 1 
Pik3r1 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 
Sin3a transcriptional regulator, SIN3A (yeast) 
Nr1h3 nuclear receptor subfamily 1, group H, member 3 
Rara retinoic acid receptor, alpha 
Rxra retinoid X receptor alpha 
Bcl2a1a B-cell leukemia/lymphoma 2 related protein A1a 
Pou1f1 POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1) 
Rarg retinoic acid receptor, gamma 
Rxrip110 retinoid X receptor interacting protein 110 
C1d nuclear DNA binding protein 
Med1 mediator complex subunit 1 
Ncoa2 nuclear receptor coactivator 2 
Ncoa3 nuclear receptor coactivator 3 
Notch1 Notch gene homolog 1 (Drosophila) 
Nr1h2 nuclear receptor subfamily 1, group H, member 2 
Rxrb retinoid X receptor beta 
Rxrg retinoid X receptor gamma 
Tshb thyroid stimulating hormone, beta subunit 
Vdr vitamin D receptor 
Ar androgen receptor 
Cbfa2t2 core-binding factor, runt domain, alpha subunit 2, translocated to, 2 (human) 
Cga glycoprotein hormones, alpha subunit 
Crebbp CREB binding protein 
Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 
Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 
Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 
Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 
Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 
Ep300 E1A binding protein p300 
Esr1 estrogen receptor 1 (alpha) 






Lrch4 leucine-rich repeats and calponin homology (CH) domain containing 4 
Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 
Nr1d1 nuclear receptor subfamily 1, group D, member 1 
Nr1h4 nuclear receptor subfamily 1, group H, member 4 
Siah2 seven in absentia 2 
Tbl1x transducin (beta)-like 1 X-linked 
Tbl1xr1 transducin (beta)-like 1X-linked receptor 1 
Tgfb1i1 transforming growth factor beta 1 induced transcript 1 
Thra thyroid hormone receptor alpha 
Tnf tumor necrosis factor 
Tfrc transferrin receptor 
Map3k7ip2 mitogen-activated protein kinase kinase kinase 7 interacting protein 2 
AF006994 EST AF006994 
Akr1b7 aldo-keto reductase family 1, member B7 
Alas1 aminolevulinic acid synthase 1 
Jun Jun oncogene 
Map2k1 mitogen activated protein kinase kinase 1 
Map3k1 mitogen activated protein kinase kinase kinase 1 
Ppara peroxisome proliferator activated receptor alpha 
Spna1 spectrin alpha 1 
Thcr T helper cell response 
Zbtb7b zinc finger and BTB domain containing 7B 
Dhx30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 
E2f1 E2F transcription factor 1 
Erbb4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 
Hr Hairless 
Myb myeloblastosis oncogene 
Nr2f1 nuclear receptor subfamily 2, group F, member 1 
Nr2f2 nuclear receptor subfamily 2, group F, member 2 
Nrg1 neuregulin 1 
Nrip1 nuclear receptor interacting protein 1 
Ppargc1b peroxisome proliferative activated receptor, gamma, coactivator 1 beta 
Psen1 presenilin 1 
  Wnt3   
Wnt1 wingless-related MMTV integration site 1 
Ctnnb1 catenin (cadherin associated protein), beta 1 
Wnt9b wingless-type MMTV integration site 9B 
Dlx1 distal-less homeobox 1 
Nodal Nodal 
T Brachyury 
Wnt3a wingless-related MMTV integration site 3A 
Bmp4 bone morphogenetic protein 4 
Dlx2 distal-less homeobox 2 
Dvl2 dishevelled 2, dsh homolog (Drosophila) 






Trp53 transformation related protein 53 
Agrn Agrin 
clf1 cleft lip 1 
Crhr1 corticotropin releasing hormone receptor 1 
En2 engrailed 2 
Fgf8 fibroblast growth factor 8 
Gsk3b glycogen synthase kinase 3 beta 
Itgb3 integrin beta 3 
Mapt microtubule-associated protein tau 
Wnt2 wingless-related MMTV integration site 2 
Wnt4 wingless-related MMTV integration site 4 
Wnt7b wingless-related MMTV integration site 7B 
Arf2 ADP-ribosylation factor 2 
Bmp2 bone morphogenetic protein 2 
Bmpr1a bone morphogenetic protein receptor, type 1A 
Cdc27 cell division cycle 27 homolog (S. cerevisiae) 
Cer1 cerberus 1 homolog (Xenopus laevis) 
Ctgf connective tissue growth factor 
Dlx3 distal-less homeobox 3 
Dlx4 distal-less homeobox 4 
Es3 esterase 3 
Fgf1 fibroblast growth factor 1 
Fgf10 fibroblast growth factor 10 
Fgf3 fibroblast growth factor 3 
Fgf4 fibroblast growth factor 4 
Fkbp10 FK506 binding protein 10 
Fzd4 frizzled homolog 4 (Drosophila) 
Gosr2 golgi SNAP receptor complex member 2 
Il3 interleukin 3 
Lhx1 LIM homeobox protein 1 
Lrp1 low density lipoprotein receptor-related protein 1 
Myl4 myosin, light polypeptide 4 
Nanog Nanog homeobox 
Nsf N-ethylmaleimide sensitive fusion protein 
Pax6 paired box gene 6 
Pou5f1 POU domain, class 5, transcription factor 1 
Prkca protein kinase C, alpha 
Ptgs2 prostaglandin-endoperoxide synthase 2 
Rac1 RAS-related C3 botulinum substrate 1 
Ryk receptor-like tyrosine kinase 
Shbg sex hormone binding globulin 
Smad1 MAD homolog 1 (Drosophila) 
Sp8 trans-acting transcription factor 8 
Tdgf1 teratocarcinoma-derived growth factor 
Tg(Wnt1)1Hev transgene insertion 1, Harold E Varmus 






Wnt7a wingless-related MMTV integration site 7A 
Mtvr2 mammary tumor virus receptor 2 
Inhba inhibin beta-A 
Inhbb inhibin beta-B 
Inhbc inhibin beta-C 
Inhbe inhibin beta E 
Itpr1 inositol 1,4,5-triphosphate receptor 1 
Krt1-14 keratin complex 1, acidic, gene 14 
Mid1 midline 1 
Postn periostin, osteoblast specific factor 
  Apop-1   
Bak1 BCL2-antagonist/killer 1 
Bax Bcl2-associated X protein 
Bcl2 B-cell leukemia/lymphoma 2 
Casp9 caspase 9 
Kit kit oncogene 
  Bcat1   
Myc myelocytomatosis oncogene 
Spna2 spectrin alpha 2 
Lrmp lymphoid-restricted membrane protein 
4930469P12Rik RIKEN cDNA 4930469P12 gene 
4933403M22Rik RIKEN cDNA 4933403M22 gene 
Calm1 calmodulin 1 
Casc1 cancer susceptibility candidate 1 
Hras1 Harvey rat sarcoma virus oncogene 1 
Idd6 insulin dependent diabetes susceptibility 6 
Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
Odc1 ornithine decarboxylase, structural 1 
Pas1 pulmonary adenoma susceptibility 1 
Ptma prothymosin alpha 
Rassf8 Ras association (RalGDS/AF-6) domain family 8 
Sspn Sarcospan 
Trp53 transformation related protein 53 
Bdnf brain derived neurotrophic factor 
Mdk Midkine 
Zfp42 zinc finger protein 42 
  Rln1   
Lgr7 leucine-rich repeat-containing G protein-coupled receptor 7 
Insl3 insulin-like 3 
Esr1 estrogen receptor 1 (alpha) 
Lgr8 leucine-rich repeat-containing G protein-coupled receptor 8 
Rln3 relaxin 3 






Oxtr oxytocin receptor 
Dmd dystrophin, muscular dystrophy 
Insl5 insulin-like 5 
Insl6 insulin-like 6 
Nos2 nitric oxide synthase 2, inducible, macrophage 
Esr2 estrogen receptor 2 (beta) 
Mmp2 matrix metallopeptidase 2 
Esrra estrogen related receptor, alpha 
Esrrb estrogen related receptor, beta 
Myl3 myosin, light polypeptide 3 
Myl4 myosin, light polypeptide 4 
Pgr progesterone receptor 
Rxfp3 relaxin family peptide receptor 3 
Rxfp4 relaxin family peptide receptor 4 
Mmp7 matrix metallopeptidase 7 
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 
Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, member 6b 
Serpinb9b serine (or cysteine) peptidase inhibitor, clade B, member 9b 
Serpinb9c serine (or cysteine) peptidase inhibitor, clade B, member 9c 
Serpinb9e serine (or cysteine) peptidase inhibitor, clade B, member 9e 
Serpinb9f serine (or cysteine) peptidase inhibitor, clade B, member 9f 
Igf1 insulin-like growth factor 1 
Gpr1 G protein-coupled receptor 1 
Lrrc1 leucine rich repeat containing 1 
Mrgpra3 MAS-related GPR, member A3 
Phgdh 3-phosphoglycerate dehydrogenase 
Asthm1 asthma 1 
Npr1 natriuretic peptide receptor 1 
Nr3c1 nuclear receptor subfamily 3, group C, member 1 
Pan1 pancreas protein 1 
Semg1 semenogelin I 
Umod Uromodulin 
MCA1 DNA segment, MCA1, multiple CA repeat 1 
an Hertwig's anemia 
Fbn1 fibrillin 1 
Fn1 fibronectin 1 
Prl Prolactin 
Bdnf brain derived neurotrophic factor 
Fbn2 fibrillin 2 
Lep Leptin 
Shh sonic hedgehog 
Myci1 myocardial infarction 1 
Cd79b CD79B antigen 
Odc1 ornithine decarboxylase, structural 1 
Sbds Shwachman-Bodian-Diamond syndrome homolog (human) 






Egf epidermal growth factor 
Gcg Glucagon 
Gja1 gap junction membrane channel protein alpha 1 
Gpr98 G protein-coupled receptor 98 
Gpx6 glutathione peroxidase 6 
Olfr140 olfactory receptor 140 
Slc22a3 solute carrier family 22 (organic cation transporter), member 3 
Ubb1 ubiquitin 1 
 
 
Legend: Italicised genes in bold belong to the microarray gene subset likely to be co-
expressed with Sox9 and upregulated in these cells. Listed beneath the lines are genes that 
interact with the respective putative upregulated gene at the protein level , identified using 
iHOP (http://www.ihop-net.org/UniPub/iHOP/). Genes in bold but without italics, have 
been shown to be part of the Sox9 gene regulatory network. Only putative upregulated 
genes that interact with other members of the Sox9 gene regulatory network are shown 








Downregulated Candidate Sox9-related Genes Identified by Microarray 
 
Genes not associated with Sox9 
 
Genes associated with developmental processes related with Sox9 
From Microarray Subset Interactors identified by iHOP 
Igf1 
 Tgfb1 
 Ear2 Ascl1 (Runx1, Dlx), Phox2a (Bmp2), 
Emilin2 Ecm1 (Tgfb1, Sparc, Agc) 
Was Fgf2 
Zfpn1a2 Runx2 
Gmfg Csf2 (Tgfb1, Runx1, Sparc) 
Gpr84 Gtpbp1 (Gnrh1, Hand1, Tgfb1, Runx1) 
Fgd2 t-complex (T) 
H2-DMb2  Cd79a (Runx1, Runx3, Tgfb1) 
Hcls1  IL2 (Runx1, Tgfb1) 
Hlx Tgfb1 
Htatip2 Ecm1 (Tgfb1, Sparc, Agc) 
Ifi30  Cck (Igf1, Gnrh1, T, Hand1) 
Ikzf1 Runx1, Hand1 
IL16 Hand1, Hand2, Ctnnb1 
Inpp5d  Tgfb1 
Itgal  Hand1, Hand2 
Laptm5 Bmp2, Ihh, Shh 
Lip1  Nr4a1  (Runx1, Runx2, Runx3) 
Lrmp  Itpr1 (Igf1, En1, Wnt3) 
Lyl1 Ptprv (Bmp2, Runx2, Igf1) 
Ncf1 Igf1, Bmp4, Hand1 
Ncf2 Ncf1 (Igf1, Bmp4, Hand1) 
Ncf4 Ncf1 (Igf1, Bmp4, Hand1) 
Pdgfb Tgfb1,Fgf2, Sox5, En1 
















Pik3cd  Runx1, Runx2, Shh, Tgfb1 
Parvg  Ilk (Bmp7), Gsk3b (Wnt3A) 
P2ry6 Cysltr1  (Hand1, Hand2) 
Pik3cg Igf1,Bmp2, Fgf2, Shh 
Plcb2  Btk (Igf1, Hand1, Hand2, Tgfb1) 
Sla Cbl(Tgfb1, Igf1, Hand1) 
Stab1 Pth (Pthr1, Igf1, Fgf2, Bmp7) 
Sp100 Crebbp (Onecut1, Bmp2, Bmp4, Tgfb1)  
Tcirg1 T 
Trf Fgf2, Igf1, Bmp2 
Vamp8 Panc1 (Igf1, Tgfb1) 
Btk  Hand1 
Cd52 Runx1 
Cnr2 Runx1 
Coro1a Runx2, Acan, Sox9, Tgfb1 
Csf1r Tgfb1, Gata6, Igf1, Fgf2 
Apbb1ip Vasp (Bmp2) 
Adcy7 Tac1 (Tgfb1, Gnrh1, Hand2) 
Arhgdib IL2 (Runx1, Tgfb1) 
Abi3 Abl1 (Tgfb1, Igf1) 
Bmp2k Cxcl11 (Hand1, Hand2, Tgfb1) 
Dok2 Tek (Fgf2, Shh, Runx1, T) 
Arpc1b  Tsc22d1 (Tgfb2, Fgf2)  
 
 
Legend: In bold are genes associated with both developmental and immunoregulatory 
processes related to Sox9. In brackets are the proteins that interact directly with 
the interactors identified by iHOP, making them indirect protein interactors 






Genes associated with immunoregulatory processes related with Sox9 
From Microarray Subset Interactors identified by iHOP 
Ear3 Nr2f1 (Nfkb1) 
Ear4 Ear3, Gba2 (IL6) 
Emp3 Csf3 (IL6) 
Zfpn1a2 Nfkb1 
Clec5a Trem1 (Nfkb1) 
Gpr84 Gtpbp1 (Nfkb1) 
Hcph Nfkb1 
H2-Q5 Ptprc (IL6) 
H2-DMb2  Cd79a (Nfkb1) 
Hcls1  IL2 (Nfkb1, IL1, IL6)  
Hlx IL6 
Icsbp1  Nfkb1, IL1 
Ifnar2  IL6 
Igh-6 IL7 
Ifi30  Cck (IL1) 
Inpp5d  Nfkb1 
Lcp2 IL2 (Nfkb1, IL1, IL6) , Ptpn6 (Nfkb1) 
Lip1  Nr4a1 (Nfkb1) 
Lst1 Slco1b2 (IL6) 
Pdgfb Nfkb1, IL6 
Pik3cd  Nfkb1 
Parvg  Ilk (Nfkb1) 
Plcb2  Btk (Nfkb1, IL6) 
Ptpn7 IL2 (Nfkb1, IL1, IL6) 
Ptpn18 Csk (Nfkb1) 
Scarf1 advillin (Nfkb1) 
Sla Cbl (IL6) 
Tbxas1 Ptgs1 (Nfkb1, IL6) 
Vav1 Nfkb1 
Vamp8 Panc1 (Nkfb1)  
Arhgap4 Nfkb1 
Btk Nfkb1, IL1 
Cd52 IL6 
Cnr2 Nfkb1 
Coro1a IL1, IL5 
Adcy7 Tac1 (Nfkb1, IL6, IL1) 
Arhgdib IL2 (Nfkb1, IL1, IL6)  
Dok3 Csk (Nfkb1) 
Clec5a Nfkb1 
Abi3 Abl1 (Nfkb1) 
Bmp2k Cxcl11 Ptgs1 (Nfkb1, IL6) 
Dok2 Tek (Nfkb1, IL6) 



























List of published Sox9 direct targets and binding regions 
Gene 






(kb) Length References 
col2a1 collagen, type II, alpha 1 15 97803 97807.3 4.3 
(Bell, Leung et al. 1997; 
Lefebvre, Huang et al. 1997) 
col4a2 collagen, type IV, alpha 2 8 11267 11320 53 (Mertin, McDowall et al. 1999) 
col9a1 collagen, type IX, alpha 1 1 24182 24186 4 
(Kamachi, Cheah et al. 1999; 
Zhang, Jimenez et al. 2003; 
Genzer and Bridgewater 2007) 
col11a2 collagen, type XI, alpha 2 17 34174 34179.3 5.3 
(Bridgewater, Lefebvre et al. 
1998; Liu, Li et al. 2000) 
col27a1 collagen, type XXVII, alpha 1 4 62874 62882.2 8.2 (Jenkins, Moss et al. 2005) 
Acan aggrecan 7 86195 86205 10 (Sekiya, Tsuji et al. 2000) 
crtl1 cartilage link protein 13 89677 89682 5 (Kou and Ikegawa 2004) 















(Xie, Zhang et al. 1999) 








List of ChIP primers used 
5' primer name 5' primer sequence 3' primer name 3' primer sequence 
>matn59-367_f GAGAGAGGCAGGGGGATTGTT >matn59-367_r GAAAGCCGAGGTGCCTATGTT 
>matn341-746_f GGCATCCTGGGCTCGTCTTC >matn341-746_r GGACCCAGCTGTACCCGTGAA 
>matn607-746_f GCAGCCCGCTTCGTTC >matn607-746_r GGACCCAGCTGTACCCGTGAA 
>matn742-1038_f CGGTTTCACGGGTACAG >matn742-1038_r TTCTCCCAAATTGTGCTACAT 
>matn858-1275_f ACCTCTCACCGTGGCCATCGT >matn858-1275_r AGTCACACAGCCGGTTCAA 
>matn1329-1541_f TGGAAAGTGGGCTGATTGATA >matn1329-1541_r CACAGCGAAGCAAGCGAGTC 
>matn1493-1968_f CATCTTCCTTCTCCGGTCTTC >matn1493-1968_r GCCCAGGTTTCTCGCTAAATA 
>matn1835-2060_f AAACACTGGATGGTCGGCTCT >matn1835-2060_r CCCGTGCTGACTTGGACCTA 
>matn2256-2591_f CCTGCCCAGTGGTTGATAAG >matn2256-2591_r GTCCTGGTGGCCTTCACTAAT 
>matn2572-2953_f GGGCAGTGGAGATAATGGTAT >matn2572-2953_r CGGGAGACCTTAAACGTGT 
>matn2816-2952_f AGTCTGTGCCATGAGATAGCC >matn2816-2952_r CGGGAGACCTTAAACGTGTT 
>matn2955-3419_f ACGTTTAAGGTCTCCCGAGAA >matn2955-3419_r AGGGCCATCAGGGTACCTA 
>matn3613-3902_f CCGAATGCCCGAGACTA >matn3613-3902_r GGTTTCACAGTGCTGGCGTAG 
>matn3754-3898_f GCCGGACACGACCCAC >matn3754-3898_r TCACAGTGCTGGCGTAGTTGA 
>crtl1480-1923_f CTGACTGGAGAAACGGAATAA >crtl1480-1923_r CGCTGAAGATCCTAGTCCTT 
>crtl1863-2051_f GACCACAGCGCACCACTTAGG >crtl1863-2051_r GCGGAGAGGGTGTAGGGA 
>crtl2096-2516_f CGAAGTGATGAACCGAATGAT >crtl2096-2516_r CGCCTCCTGAACAAATAGACA 
>crtl2519-3059_f CTATTTGTTCAGGAGGCGTTT >crtl2519-3059_r CCCCCACCCACACTGTACCTC 
>crtl3047-3269_f GACAGGCAACAGGAGGTACAG >crtl3047-3269_r AGAAAGGCAAAGCGTCAC 
>crtl3209-3701_f AAGTCTCCTGGTGACGCTTTG >crtl3209-3701_r CTGAACCTGTTTATTGCGATG 
>crtl3701-4007_f CATCGCAATAAACAGGTTCAG >crtl3701-4007_r AGAATTACCCACAATCTGACG 
>crtl4143-4437_f GTATTCCAAACCGTAGCTGTT >crtl4143-4437_r CTAAGAAGCCAGCCAGTATGT 
>crtl4448-4890_f GGCTTCTTAGAACCGAATGG >crtl4448-4890_r TAAGATTGTTGGCATGACCCT 
>col2a1_307-750_f GATAAAGGAGGGCTGTTACT >col2a1_307-750_r TTCTTGGAGAACGCAGGTCTA 
>col2a1_743-1214_f ACCAGTCTAGACCTGCGTTCT >col2a1_743-1214_r TCCTCACCTCCAGCGATATT 
>col2a1_1241-1640_f GTGACGCCCTGTCTTGACTAA >col2a1_1241-1640_r CGGCCACAAAGAATCACTTAT 
>col2a1_1512-1866_f CCAACGCTGTAACCAGATCGC >col2a1_1512-1866_r AATCGGGCTCTGTATGC 
>col2a1_1864-2062_f GCGCATACAGAGCCCGATTCA >col2a1_1864-2062_r AACTTGTTGGCCGCGAAGAC 
>col2a1_2110-2499_f GGAGCGCGGTGGACTCTA >col2a1_2110-2499_r CCCACAAAGCTGCGGTCTTGA 
>col2a1_2730-3137_f GGGTCCGCCAAGCTAA >col2a1_2730-3137_r ACAGCGTGTGTAGCCGTGGAT 
>col2a1_2867-3148_f ACAGTTTCACCTGCGATT >col2a1_2867-3148_r TGAGTTACTTTACAGCGTGTG 
>col2a1_3086-3500_f TGCCACCTCTAACGATAGCCA >col2a1_3086-3500_r AGACGCCTACGGGTTGAT 
>col2a1_3359-3746_f GGACTGGAGAGCTGCGCTGAA >col2a1_3359-3746_r CGGGTTAGGGCGCTAAGT 
>col2a1_3586-4002_f GGTGGAAGGTGATGCGTCTGT >col2a1_3586-4002_r CATGAGGGAGCGGTAGAG 
>col2a1_3845-4251_f TCCTGGCCCTGACACCGTAG >col2a1_3845-4251_r CGGGAAGCTGGGCTCACGAA 
>col2a1_4240-4680_f CAGTCGCCCCTTTCGTGAG >col2a1_4240-4680_r AGTTGGATGGGGGATGGGTTA 
>col2a1_4389-4821_f CCCCTTTCCTCGGAGTT >col2a1_4389-4821_r GTTGTCTGCAGTCCCGTTAGT 
>col2a1_4428-4877_f GGTTGTTTGCAGAGGCATAAG >col2a1_4428-4877_r AGGAAGAGCCGAACTAGA 
>col2a1_4805-5150_f ACAGGCCAGGGAAGGGACTAA >col2a1_4805-5150_r CTCCGCAGTTTGGGCTAAG 
>col2a1_5259-5735_f TGAGATGGTCCTCCGGTGAAC >col2a1_5259-5735_r TGGGCACTGCAGACTTAAAGC 
>col2a1_6018-6443_f CAGTGGTGTTGCACGCCTTTA >col2a1_6018-6443_r CCTTGCTGCGCTCCTTATGT 
>col2a1_6679-6823_f CTCCCTCATGGCGAAGT >col2a1_6679-6823_r CATCCTGCACCCTTGGGTTAT 
>col27a1_1399-1823_f CGCCTAAGAACCGACC >col27a1_1399-1823_r CTAGCTTCTGGCCTCTACAAG 
>col27a1_1809-2284_f GTGGTATGAATCGCCTTGTAG >col27a1_1809-2284_r CGCGACCGTCCACCTATC 
>col27a1_1943-2282_f AATGCAGAAAGGCCGAACACA >col27a1_1943-2282_r CGCGACCGTCCACCTATCCA 
>col27a1_3306-3749_f CCTCGGGTTCTGCACGTTCC >col27a1_3306-3749_r GGGTGGGCGGTACTATAACTC 
>col27a1_4139-4561_f GGGCTCTGGGATCTTCGTTGA >col27a1_4139-4561_r GCTTCCTGGGCACGCTTCT 
>col27a1_4565-4831_f GCGTGCCCAGGAAGCGTAGAG >col27a1_4565-4831_r CTGGGAAGGGCGTGAGTC 
>col27a1_4769-5184_f GGTGTGGCTGTCTTGGGTACA >col27a1_4769-5184_r CCTTGGCTTGGCTATGGA 
>col27a1_5511-5928_f TGTGTGGCTTTGGGCTAGTC >col27a1_5511-5928_r AGTCTGCCGAAGCTATATCAT 






>col27a1_6231-6477_f GAGGCTGCCCGTGACTT >col27a1_6231-6477_r GGGCTCTGGGATGCTGACGAT 
>col27a1_6434-6797_f AGACTTCAGGGCTATCGTCAG >col27a1_6434-6797_r GTTCGGAAAGGCAAACGTGA 
>col27a1_6815-7435_f ACTAGTCACTGTGTGATCCGT >col27a1_6815-7435_r CTGGTCCTATGTAGCACGTAC 
>col27a1_7315-7790_f GTGGTAGCAGCGGGGTTACAG >col27a1_7315-7790_r CAAGACGTTGGGTGGCTAGAG 
>col27a1_7787-8081_f GGACTCTAGCCACCCAACGTC >col27a1_7787-8081_r AGGCCAGGTGACAGGTAAAT 
>col9a1_255-580_f GGGTACCGCTTGATCTAAACA >col9a1_255-580_r TGAGAGAACTCGCCTTCGT 
>col9a1_573-996_f GGCAAGCACGAAGGCGAGTTC >col9a1_573-996_r GCCGGAGAGTTTCTGATTGGA 
>col9a1_1020-1474_f CTGAGAGAGGCCAAAGTAAGA >col9a1_1020-1474_r ATGTCGGAGGAACGCAGAA 
>col9a1_1239-1700_f CTTAAATCAAGTAGCGAATTA >col9a1_1239-1700_r AGTATGCGATTGAATAGACC 
>col9a1_1631-1964_f GTCTAGGCCTGTGATGCTAGT >col9a1_1631-1964_r TCCGCTGGCAACCTTA 
>col9a1_1933-2385_f GAGGGGTGCACACAATGAC >col9a1_1933-2385_r GAATGGGAAAAGCCTTACTGA 
>col9a1_2185-2598_f CACACCTCTGCCACGGAATAG >col9a1_2185-2598_r CCCTCTCTACCCTTCTCGGAC 
>col9a1_2270-2936_f GCCTCTACTGTGCCCTAT >col9a1_2270-2936_r CACCTAGGAACTCTGCGAATA 
>col9a1_2408-2749_f TCCCTCCTTCAGTGTGACCTT >col9a1_2408-2749_r CCCTTATGCTACCAATACTGC 
>col9a1_2649-3059_f ACCCTTTACGGTGACTCTTAT >col9a1_2649-3059_r ACCCAAACAGGAACCTCT 
>col9a1_2987-3368_f ATGCCTTGGGATTTGGTTGTC >col9a1_2987-3368_r ACACCATGTTCAGCCCTAGA 
>col9a1_3142-3501_f TGGGTATCCGCAACTCT >col9a1_3142-3501_r GCCCTACCCATTAAAGTACAT 
>col11a2_332-657_f TTGCCAAGCTGCTGTTACGTC >col11a2_332-657_r TCAAGGCCACTGAAGGTAGA 
>col11a2_1378-1732_f GGTGGGCACCAGGGCATCTAC >col11a2_1378-1732_r GGGTCGTGGCCGTTCTA 
>col11a2_1731-2242_f CTAGAACGGCCACGAC >col11a2_1731-2242_r CGCTAGCCCTGGAATGGTACA 
>col11a2_1911-2242_f CACCTTTGGGTCGCTATCTAT >col11a2_1911-2242_r TAGCCCTGGAATGGTACA 
>col11a2_2205-2531_f GGGCACGCGAGCTACCTAATC >col11a2_2205-2531_r AGCCAGCTGAGCCTCGGAACC 
>col11a2_2500-2922_f CCACTGAAAGCTGCTGACATC >col11a2_2500-2922_r AACCAAGAATCCAGCCTACTC 
>col11a2_2789-3083_f TTTGGGCACCAGGATTTAGAT >col11a2_2789-3083_r CGGGACAGTGGAGGTAGCTT 
>col11a2_2908-3273_f ACCGTCCAGAGGCTGAGTAGG >col11a2_2908-3273_r AGGTCCCACGGGAGTC 
>col11a2_3252-3719_f CCCCTCCCCTCTAGCCAG >col11a2_3252-3719_r ATGCCCTGTCCTATACCCTCA 
>col11a2_3546-3755_f TTGGCAGGATGACCGTGTAAA >col11a2_3546-3755_r CCCACTGCCACTCCACCTATC 
>col11a2_3774-4218_f GGTCTGAGACAGTGGGGTTAG >col11a2_3774-4218_r GCCCAAACTCGATGATG 
>col11a2_4236-4501_f CGGGAAGCTGAAACCTAAG >col11a2_4236-4501_r GCTAAGGAAGGGCATATAAGA 

















Humanised-BirA Protein and DNA sequence 
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